Cognitive-behavioural therapy for clozapine-resistant schizophrenia: The FOCUS RCT by Morrison, AP et al.
Morrison, AP and Pyle, M and Gumley, A and Schwannauer, M and Turking-
ton, D and MacLennan, G and Norrie, J and Hudson, J and Bowe, S and
French, P and Hutton, P and Byrne, R and Syrett, S and Dudley, R and Grif-
fiths, H and Barnes, TRE and Davies, L and Shields, G and Buck, D and
Tully, S and Kingdon, D (2019)Cognitive-behavioural therapy for clozapine-
resistant schizophrenia: The FOCUS RCT. Health Technology Assessment,
23 (7). pp. 1-143. ISSN 1366-5278
Downloaded from: http://e-space.mmu.ac.uk/624463/
Version: Published Version
Publisher: NIHR Journals Library
DOI: https://doi.org/10.3310/hta23070
Usage rights: Creative Commons: Attribution-Noncommercial 4.0
Please cite the published version
https://e-space.mmu.ac.uk
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 23 ISSUE 7 FEbrUary 2019
ISSN 1366-5278
DOI 10.3310/hta23070
Cognitive–behavioural therapy for clozapine-resistant 
schizophrenia: the FOCUS RCT
Anthony P Morrison, Melissa Pyle, Andrew Gumley, Matthias Schwannauer, 
Douglas Turkington, Graeme MacLennan, John Norrie, Jemma Hudson, 
Samantha Bowe, Paul French, Paul Hutton, Rory Byrne, Suzy Syrett,  
Robert Dudley, Hamish J McLeod, Helen Griffiths, Thomas RE Barnes,  
Linda Davies, Gemma Shields, Deborah Buck, Sarah Tully and David Kingdon

Cognitive–behavioural therapy for
clozapine-resistant schizophrenia:
the FOCUS RCT
Anthony P Morrison,1,2*† Melissa Pyle,1,2†
Andrew Gumley,3 Matthias Schwannauer,4
Douglas Turkington,5 Graeme MacLennan,6
John Norrie,7 Jemma Hudson,6 Samantha Bowe,1
Paul French,1,8 Paul Hutton,9 Rory Byrne,1,2
Suzy Syrett,3 Robert Dudley,10 Hamish J McLeod,3
Helen Griffiths,4 Thomas RE Barnes,11 Linda Davies,12
Gemma Shields,12 Deborah Buck,12 Sarah Tully1,2
and David Kingdon13
1Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation
Trust, Prestwich, UK
2Division of Psychology and Mental Health, University of Manchester,
Manchester, UK
3Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
4Department of Clinical Psychology, Edinburgh Medical School, University of
Edinburgh, Edinburgh, UK
5Academic Psychiatry, Northumberland, Tyne and Wear NHS Foundation Trust,
Centre for Ageing and Vitality, Newcastle General Hospital, Newcastle upon
Tyne, UK
6Centre for Healthcare Randomised Trials, Health Services Research Unit,
University of Aberdeen, Aberdeen, UK
7Clinical Trials Unit, Edinburgh Medical School, University of Edinburgh,
Edinburgh, UK
8Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK
9School of Health and Social Care, Edinburgh Napier University, Edinburgh, UK
10School of Psychology, Newcastle University, Newcastle upon Tyne, UK
11Centre for Mental Health, Imperial College London, London, UK
12Division of Population Health, University of Manchester, Manchester, UK
13Department of Psychiatry, University of Southampton, Academic Centre,
Southampton, UK
*Corresponding author
†First author

Declared competing interests of authors: Anthony P Morrison reports personal fees from the provision
of training workshops in cognitive–behavioural therapy (CBT) for psychosis and royalties from books on the
topic, outside the submitted work. Andrew Gumley reports grants from the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) programme (grant number 13/15/04) outside the
submitted work. Douglas Turkington reports personal fees from Insight–CBT partnership (Insight Healthcare,
Newcastle upon Tyne), outside the submitted work. Gemma Shields reports grants from NIHR during the
conduct of the study. Graeme MacLennan reports grants from the NIHR HTA programme during the
conduct of the study. Hamish J MacLeod reports that he occasionally provides CBT for psychosis workshops
and receives fees for this work. John Norrie reports personal fees from the NIHR Editors Board and grants
from NIHR HTA General Board Deputy Chairperson, outside the submitted work, and has membership of
the HTA Funding Boards Policy Group and Pre-Exposure Prophylaxis Impact Review Panel. Linda Davies
reports grants from the NIHR HTA programme during the conduct of the study. Paul French has membership
of the HTA prioritisation Panel. Paul Hutton reports that he sits on an Expert Steering Group for Professor
Jill Stavert’s Centre for Mental Health and Incapacity Law Rights and Policy at Edinburgh Napier University,
and that he is a member of a committee developing National Institute for Health and Care Excellence (NICE)
guidelines on supporting decision-making for people who may lack mental capacity. Robert Dudley reports
receiving a NIHR Comprehensive Local Research Network Greenshoots award to fund time to support his
contribution to the FOCUS (Focusing on Clozapine Unresponsive Symptoms) trial, royalties from Guilford
Press and personal fees from Trinity College Dublin, outside the submitted work. Samantha Bowe reports
personal fees from Pennine Care NHS Foundation Trust and personal fees from Cheshire & Wirral
Partnership NHS Foundation Trust, outside the submitted work. Thomas RE Barnes reports personal fees
from Sunovion (Marlborough, MA, USA) and Otsuka (Tokyo, Japan)/Lundbeck (Copenhagen, Denmark),
outside the submitted work.
Published February 2019
DOI: 10.3310/hta23070
This report should be referenced as follows:
Morrison AP, Pyle M, Gumley A, Schwannauer M, Turkington D, MacLennan G, et al.
Cognitive–behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. Health
Technol Assess 2019;23(7).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.513
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science
Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods
(to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 10/101/02. The contractual start date
was in December 2012. The final report began editorial review in August 2017 and was accepted for publication in February 2018. The authors
have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher
have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft
document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed
by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC,
the HTA programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Morrison et al. under the terms of a commissioning
contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private
research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief
Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, 
University of Exeter Medical School, UK
NIHR Journals Library Editors
Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, 
University of Exeter Medical School, UK
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management 
and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK
Ms Tara Lamont  Scientific Advisor, NETSCC, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, 
University of York, UK 
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK
Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK
Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Cognitive–behavioural therapy for clozapine-resistant
schizophrenia: the FOCUS RCT
Anthony P Morrison,1,2*† Melissa Pyle,1,2† Andrew Gumley,3
Matthias Schwannauer,4 Douglas Turkington,5 Graeme MacLennan,6
John Norrie,7 Jemma Hudson,6 Samantha Bowe,1 Paul French,1,8
Paul Hutton,9 Rory Byrne,1,2 Suzy Syrett,3 Robert Dudley,10
Hamish J McLeod,3 Helen Griffiths,4 Thomas RE Barnes,11
Linda Davies,12 Gemma Shields,12 Deborah Buck,12 Sarah Tully1,2
and David Kingdon13
1Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust,
Prestwich, UK
2Division of Psychology and Mental Health, University of Manchester, Manchester, UK
3Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
4Department of Clinical Psychology, Edinburgh Medical School, University of Edinburgh,
Edinburgh, UK
5Academic Psychiatry, Northumberland, Tyne and Wear NHS Foundation Trust, Centre for
Ageing and Vitality, Newcastle General Hospital, Newcastle upon Tyne, UK
6Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen,
Aberdeen, UK
7Clinical Trials Unit, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
8Institute of Psychology, Health and Society, University of Liverpool, Liverpool, UK
9School of Health and Social Care, Edinburgh Napier University, Edinburgh, UK
10School of Psychology, Newcastle University, Newcastle upon Tyne, UK
11Centre for Mental Health, Imperial College London, London, UK
12Division of Population Health, University of Manchester, Manchester, UK
13Department of Psychiatry, University of Southampton, Academic Centre, Southampton, UK
*Corresponding author tony.morrison@manchester.ac.uk
†First author
Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people with
schizophrenia who have a poor response to standard antipsychotic medication. However, a significant
number of patients who trial clozapine have an inadequate response and experience persistent symptoms,
called clozapine-resistant schizophrenia (CRS). There is little evidence regarding the clinical effectiveness of
pharmacological or psychological interventions for this population.
Objectives: To evaluate the clinical effectiveness and cost-effectiveness of cognitive–behavioural therapy
(CBT) for people with CRS and to identify factors predicting outcome.
Design: The Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial was a parallel-group,
randomised, outcome-blinded evaluation trial. Randomisation was undertaken using permuted blocks of
random size via a web-based platform. Data were analysed on an intention-to-treat (ITT) basis, using
random-effects regression adjusted for site, age, sex and baseline symptoms. Cost-effectiveness analyses
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were carried out to determine whether or not CBT was associated with a greater number of quality-adjusted
life-years (QALYs) and higher costs than treatment as usual (TAU).
Setting: Secondary care mental health services in five cities in the UK.
Participants: People with CRS aged ≥ 16 years, with an International Classification of Diseases, Tenth
Revision (ICD-10) schizophrenia spectrum diagnoses and who are experiencing psychotic symptoms.
Interventions: Individual CBT included up to 30 hours of therapy delivered over 9 months. The comparator
was TAU, which included care co-ordination from secondary care mental health services.
Main outcome measures: The primary outcome was the Positive and Negative Syndrome Scale (PANSS)
total score at 21 months and the primary secondary outcome was PANSS total score at the end of treatment
(9 months post randomisation). The health benefit measure for the economic evaluation was the QALY,
estimated from the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), health status measure. Service use
was measured to estimate costs.
Results: Participants were allocated to CBT (n = 242) or TAU (n = 245). There was no significant difference
between groups on the prespecified primary outcome [PANSS total score at 21 months was 0.89 points
lower in the CBT arm than in the TAU arm, 95% confidence interval (CI) –3.32 to 1.55 points; p = 0.475],
although PANSS total score at the end of treatment (9 months) was significantly lower in the CBT arm
(–2.40 points, 95% CI –4.79 to –0.02 points; p = 0.049). CBT was associated with a net cost of £5378
(95% CI –£13,010 to £23,766) and a net QALY gain of 0.052 (95% CI 0.003 to 0.103 QALYs) compared
with TAU. The cost-effectiveness acceptability analysis indicated a low likelihood that CBT was cost-effective,
in the primary and sensitivity analyses (probability < 50%). In the CBT arm, 107 participants reported at least
one adverse event (AE), whereas 104 participants in the TAU arm reported at least one AE (odds ratio 1.09,
95% CI 0.81 to 1.46; p = 0.58).
Conclusions: Cognitive–behavioural therapy for CRS was not superior to TAU on the primary outcome
of total PANSS symptoms at 21 months, but was superior on total PANSS symptoms at 9 months (end of
treatment). CBT was not found to be cost-effective in comparison with TAU. There was no suggestion that
the addition of CBT to TAU caused adverse effects. Future work could investigate whether or not specific
therapeutic techniques of CBT have value for some CRS individuals, how to identify those who may benefit
and how to ensure that effects on symptoms can be sustained.
Trial registration: Current Controlled Trials ISRCTN99672552.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 7.
See the NIHR Journals Library website for further project information.
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Plain English summary
People who experience schizophrenia are usually prescribed antipsychotic medication. Some who takean antipsychotic continue to experience distressing and persistent symptoms; for these people the
antipsychotic clozapine has been shown to be effective in reducing symptoms. About 30–40% of people
who try clozapine experience persistent symptoms and there is little research to indicate what treatments
are effective if clozapine has a poor impact. The Focusing on Clozapine Unresponsive Symptoms (FOCUS)
trial was designed to test whether or not a talking treatment called cognitive–behavioural therapy (CBT)
is clinically effective in reducing the symptoms of schizophrenia, and whether or not CBT is cost-effective.
A total of 487 participants who met the criteria for a schizophrenia diagnosis and who had tried clozapine
but experienced a poor response were recruited. Participants were randomly allocated to receive CBT plus
treatment as usual (TAU) or TAU alone. CBT lasted for 9 months, and participants could have up to 30 hours
of CBT. Participants were followed up at 9 and 21 months and it was found that those who had CBT
experienced some small improvements in symptoms of schizophrenia at 9 months, but this did not last to
21 months. The data suggest that CBT was not cost-effective compared with TAU. Some benefits of CBT
were evident at 21 months, such as feeling less emotional distress, a better understanding of ‘delusional’
beliefs and better self-rated recovery. The small benefit of CBT at 9 months is the same level of benefit people
get from taking a second antipsychotic medication, but without the medication side effects. Although CBT
cannot be recommended routinely for all people who have a poor response to clozapine, it may be helpful
for some.
The results cannot answer questions about how helpful CBT is for people who have received a diagnosis of
schizophrenia who have not tried clozapine. Better ways to help this population needed to be developed.
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Scientific summary
Background
For around one-third of the people who meet the criteria for a schizophrenia diagnosis, treatment with
antipsychotic medication will result in little change in symptoms and, commonly, the symptoms become
progressively more unresponsive to medication, with subsequent relapses. For people who experience a
poor response to treatment with standard antipsychotic medication, the antipsychotic clozapine is currently
considered the mainstay of treatment for those who meet the criteria for treatment-resistant schizophrenia
(TRS). However, a significant proportion of people will experience persistent symptoms after an adequate
trial of clozapine. For this group of people, who meet the criteria for clozapine-resistant schizophrenia
(CRS), the evidence base for treatments is limited; augmentation strategies with a second antipsychotic
are a common clinical practice, but meta-analyses demonstrate small effects for this treatment strategy.
There is a clear indication from cognitive–behavioural therapy (CBT) trials that people who meet the
criteria for both TRS and CRS can be engaged in CBT. There is emerging evidence to suggest that,
for this population, CBT can have small to moderate effects on overall symptoms and may be particularly
beneficial for auditory hallucinations. However, the field has lacked a large high-quality trial of CBT for
people with CRS.
Objectives
The objectives of the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial were to provide evidence
of the clinical effectiveness and cost-effectiveness of CBT for people who meet the criteria for CRS and to
utilise baseline data from this randomised controlled trial (RCT) to develop a risk model that identifies factors
that predict a good outcome from CBT. Our objectives were to test the following hypotheses:
l In people with a diagnosis of a schizophrenia spectrum disorder, who have an inadequate response to
or are unable to tolerate clozapine, CBT plus treatment as usual (TAU) will lead to an improvement in
psychotic symptoms, measured using a psychiatric interview [Positive and Negative Syndrome Scale
(PANSS)] over a 21-month follow-up period, compared with TAU alone.
l Cognitive–behavioural therapy plus TAU will lead to an improved quality of life and user-defined
recovery compared with TAU alone.
l Cognitive–behavioural therapy plus TAU will lead to a reduction in affective symptoms and negative
symptoms compared with TAU alone.
l Cognitive–behavioural therapy plus TAU will be cost-effective compared with TAU alone.
Methods
The FOCUS trial was a parallel-group, randomised, outcome-blinded evaluation (PROBE) trial, conducted
to evaluate the addition of a standardised CBT intervention to TAU for individuals who are unable to
tolerate or have had an inadequate response to clozapine. The comparison group received TAU only.
CBT was delivered over a 9-month treatment window and participants received up to 30 hours of CBT.
The FOCUS trial was conducted over a 4-year period across five sites in the UK. Recruitment for the trial
commenced on 1 January 2013 and ended on 1 June 2015. The follow-up phase of the trial ended in
February 2017. Participants were recruited from a number of NHS mental health services, including
community mental health teams (CMHTs), early intervention teams, recovery teams and inpatient services.
People were eligible to take part in the FOCUS trial if they were considered to have had an inadequate
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response to a trial of clozapine treatment. This was defined as treatment with clozapine at a stable
dose of ≥ 400 mg (unless limited by tolerability) for ≥ 12 weeks, or, if currently augmented with a
second antipsychotic, for ≥ 12 weeks, without remission of psychotic symptoms. Alternatively, potential
participants could have discontinued clozapine in the preceding 2 years because of side effects, lack of
efficacy or a problem identified during routine blood monitoring appointments. Potential participants were
also required to meet the following inclusion criteria: have an International Classification of Diseases, Tenth
Revision (ICD-10), diagnosis on the schizophrenia spectrum or meet the criteria for an Early Intervention
in Psychosis (EIP) service; have a minimum total PANSS score of 58 points at baseline assessment; score
≥ 4 points on items for delusions or hallucinations or ≥ 5 points for items on suspiciousness or grandiosity
on the PANSS; be aged ≥ 16 years; have an identified care co-ordinator or consultant psychiatrist; and be
competent and willing to provide written informed consent to take part. Participants were excluded based
on the following criteria: a primary diagnosis of substance or alcohol dependence when this could be the
cause of the psychotic experiences; diagnosis of developmental disability; organic impairment; non-English
speaking (in cases in which this would prevent engagement in assessment and CBT); and currently
receiving or had received structured CBT for psychosis from a qualified psychological therapist within the
previous 12 months.
The primary outcome was the total PANSS score at 21 months (i.e. at the 12-month follow-up). Secondary
outcomes were the total PANSS score at 9 months (end of treatment), PANSS subscales, self-rated recovery,
social and occupational functioning, Clinical Global Impression (CGI), depression, anxiety, adverse effects and
substance use. Other measures, including measures of psychological processes, included appraisals of voices
and paranoia, beliefs about self and others, working memory, attachment, childhood trauma and stigma.
Health benefit data were collected using the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), and data
on the resources used for each participant were collected using the Economic Patient Questionnaire (EPQ).
All measures were collected at baseline, 9 months and 21 months, except for the EPQ score, which was also
collected at 3, 6, 13 and 17 months.
The primary outcome, total PANSS score at 21 months, was analysed using an intention-to-treat (ITT)
linear model with adjustment for prespecified baseline covariates of sex, age and baseline PANSS score.
The treatment effects over time were explored using repeated-measures mixed-effects models. The
secondary outcomes were analysed in a similar way using an ITT linear model adjusted for prespecified
baseline covariates.
Results
A total of 487 participants were recruited to the trial; of these, 242 were allocated to CBT and 245 to TAU.
The median number of CBT sessions attended was 23, and 88% of participants attended at least six sessions
of CBT, which was the minimum number of sessions needed to be classified as having received CBT.
At 9 months, the total PANSS score was 2.4 points lower in the CBT group (95% CI –4.79 to –0.02 points;
p = 0.049) than in the TAU group. At 21 months, the total PANSS score was 0.89 points lower in the CBT
arm, but this difference was not statistically significant (95% CI –3.32 to 1.55 points; p = 0.475).
Analysis of secondary outcomes at 9 months showed that the following outcomes were significantly lower
in the CBT arm than in the TAU arm: PANSS positive 1.56 points lower (95% CI –4.79 to –0.02 points;
p = 0.049), PANSS emotional distress 1.08 points lower (95% CI –2.02 to –0.13 points; p = 0.025) and
Psychotic Symptom Rating Scale (PSYRATS) auditory hallucinations 2.56 points lower (95% CI –4.87 to
–0.26 points; p = 0.029). At 21 months, PSYRATS delusions emotional distress was 0.53 points lower in
the CBT arm (95% CI –1.05 to –0.00 points; p = 0.049), CGI was 0.33 points lower in the CBT arm (95% CI
–0.54 to –0.11 points; p = 0.013) and self-rated recovery was 2.03 points higher in the CBT arm (95% CI
0.04 to 4.01 points; p = 0.045). Risk modelling did not reveal any subgroups of people who had a good
response to CBT. There was no evidence that the treatment effect was moderated by any of the prespecified
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subgroups. The number of reportable serious adverse events was two in the CBT arm and one in the TAU arm.
There were 107 people with one or more adverse events in the CBT arm and 104 in the TAU arm (p= 0.58).
However, there were no significant differences between the CBT and TAU arms on other prespecified
outcomes for potential unwanted side effects of trial participation including suicidal crisis, severe symptomatic
exacerbation or PANSS deterioration. CBT was associated with a net cost of £5378 (95% CI –£13,010 to
£23,766) and net quality-adjusted life-year (QALY) gain of 0.052 (95% CI 0.003 to 0.103 QALYs) compared
with TAU. The probability that CBT was cost-effective was 0.13.
Conclusions
The FOCUS trial is the first study to provide high-quality evidence with a low risk of bias regarding the
clinical effectiveness and cost-effectiveness of CBT for people who meet the criteria for CRS. CBT for CRS
was not superior to TAU on the primary outcome of total PANSS score at 21 months, but was superior on
total PANSS score at 9 months (end of treatment). CBT was not found to be cost-effective compared with
TAU, despite producing a net gain in overall health measured by QALYs. However, self-rated recovery did
differ between the groups at 21 months (i.e. at the12-month follow-up).
Trial registration
This trial is registered as ISRCTN99672552.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Psychosis and schizophrenia
The term psychosis is used to refer to a mental health problem that can involve changes to a person’s
perceptions and/or to their thoughts. A person who has experience of psychosis may report perceptual
changes such as hearing a voice that another person cannot hear, or seeing something that another
person cannot see. Perceptual changes may also occur to a person’s taste, smell and/or bodily sensations.
Such perceptual changes are typically referred to as hallucinations. A person experiencing psychosis may
also report beliefs that others around them consider unusual, that are out of keeping with their social or
cultural background and that are lacking rational grounds (often referred to as delusions). Common
delusional beliefs include feelings of being persecuted, ideas of reference and feelings of importance.1
Persecutory beliefs are thought to be the most commonly occurring of the range of delusional beliefs.2
Experiences of hallucinations and delusions can be distressing and confusing and can have a negative
impact on functioning. In addition, a person with experience of psychosis may report changes in their
ability to concentrate or may communicate in a manner that is hard for other people to understand,
which is commonly referred to as thought disorder. In both clinical practice and research, delusions,
hallucinations and thought disorder are typically referred to as positive symptoms of psychosis. In addition,
people who experience psychosis may report flat affect (blunted affect), a decrease in verbal output and
verbal expressiveness, loss of motivation (including social withdrawal) and loss of enjoyment.3 These
experiences are often referred to as negative symptoms. This term was originally proposed because
these changes refer to the loss or absence of usually present functions or characteristics.4–6 Estimates
suggest that 15–20% of people who receive a schizophrenia diagnosis will experience persistent
negative symptoms.7,8
Psychosis is considered to exist on a continuum,9 from the occasional occurrence of psychotic phenomena
in the general population9–12 to persistent and frequent psychotic symptoms resulting in distress and, in
many cases, the need for care from a mental health service. Someone who experiences psychosis and
presents to mental health services for care may receive a schizophrenia spectrum diagnosis. Experiences
of psychosis are often categorised using a diagnostic classification system, namely the International
Classification of Diseases, Tenth Revision (ICD-10),13 or the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-V).14 Schizophrenia spectrum diagnoses include schizophrenia, schizoaffective
disorder, delusional disorder and schizophreniform disorder. However, there has been considerable debate
over the use of such diagnostic terms and classification systems.15 One argument is that these classification
systems suggest that psychosis difficulties are dichotomous rather than continuum based.9 In addition,
concerns have been raised regarding the reliability of the diagnostic classification systems used.16 The
diagnostic label of schizophrenia has become stigmatising, with intrinsic negative associations about
prognosis17 leading some countries to drop the term schizophrenia.18 The use of diagnostic terminology
has, therefore, been contentious and Murray,19 in 2017, highlighted the burgeoning evidence that
schizophrenia is not a dichotomous condition, but rather the severe end of a continuum. Murray19
expects to see the end of the concept of schizophrenia in the future. However, diagnosis and diagnostic
terminology is commonly utilised throughout both clinical practice and research. For the purpose of this
report, we wish to acknowledge this debate and, throughout, we will adopt respectful terminology.
When reviewing the literature relevant to the Focusing on Clozapine Unresponsive Symptoms (FOCUS)
trial, we use the terms psychosis and schizophrenia, depending on the sample of participants recruited to
the studies being referred to. In relation to the sample of participants included in the FOCUS trial, we refer
to the population as people who meet the criteria for a schizophrenia spectrum diagnosis or people who
meet the criteria for clozapine-resistant schizophrenia (CRS).
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Prevalence rates and the personal, social and economic impact
of schizophrenia
A first episode of psychosis typically occurs in young adults; a review of the literature on the age at onset
of mental health disorders by Kessler et al.20 found that, for those with a schizophrenia diagnosis, the age
at onset is usually between 15 and 35 years of age. Reports of the lifetime prevalence in the literature vary
from 0.12 to 1.6 per 100 persons.21 In the UK, a systematic review22 commissioned by the Department of
Health and Social Care reported that the incidence rate for all clinically relevant psychosis diagnoses is
31.72 per 100,000 persons per year, and for schizophrenia is 15 per 100,000 persons per year; the
incidence of the latter being the same as the international incidence rate for schizophrenia reported by
McGrath et al.23
Although the prevalence of schizophrenia is relatively low, the personal, social and economic costs are
considerable and the management of schizophrenia is among one of the largest health challenges globally
as well as for the UK NHS. For example, Kirkbride et al.22 report that, in 2009, the estimated economic
costs for services and society attributable to broadly defined schizophrenia amounted to £8.8B. The
majority of the costs were attributable to lost employment (47%) and service costs (40%). Using disability-
adjusted life-years lost as a measure of the overall number of years lost as a result of ill health, disability
or early death, schizophrenia was ranked eighth among mental health diagnoses and brain disorders in
Europe in 2010.24
Considerable health inequalities are reported for people who have a schizophrenia diagnosis, with increased
risk of serious diseases, such as diabetes mellitus, cardiovascular disease (CVD), a human immunodeficiency
virus (HIV) infection and respiratory problems.25 The prevalence of CVD among those with a schizophrenia
diagnosis is estimated to be 75%, compared with an estimated 50% in the general population.26 Of great
concern is the mortality risk associated with schizophrenia. A recent systematic review and meta-analysis27 of
the literature on potential life lost and life expectancy in schizophrenia found that, on average, people with
a diagnosis of schizophrenia die 14.5 years earlier than those in the general population. The same authors27
report that the average life expectancy for people with a schizophrenia diagnosis is 64.7 years (for men and
women combined); among men only, the average life expectancy is 8 years shorter than in the general
population. The estimated risk of suicide in the general population is 1%, in comparison with 10% in those
with a schizophrenia diagnosis.26 In addition to the health inequalities outlined above, people with a
schizophrenia diagnosis face widespread public stigma and discrimination, representing further inequalities
and a major challenge to recovery. The incidence of anticipated, experienced and internalised stigma is
high among people with psychosis.28,29 A large-scale survey of people with schizophrenia diagnoses across
27 different countries found that nearly half of the respondents felt at a disadvantage as a result of having
a diagnosis of schizophrenia, because of stigma.29 Nearly half of the sample reported interpersonal/social
difficulties with making or keeping friends and around one-quarter identified feeling at a disadvantage in
terms of finding and keeping work and in relation to their personal safety.29
Given the significant personal, societal and economic costs associated with schizophrenia, the treatment
and care provided for people who meet the criteria for schizophrenia spectrum diagnoses should be a
priority for policy-makers, commissioners and service providers.
Treatment options for people with a schizophrenia diagnosis
In this section of the report, we will consider the evidence base for treatments for people with a
schizophrenia diagnosis considering both pharmacological and psychological interventions. We will begin
the section with a consideration of the efficacy of antipsychotic medication, with a particular emphasis on
treatment options for people with a schizophrenia diagnosis who have a poor response to antipsychotic
medication. We will outline the psychological interventions recommended by the National Institute for
Health and Care Excellence (NICE), with a specific emphasis on cognitive–behavioural therapy (CBT),
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given that this is the intervention evaluated by the FOCUS trial. We will consider the efficacy of CBT in
conjunction with antipsychotic medication with a particular emphasis on efficacy for CRS.
Antipsychotic medication
The NICE guideline30 for psychosis and schizophrenia in adults recommends, for people with a first episode
of psychosis, an acute exacerbation or recurrence of psychosis or schizophrenia, that oral antipsychotic
medication be offered. The NICE guideline30 does not make a specific recommendation for the type
of antipsychotic offered, that is first-generation antipsychotics (FGAs) or atypical/second-generation
antipsychotics (SGAs). The range of antipsychotic medications in both of these classes differ in their
psychopharmacological properties, efficacy and adverse effect profiles.31 A recent systematic review and
meta-analysis32 of placebo-controlled antipsychotic medication trials identified a total of 167 double-blind
randomised controlled trials (RCTs) with a total sample of 28,102 people with a schizophrenia diagnosis.
Meta-analysis of the data found a small to medium effect size (ES) for overall efficacy of 0.47, but this
reduced to a small ES of 0.38 when looking at rigorous trials. Leucht et al.32 reported that 23% of the
participants who received antipsychotic medication had a ‘good’ response (defined as ≥ 50% change
on the primary outcome), compared with 14% in the placebo group, with an absolute difference of 9%.
Although the percentage is greater for those who receive antipsychotic medication, the authors32 conclude
that this is still only a minority of participants who have a good response. With regard to the superiority
of FGAs versus SGAs, a meta-analysis31 of studies comparing FGAs and SGAs found that four SGAs
demonstrated superiority over FGAs in reducing overall symptoms for people with a schizophrenia diagnosis,
with small to moderate ESs; specifically, these were amisulpride (ES= 0.31), clozapine (ES= 0.52), olanzapine
(ES = 0.28) and risperidone (Risperdal, McGregor Cory Ltd) (ES= 0.13). However, direct comparisons of FGAs
with SGAs in large, rigorously conducted, publicly funded RCTs33,34 have found no differences in efficacy,
leading some to conclude that the class of ‘atypical’ antipsychotics has been fabricated for marketing
purposes and has no basis in science or clinical practice.35
Antipsychotic medication is the mainstay of treatment for people who meet the criteria for a schizophrenia
diagnosis; however, it has been argued that evidence from meta-analyses demonstrates that the superiority of
antipsychotic medication over placebo has been overestimated.36 In addition, antipsychotics have a wide range
of side effects, such as metabolic effects (including weight gain), cardiovascular effects, hyperprolactinaemia,
antimuscarinic side effects (dry mouth, blurred vision and cognitive impairment), sexual dysfunction and
movement disorders.37 The adverse effects of antipsychotic medication are associated with increased stigma,
physical morbidity and mortality, poor adherence and reduced quality of life.37 A systematic review38 of the
effects of antipsychotic drugs on brain volume concluded that some of the structural brain changes found in
people with a schizophrenia diagnosis may be the result of antipsychotic medication. The headline result from
the largest study34 to date to compare FGAs with SGAs was that 74% of participants discontinued their study
medication before 18 months, which indicates issues of tolerability and adherence to antipsychotic medication.
Morrison et al.36 argue that the adverse effects of antipsychotic medication have been underestimated, and
authors of a recent review39 of antipsychotic medication as a treatment for people with a schizophrenia
diagnosis concluded that ‘we still remain a long way from being able to recommend with precision, specific
treatments for individual patients, in terms of the clinical response and lack of adverse events’ (Lally and
MacCabe39).
A choice of treatments for people with experience of psychosis or with a schizophrenia diagnosis and an
evidence base for these treatments is, therefore, imperative.
Treatment-resistant schizophrenia
It is common for the symptoms experienced by someone with a diagnosis of schizophrenia to become
progressively more unresponsive to medication with subsequent relapses.40 Findings from a recent
systematic review conducted by Kennedy et al.41 indicate a 60% failure rate to achieve a response to
treatment with standard antipsychotic medication after 23 weeks. The persistence of symptoms after
adequate treatment with antipsychotic medication is commonly referred to in the literature and clinical
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practice as ‘treatment-resistant’ schizophrenia (TRS); for comparison with the literature, we will utilise the
terminology ‘people with experience of TRS’ throughout this report. Global estimates of the prevalence of
TRS would suggest that 7.8 million people worldwide are experiencing TRS.42 As outlined in Prevalence
rates and the personal, social and economic impact of schizophrenia, people with a schizophrenia diagnosis
frequently experience health inequalities; for the TRS group, these health inequalities are inflated. The
mean quality of life score for those who meet TRS criteria is 20% lower than for people with a diagnosis of
schizophrenia whose symptoms are considered to be in remission.41 Moreover, in comparison with other
mental health diagnoses that are considered to be ‘severe and enduring’, those with TRS have worse
outcomes in terms of both symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS),
and social/functional outcomes, with TRS being a predictor for poor community functioning.43 For the
person experiencing TRS, the continued presence of symptoms represents a barrier to recovery and
improvements in quality of life, and increased personal social/economic costs.41 In sum, the importance
of identifying effective treatments for this group cannot be overstated.
In defining criteria for TRS, many researchers and clinicians have referred to the following conceptualisation
of TRS, outlined by Kane et al.:44 two periods of treatment with different antipsychotics at an adequate dose
for ≥ 4 weeks without a ≥ 20% reduction in symptoms. Since the publication of the Kane et al.44 study, there
have been numerous investigations of treatments for people with TRS; however, these studies often use
different definitions of TRS. A systematic review45 of the TRS literature highlights the fact that the definition
of TRS has been inconsistent across numerous clinical trials for TRS, and it is argued that the lack of clarity
regarding the definition of TRS is a limiting factor for translating the research findings into clinical practice.
It also increases heterogeneity across the studies and, therefore, reduces the conclusions that can be drawn
from meta-analyses.45 Furthermore, the international guidelines utilised by clinicians working in the field use
varying definitions of TRS (e.g. NICE guidelines30). In the UK, NICE does not specify a duration of treatment
of an episode that it deems adequate, unlike the American Psychiatric Association, which specifies a duration
of ≥ 6 weeks. In response, the Treatment Response and Resistance in Psychosis (TRRIP) working group was
convened to develop criteria for treatment resistance in schizophrenia. This work represents an important
development in research and practice in the field of TRS. Howes et al.45 note that, of the 42 studies identified
as eligible for their systematic review, only two, from the same research group, used identical TRS criteria.
Based on the systematic review conducted by Howes et al.,45 an online survey of the TRRIP group members
(identifying agreements and disagreements) and meetings of the TRRIP group members, the following criteria
for TRS have been recommended: (1) current symptoms of a minimum duration and severity determined by a
standardised rating scale that includes both positive and negative symptoms, that is, the Brief Psychiatric
Rating Scale (BPRS) or PANSS; (2) moderate or worse functional impairment; (3) prior treatment of at least
two different antipsychotics, each for a minimum duration and dosage; (4) systematic monitoring of
adherence and meeting of minimum adherence criteria; (5) at least one prospective treatment trial; and
(6) criteria that clearly separate responsive from treatment-resistant patients.45
The NICE guideline30 treatment recommendation for people diagnosed with TRS is to review diagnosis
and adherence to medication, ensure that the medication prescription is at an adequate dose for the
correct period of time, consider possible causes of non-response, such as substance misuse and physical
health problems, and offer psychological intervention [CBT and family intervention (FI)]. For those who
experience persistent symptoms of schizophrenia following adequate treatment with at least two different
antipsychotic drugs (at least one of which should be a non-clozapine SGA), a trial of clozapine should be
offered.30 Clozapine is a SGA and it is currently considered to be the treatment of choice for people with
TRS,46 as demonstrated by the NICE guideline recommendation.30 However, clozapine has a number of
adverse effects and, in comparison with FGAs, clozapine is associated with more frequent haematological
problems, drowsiness, hypersalivation and temperature increases.47 The most dangerous adverse effect
associated with clozapine is agranulocytosis, which is a haematological disorder of the white blood cells
that help fight infection. The unwanted side effects of clozapine can prevent the optimal dose of clozapine
being reached or tolerated over time, and data from a cohort study in the UK showed that 45% of people
discontinued treatment with clozapine within the first 2 years of the drug being initiated.48 Results of the
same study also suggest that tolerability and adverse drug reactions play a key role in patient-led decisions
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to discontinue clozapine: in just over half of cases, the reason given for discontinuation was adverse drug
reactions, with sedation being the most frequently reported.48
The use of clozapine as a treatment for TRS grew in popularity following the highly influential double-blind
study of clozapine versus chlorpromazine conducted by Kane et al.44 Since this study, there has been an
increased number of RCTs comparing clozapine with FGAs, paving the way for subsequent meta-analyses
of these trials. Essali et al.47 conducted a systematic review and meta-analysis of trials comparing clozapine
with FGAs, identifying a total of 42 eligible trials with 3950 participants. Although there was no difference
in mortality or employment status between those on clozapine and those receiving FGAs, clozapine was
superior in relation to clinical improvements, reduced relapse rates and greater reduction in BPRS scores.
Although the meta-analysis conducted by Essali et al.47 suggests superiority of clozapine over FGA, the
authors note problems of heterogeneity with the data and the high risk of bias across the studies.47
There has been some debate regarding the efficacy of clozapine in comparison with other antipsychotic
medications. Two meta-analyses49,50 of clozapine versus treatment with standard antipsychotic medication
were published in 2016. Both meta-analyses found that clozapine was no more effective in the long term
for total psychotic symptoms than other antipsychotic medications. However, Siskind et al.49 report that
for positive symptoms clozapine is superior to other antipsychotic medications in both the short and the
long term. Given the absence of superiority over other antipsychotic medications for total symptoms in the
long term, Siskind et al.49 recommend that, for patients who do not respond to clozapine by 6 months,
other antipsychotic medications with lower side effect profiles should be considered. The network
meta-analysis by Samara et al.,50 which integrated all published and unpublished single- and double-blind
RCTs of all antipsychotic medications for TRS, found that there was little evidence of efficacy of antipsychotic
medications other than clozapine, haloperidol, olanzapine and risperidone. The authors50 concluded that
there is, however, insufficient evidence to determine which of these medications are most effective for
people with TRS, commenting that ‘The most surprising finding was that clozapine was not significantly
more efficacious than most other drugs’ (Samara et al.50) and arguing that there is a need for blinded studies
of antipsychotic medication for TRS.50 Howes et al.45 note that the conclusions that can be drawn from the
network meta-analysis by Samara et al.50 may be limited by the heterogeneity across the studies included in
the review. Clearly, it is challenging when two meta-analyses with similar research questions are published
within the same year, making it difficult for clinicians, researchers and commissioners to interpret the data;
however, clozapine remains the mainstay of treatment for TRS.
Clozapine-resistant schizophrenia
Around 30–40% of people who trial clozapine will experience a poor response to this medication.51
Moreover, the range of adverse effects from clozapine means that the optimal dose may not always be
reached or clozapine may not be tolerated long term. In both the research literature and clinical practice,
a person who experiences a poor response to clozapine is typically said to have ‘clozapine-resistant
schizophrenia’ (CRS) and, for this reason, we use that term in this report. CRS is defined as the persistence
of symptoms after treatment with clozapine for ≥ 12 weeks at a stable dose of ≥ 400 mg per day, unless
the dose was limited by side effects.52
The most frequent approach to the treatment of CRS is to augment clozapine with another antipsychotic
medication.53,54 This is an approach taken frequently in clinical practice.53,54 Clozapine has low antidopaminergic
properties and, therefore, is often combined with an antipsychotic medication that has dopaminergic
properties.53 There is some evidence of small but significant benefits of clozapine augmentation with a
second antipsychotic,54,55 but studies are scarce.56 There is some indication that augmentation with
risperidone may have adverse effects, as evidence from the Cochrane review57 comparing risperidone with
placebo suggests that adding risperidone to clozapine treatment leads to reduced functioning. Not only are
antipsychotic augmentation studies infrequent, but their results are highly heterogeneous, which limits the
conclusions that can be drawn from meta-analyses.54 Many of the studies to date are subject to detection
bias, with concealment of allocation unclear in eight of the studies included in the meta-analysis of
antipsychotic augmentation conducted by Taylor et al.55 With this representing just over 50% of the studies
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included in the review, findings may be compromised by the risk of detection bias. Moreover, several
of the studies included in the systematic review conducted by Porcelli et al.54 were rated as being of low
quality, with the mean quality assessment score across the 24 studies being 5.43 points (SD 1.88 points,
range 3–8 points), with 0 points being the minimum score and 9 points being the maximum score.
A systematic review and meta-analysis conducted by Taylor et al.55 identified 14 RCTs, with a total sample
of 734 participants, that compared clozapine plus a second antipsychotic with clozapine plus placebo for
≥ 6 weeks’ duration. Augmentation with a second antipsychotic was found to have a small but significant
effect over placebo, with an ES of 0.239. The long-term adverse effects of clozapine augmentation with
a second antipsychotic are unclear from the Taylor et al.55 review because 11 of the 14 trials followed up
participants for only ≤ 10 weeks. Potential long-term adverse effects include hyperprolactinaemia and
increased striatal dopamine blockade.55 There is scarce evidence to answer the question of which combination
strategy of clozapine and another antipsychotic medication is more effective. Sommer et al.56 conducted a
systematic review of 29 randomised, double-blind, placebo-controlled trials of clozapine augmentation with
a second drug, including augmentation with drugs from a different class (i.e. not an antipsychotic). Of these,
10 trials evaluated the efficacy of augmentation with another antipsychotic and included amisulpride,
aripiprazole, haloperidol, risperidone and sulpiride. Only clozapine augmented with sulpiride proved superior
to placebo in reducing symptom severity, and this finding was from one small trial (with a sample size
of n= 28).
The most recent review of clozapine augmentation with another antipsychotic medication was carried
out by Barber et al.58 The aim was to evaluate the efficacy and tolerability (in terms of side effects) of
clozapine combined with various antipsychotic medications. The search yielded a limited number of
studies, which were of low quality and high heterogeneity. In total, five studies met the inclusion criteria,
yielding a total of 309 participants. Findings from the review demonstrated that there are a very limited
number of studies that can indicate the superiority of one clozapine combination strategy over another,
and the evidence that is available is of low quality. The current evidence does not allow a specific clozapine
augmentation strategy to be recommended; individual pragmatic trials may be indicated, but, given the
increased risk of adverse effects from polypharmacy, augmentation with a second antipsychotic should be
discontinued if the benefits do not outweigh the risks.
An alternative strategy that has been evaluated is augmenting clozapine with another medication of a
different class, namely benzodiazepines or antidepressants. In a review, Dold and Leucht53 argued that
there is currently insufficient evidence for this approach, although they do recognise that targeted use of
augmentation may be indicated in specific cases, such as the use of medication to target agitation.
In summary, the literature regarding the efficacy of treatments for TRS indicates that a significant
proportion of people will experience CRS and continue to experience persistent difficulties. The evidence
base for treatments for CRS is sparse59 and augmentation strategies with a second antipsychotic
demonstrate small effects.55
Psychological interventions
Psychological therapies for people with psychosis have been extensively evaluated in recent years. Clinical
trials and subsequent meta-analyses have evaluated individual and group treatments (including CBT,
supportive counselling, befriending, narrative therapies and psychodynamic approaches), FIs (individual or
multifamily) and art therapies (including music therapies, dance therapy and art therapy). After thoroughly
reviewing the evidence base, the NICE guideline30 currently recommends that all people with experience of
psychosis or with a schizophrenia diagnosis should be offered CBT and FI, and for those who experience
TRS or CRS it is recommended that the care team review the person’s engagement with and use of both
of these psychological treatments.30
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
Cognitive–behavioural therapy
The generic cognitive model60 has been applied to our understanding and treatment of schizophrenia.
This cognitive model suggests that the way in which we interpret events has consequences for how we
feel and behave, and that such interpretations are often maintained by unhelpful thinking biases and
behavioural responses. Cognitive models of psychosis and psychotic experiences suggest that it is the way
in which people interpret and respond to psychotic phenomena that accounts for distress and disability,
rather than the psychotic experiences themselves.61–63
Key elements of CBT include a shared, individualised formulation of the problem, which can include
consideration of life events that may contribute to the development and/or maintenance of psychosis,
such as trauma and deprivation; evaluating unhelpful thoughts; and conducting behavioural experiments.64
Morrison et al.64 place emphasis on the importance of CBT being conducted via a strong therapeutic
relationship for people who experience psychosis and schizophrenia, the use of normalising information,
collaboration between the client and the therapists, and therapy being based on a client’s problem list
and idiosyncratic goals.
The importance of delivering CBT in an empowering and recovery-orientated manner has been highlighted
in a 2016 article by Brabban et al.,65 who suggest 10 key considerations to ensure that CBT is delivered
ethically, in a manner that is recovery orientated and promotes therapeutic relationships: (1) collaboration,
(2) use of everyday language, (3) acknowledging the historical and developmental context of the client’s
difficulties, namely adverse life experiences, so as not to minimise the impact of these, (4) evaluating rather
than challenging beliefs, (5) applying caution with use of the stress vulnerability model of psychosis and
schizophrenia, (6) validating the client’s experience using a cognitive formulation, (7) delivering hope to the
client, (8) offering informed choice about engaging with CBT, (9) ensuring that CBT training is extensive
and specialist and (10) ensuring that there is access to continued supervision.
Cognitive–behavioural therapy has been shown to have small to moderate effects when delivered in
combination with antipsychotic medication, with several meta-analyses showing support for this approach.66–68
The most conservative ES estimate for total symptoms is 0.33, demonstrating small but significant effects
of CBT for psychosis over treatment as usual (TAU); however, the ES for total symptoms reduces to 0.15
for studies with a low risk of bias from masking.69 The same meta-analysis69 reports small ESs for positive
symptoms (ES= 0.25) and negative symptoms (ES= 0.13). A 2014 meta-analysis conducted by Turner et al.,70
which compared CBT for psychosis with other psychological therapies, found that, across the 48 included
studies, CBT was more efficacious in improving overall and positive symptoms of psychosis than in improving
other psychological therapies. van der Gaag et al.71 note that there has been a focus on positive and negative
symptoms in meta-analyses of CBT; however, CBT is a formulation-based approach that aims not necessarily
to reduce the frequency or severity of positive and negative symptoms, but rather to help service users make
sense of distressing hallucinatory experiences and delusional beliefs, with the aim of reducing distress and
increasing coping. In a meta-analysis of treatment effects of individually tailored case-formulation CBT on
auditory hallucinations and delusions, van der Gaag et al.71 found modest and significant ESs for auditory
hallucinations at the end of treatment (ES= 0.44), and this increased when contrasted with active treatment
(ES= 0.49) and for blinded studies (ES= 0.46). Although modest significant ESs were found for delusions
at the end of treatment (ES = 0.36), these ESs lost significance when (1) contrasted with active treatment
and (2) the ES was reduced for blinded studies (ES = 0.24). Findings from the meta-analysis conducted by
van der Gaag et al.71 suggest that CBT can be effective in treating auditory hallucinations, but that the
evidence for treating delusions is less robust.
Although meta-analyses suggest small to moderate ESs for CBT, in comparison with other psychological
approaches, there remains debate in the literature about CBT’s value for psychosis and schizophrenia.69,72
In particular, McKenna,72 in the 2014 Maudsley Debate, suggest that the meta-analysis carried out by NICE
in 2009 for the schizophrenia guideline was methodologically flawed, leading to an increased chance of
type I error and the probability that any positive findings were as a result of chance. In addition, Jauhar et al.69
suggest that the conclusions regarding efficacy of CBT are mistaken, because the most large, well-conducted
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trials have failed to demonstrate a significant effect at the end of treatment, and the supportive meta-analyses
overestimate the effects from smaller, low-quality trials. They also argue that their finding of ‘non-significant
effects on positive symptoms in a relatively large set of 21 masked studies also suggests that claims that CBT
is effective against these symptoms of the disorder are no longer tenable’.69
Cognitive–behavioural therapy for treatment-resistant schizophrenia
In relation to TRS, the efficacy of CBT has been evaluated in a number of RCTs with some encouraging
evidence; key details of these studies are presented below. Tarrier et al.73 conducted one of the earliest
trials of CBT for TRS using a three-arm RCT design in which participants were randomly allocated to
CBT, supportive counselling or TAU. In total, 87 eligible participants were randomised, and those who
received CBT exhibited significantly greater improvements in positive symptoms at the 3-month assessment
than those who received supportive counselling or TAU. Because the authors did not provide further
definition of ‘stable medication’, it is difficult to establish whether or not this group would meet strict TRS
criteria. Augmenting clozapine with CBT was first evaluated by Pinto et al.74 In their RCT74 of CBT with
social skills training compared with supportive therapy as an adjunct to clozapine, 41 treatment-resistant
participants who had recently started taking clozapine were recruited. Treatment resistance was defined
as non-response to at least two antipsychotic medication trials, each ≥ 6 weeks in duration, at a dose of
> 600 mg per day of chlorpromazine equivalents. At the end of treatment, both the CBT plus social skills
training and supportive counselling groups showed statistically significant improvement in total BPRS score
and positive and negative symptom ratings. However, comparisons between the groups showed that, post
intervention, participants who had received CBT plus social skills training had lower total BPRS score and
lower negative symptoms scores than participants who had received supportive therapy.74 This study74
provided preliminary evidence for augmenting clozapine with a psychological intervention; however, as
this study is non-blind there is a risk of bias that limits the conclusions that be drawn from the findings.
In another RCT of CBT for TRS, Kuipers et al.75 found that the CBT group had a significant improvement
on the BPRS, as defined by a 25% reduction in the BPRS score; however, significant differences were
not observed between the CBT and control groups on any of the other clinical outcomes. Findings from
the study75 also suggested that CBT was considered an acceptable treatment, because participants had a
low drop-out rate from therapy (11%), and 80% of those who received CBT expressed high levels of
satisfaction with the intervention. Sensky et al.76 recruited 90 participants to a RCT comparing CBT with
befriending for people with TRS. For this study, treatment resistance was defined as the persistence of
symptoms resulting in distress or dysfunction for ≥ 6 months despite an adequate trial of antipsychotic
medication.76 Analysis of the data demonstrated no significant difference between the groups at the end
of treatment, but an effect was observed at follow-up for positive and negative symptom ratings and
depression for the CBT group. A 5-year follow-up study77 of these participants indicated some evidence
for the medium-range effectiveness of CBT: participants who received CBT had significantly lower overall
symptom severity scores than those in the befriending group. A three-arm RCT78 of CBT versus supportive
psychotherapy (SP) versus TAU, for people with a schizophrenia diagnosis who experienced persistent
delusions and/or hallucinations after treatment with antipsychotic medication for 6 months, found greater
improvement in PANSS total score among those allocated to CBT. In addition, the results of the study
demonstrated that those in the psychological intervention arms (CBT or SP) experienced a greater
reduction in the severity of delusions and that more people in the CBT arm than in the SP and TAU arms
achieved a ≥ 25% reduction in PANSS scores.78 Although the study indicates promise for the acceptability
of CBT for this group, and promise for the effects of CBT on total PANSS score and delusion severity, this
was a small study with between 19 and 23 participants in each arm. Valmaggia et al.79 carried out a small
RCT of manualised CBT for psychosis versus a time-matched control intervention of supportive counselling
for people with TRS, matching the Kane et al.44 definition. Sixty-two participants were randomised and
the between-group analyses at the end of treatment demonstrated no significant difference between the
CBT and supportive counselling groups on positive, negative or general subscale of the PANSS, or the
delusion subscale of the Psychotic Symptom Rating Scale (PSYRATS). There was however, a significant
improvement in the CBT group on two items of the PSYRATS voices subscale (the physical characteristics
and interpretation of voices). These differences were not sustained at follow-up, indicating some
short-term effects of CBT on voices for the TRS group.
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To date, there have been no published meta-analyses of CBT specifically for TRS. However, a meta-analysis
of CBT and FIs for people with a diagnosis of schizophrenia reported that the majority of the studies included
in the review included participants who would appear to meet TRS criteria, that is, they were prescribed
an antipsychotic medication and had a long duration of illness (DI), and concluded that CBT may be useful
for those with TRS.66 A more recent systematic review80 of the literature on interventions for TRS found
13 studies investigating CBT for TRS. This review included any paper in which the authors had considered the
participants to be experiencing TRS, and so did not follow a strictly defined definition of TRS, with the result
that the samples included are likely to be highly heterogeneous; this raises the question of whether or not the
studies included are reflective of intervention studies for the TRS group. In addition, closer inspection of the
CBT studies included in the review80 reveals that the CBT intervention usually targeted specific symptoms of
psychosis (i.e. command hallucinations81 and auditory hallucinations82) or was aimed at improving outcomes
that were not directly related to symptoms, such as therapeutic alliance.83
Cognitive–behavioural therapy for clozapine-resistant schizophrenia
To date, only one study has examined the efficacy of CBT for CRS.84 In this controlled trial, treatment
resistance was evaluated using Kane et al.’s44 criteria and, to meet trial inclusion criteria, participants
were required to have taken clozapine for ≥ 6 months without improvement of symptoms of psychosis.
Twenty-two participants who met the inclusion criteria were allocated to either CBT (n = 10) or befriending
(n = 12). CBT was found to be significantly more effective in reducing BPRS total score, PANSS total
score and PANSS general psychopathology subscale score at the end of treatment and at the 6-month
follow-up. However, an effect was not found for the reduction of positive symptoms. Although the result
of the study by Barretto et al.84 is encouraging, there are significant methodological limitations. The sample
size was very small, limiting the power of the study to detect an effect of CBT for positive symptoms.
Moreover, the study design is limited by the absence of randomisation.
Predictors of response to cognitive–behavioural therapy
In addition to understanding the overall efficacy of CBT relative to standard treatment, a further important
research consideration is determining predictors of response to CBT, to better understand who will benefit
from CBT. In determining who will have a good response to CBT, secondary analyses of CBT trials have
indicated that patient characteristics including sex, ethnicity and baseline symptom severity may moderate
the outcomes of CBT for people with a schizophrenia diagnosis.85–88 More specifically in relation to TRS,
studies of CBT in this group have indicated that fewer recent hospital admissions,89 greater cognitive flexibility
concerning delusions89 and less severe symptoms on allocation73 are associated with a better response to CBT.
The DI has been shown to be associated with response to CBT,90–92 and this has also been demonstrated
in TRS groups.73 Similarly, insight at baseline has been shown to be associated with good outcomes in CBT
for psychosis.93
It is likely that the way in which events are appraised will be dependent on the experiences a person has
had in life and the way in which they view themselves and other people.63 Experience of traumatic life
events, such as abuse, could lead to the development of a view that other people are threatening, causing
later experiences to be interpreted in this light.62,63 Research in the general population that has found
an association between negative life events and unusual beliefs or perceptual experiences has provided
support for this view.94 There is increasing evidence of a link between abuse and psychosis95 as well as
other types of traumatic or difficult life experiences and psychosis, for example being held hostage,96 living
in highly urbanised areas,97 refugee migrant status,98 low social capital99 and racial discrimination.100 A
2012 meta-analysis101 of 41 studies found a significant relationship between adversity in childhood and risk
of psychosis later in life. The types of traumatic childhood experience that were included in the review101
were emotional, physical and sexual abuse; neglect; bullying; and death of a parent. It was found that,
apart from parental death, each of these factors was significantly related to psychosis. Loss of a parent was
also found to be significantly related to psychosis when the data from one paper with outlying results were
removed from the analysis. This review,101 therefore, concluded that the experience of trauma in childhood
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is strongly related to an increased risk of psychosis. Specific types of traumatic experience have also
been found to relate to specific psychotic experiences. It has been found that sexual abuse is related to
voice-hearing, whereas growing up in care is related to experience of paranoia.102 A longitudinal study103
found that experience of psychosis in children aged 12 years was particularly associated with traumatic
events, characterised by intention to harm. This suggests that it could be the perception of threat that is of
significance to the development of psychotic experiences.103 Experiences, such as those described above,
could lead to beliefs that others are dangerous, and increase the likelihood that future experiences will be
interpreted as threatening.2 Use of a longitudinal formulation within CBT can, therefore, provide validation
of the experiences that an individual has suffered and make sense of current experiences in the context of
a traumatic history.104 This process can also foster hope of recovery by identifying specific areas in which
change strategies could be applied.104
Cognitive difficulties, that is, difficulties with attention, memory and working memory, are frequently
experienced by people with a schizophrenia diagnosis.105,106 Working memory has been described as a
system for temporarily storing information while using it to complete tasks involving cognitive function,
such as problem-solving.107 A large meta-analysis investigating working memory in schizophrenia
consistently found that participants with a diagnosis of schizophrenia performed worse than control
groups on a range of tests of working memory.108 Furthermore, it has been found that those individuals
with a longer-term diagnosis and receiving antipsychotic medication are likely to be the most seriously
affected. For example, it has been shown that participants with a greater DI demonstrate the poorest
performance on working memory tasks.108 In relation to spatial working memory, it was found that
participants’ performances significantly worsened after receiving clozapine for just 17 weeks.109 It has
previously been demonstrated that anticholinergic drugs, including clozapine, affect memory performance.110
It has been proposed that neurocognitive deficits in people with a diagnosis of depression are likely to
predict outcome from CBT.111 The same is likely to be true for people with a schizophrenia diagnosis,
given that CBT relies on skills, such as memory and generating alternative hypotheses.112 Neurocognition
is also known to be associated with functional outcomes, such as social skills and ability to perform daily
activities.113 Neuropsychological impairment has been found to be predictive of poorer outcome among
participants receiving Cognitive Behavioural Social Skills Training.112 It was hypothesised that neuropsychological
inpairment could be related to poorer attendance and reduced engagement with homework in this group.
Memory difficulties could make engaging with homework tasks, a factor thought to improve outcome,
more problematic.114 However, few studies have formally evaluated the impact of neurocognitive variables on
outcome with CBT, and a clear relationship has not been identified.115
Although some researchers have endeavoured to identify who has a good response to CBT, the current
evidence for predictors of a good response to CBT is limited and the findings are often unreliable because
of insufficient statistical power, with very few findings surviving replication. There is a clear benefit to
understanding how best to target CBT at those who are most likely to respond, and further research
is required.
Important outcomes for trials
A further criticism of these studies is the absent or limited focus on outcome measures that service users
consider meaningful and important to their recovery. A review116 of 24 measures commonly used to
evaluate psychosis and mood disorders found that service user preference was for measures that were
patient rated rather than clinician rated and that evaluated side effects of both pharmacological and
psychological interventions; interestingly, measures of social functioning were rated particularly low
because of the assumptions made about ‘good’ social functioning. However, it is interesting to note
that the PANSS, a commonly used outcome measure, was rated as the most acceptable of the psychosis
outcome measures.116 Although this suggests that measuring these symptom-based domains is important
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to service users, there is also clear evidence that recovery-orientated outcomes are a priority.117 A recovery-
orientated model of care engenders values of hope, independence and control over one’s life following
a mental health problem, connection with a self-identity and having meaning to life and being able to
take responsibility for one’s recovery.117 The emphasis is not on the remission or absence of symptoms.118
A qualitative study119 investigating how service users with experience of psychosis or schizophrenia diagnoses
defined recovery identified three key themes: (1) rebuilding self, (2) rebuilding life and (3) hope for a better
future. Within these key themes, processes of recovery included understanding oneself, empowerment,
participation in life activities and social support, understanding a personal process for change and a personal
desire for change. Importantly, Pitt et al.119 emphasised that recovery is a journey, not a linear process with
a clear end point. A 2011 systematic review120 of the literature on personal recovery from a mental health
problem identified a total of 97 papers; synthesis of the findings from these papers resulted in five key
processes of recovery: (1) connectedness, (2) hope and optimism for the future, (3) identity, (4) meaning
and (5) empowerment.
It has also been argued, especially in relation to the evaluation of psychological therapies for people with
psychosis, that affective processes or emotional distress or dysfunction should be the outcomes that are
evaluated in trials. For example, CBT for psychosis trials have been criticised as inappropriately conceiving CBT
as a quasi-neuroleptic on the basis of adopting methodologies designed to evaluate antipsychotic medication,
including use of psychiatric symptoms as the primary outcome rather than affective dysfunction.121
The importance of recovery-orientated services and treatments for people with experience of psychosis or
for people with a schizophrenia diagnosis is in the NICE guideline,30 which emphasises the importance of
recovery-orientated values in the treatment of psychosis and schizophrenia. The Schizophrenia Commission
report122 makes a call for all mental health services working with people with experience of psychosis and
schizophrenia to work in a person-centered approach that embraces the interests and opinions, as well as
the strengths and aspirations of the person with psychosis.
Arguably, the lack of specific focus on outcome measures that evaluate these domains, which are important
to service users, limits any conclusions that can be drawn from previous treatment studies, both psychological
and pharmacological. Similarly, trials that use symptom-focused measures, such as the PANSS, often fail to
demonstrate clinically significant change, even if treatments demonstrate statistical superiority. This has
led to attempts to define clinically significant response,123 and meta-analyses of trials often use a > 50%
improvement on the PANSS as an operational definition of a good outcome.32
Summary
To summarise, there is clear evidence from the CBT trials that people with TRS and CRS can be engaged
in CBT, and that CBT can have small to moderate effects on overall symptoms and may be particularly
beneficial for auditory hallucinations. However, it has been highlighted in a 2014 meta-analysis69 that
the large and methodologically robust trials of CBT for psychosis have not demonstrated a significant
advantage of CBT for either symptoms or relapse, and to date there have been no large high-quality
trials of CBT for people with CRS. Moreover, CBT trials have been criticised for poor reporting of adverse
effects,124 and future trials should report adverse effects as an outcome. Klingberg et al.125,126 have provided
a useful template for assessing adverse effects that includes death caused by suicide, suicide attempt, suicidal
crisis [as defined in the Calgary Depression Rating Scale for Schizophrenia (CDSS), item 8, rating 2] and severe
symptomatic exacerbation, defined by the Clinical Global Impression (CGI) scale, which includes ratings of
illness severity, changes in overall clinical status, and therapeutic effects. In addition, further research is
needed to identify factors that predict a good outcome from CBT.
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Rationale for the research/trial aims and objectives
The objectives of this RCT were to provide evidence of the clinical effectiveness and cost-effectiveness of
CBT for people with CRS and to utilise baseline data from the RCT to develop a risk model that identifies
factors that predict good outcome from CBT. Using the patient-level data available from the trial, the
objectives for the economic evaluation were to:
l estimate the costs of health and social care in the intervention and TAU groups, and assess whether or
not there were differences between the groups
l estimate the quality-adjusted life-years (QALYs) of participants in the intervention and TAU groups,
and assess whether or not there were differences between groups
l assess whether or not any additional benefit is worth any additional cost.
The research objectives of this RCT were to test the following hypotheses:
l In people with a diagnosis of a schizophrenia spectrum disorder who have an inadequate response to
or are unable to tolerate clozapine, CBT plus TAU will lead to improvement in psychotic symptoms,
measured using a psychiatric interview (PANSS) over a 21-month follow-up period compared with
TAU alone.
l Cognitive–behavioural therapy plus TAU will lead to improved quality of life and user-defined recovery
compared with TAU alone.
l Cognitive–behavioural therapy plus TAU will lead to a reduction in affective symptoms and negative
symptoms compared with TAU alone.
l Cognitive–behavioural therapy plus TAU will be cost-effective compared with TAU alone.
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Chapter 2 Methods
Trial design
The FOCUS trial was a parallel-group, randomised, outcome-blinded evaluation (PROBE) to evaluate the
addition of a standardised CBT intervention to TAU for individuals who are unable to tolerate or have had
an inadequate response to clozapine. The comparison group received TAU only. The trial was intended to
be a definitive, pragmatic clinical effectiveness and cost-effectiveness trial. It was conducted over 4 years
across five sites within the UK, with recruitment commencing on 1 January 2013 and ending on 1 June 2015.
The follow-up phase for the trial ended in February 2017. A copy of the full ethics-approved trial protocol
can be found on the project web page: www.journalslibrary.nihr.ac.uk/programmes/hta/1010102#/.
In addition, the study protocol has been published in a peer-reviewed journal.127
Role of funding source
The FOCUS trial was funded as a result of a National Institute for Health Research (NIHR) Health
Technology Assessment-commissioned call. The call specified the design in PICO (population, intervention,
comparator and outcome) terms, requiring that the population be patients with schizophrenia who had
not responded to an adequate dose of clozapine or were unable to tolerate it, the intervention was CBT,
the comparator was TAU and the outcome was psychiatric symptoms.
Approval
The National Research Ethics Service (NRES) Committee North West – Lancaster (reference 12/NW/0520)
approved the FOCUS trial. Ethics approval was granted on 13 August 2012. The trial was also registered
on the International Standard Randomised Controlled Trial Number (ISRCTN) clinical trial registry (reference
ISRCTN99672552). The trial was registered on 29 November 2012, before recruitment was started in
January 2013.
Trial sites
The study was conducted in secondary care mental health services (community mental health, residential
rehabilitation and inpatient settings) at five UK centres. These were (1) Manchester, (2) Edinburgh,
(3) Glasgow, (4) Newcastle upon Tyne and (5) Southampton.
Participants
A total of 487 participants were recruited across the five sites between 1 January 2013 and 1 June 2015.
The Manchester site recruited 108 of the total participants, Southampton recruited 105, Edinburgh
recruited 94, Newcastle upon Tyne recruited 92 and Glasgow recruited 88. Participants were recruited
from a range of services and settings including community mental health teams (CMHTs), early intervention
teams, recovery teams and inpatient services.
Inclusion and exclusion criteria
Participants were eligible to take part in the FOCUS trial if they were considered to have had an inadequate
response to a trial of clozapine treatment, specifically treatment with clozapine at a stable dose of ≥ 400 mg
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(unless limited by tolerability) for ≥ 12 weeks, or, if currently augmented with a second antipsychotic, for
≥ 12 weeks, without remission of psychotic symptoms. This criterion was selected as a review of medication
trials found 400 mg to be the minimum dose necessary for effective treatment with clozapine.128 Other
clinical trials looking at CRS have employed the same criteria.52 Alternatively, participants were eligible for
the trial if they had discontinued clozapine in the preceding 2 years because of side effects, lack of efficacy
or a problem identified during routine blood monitoring appointments.
Participants were also required to have been given an ICD-10 diagnosis on the schizophrenia spectrum,
or to meet criteria for an Early Intervention in Psychosis (EIP) service.
To be included, participants were also required to achieve a minimum total score on the PANSS of 58
(equivalent to a CGI scale of at least mild difficulties),129 as well as a score of ≥ 4 on items for delusions or
hallucinations, or of ≥ 5 for items on suspiciousness or grandiosity, to ensure that symptoms of psychosis
had not remitted. The research assistant (RA) assessed this at baseline. Participants had to be aged
≥ 16 years and have an identified care co-ordinator or consultant psychiatrist. In additional, participants
were required to be competent and willing to provide written informed consent to take part.
Exclusion criteria were having a primary diagnosis of substance or alcohol dependence if this could be the
cause of the psychotic experiences, having a diagnosis of developmental disability or organic impairment
and being non-English-speaking. Individuals who were currently receiving or had received structured CBT
from a qualified psychological therapist within the preceding 12 months were also excluded from the trial.
This was operationalised as CBT delivered in line with the NICE guidelines30 for the treatment of psychosis
and schizophrenia as ≥ 16 sessions of CBT that is delivered in line with a CBT treatment manual.30
Data collection
In accordance with the approved protocol, potential participants were initially informed about the study by
a member of their care team and, if they expressed interest, were asked to consent to being contacted by
the FOCUS trial research team. If they did so, a member of the research team briefly described the study
and sent the participant information sheet (PIS) by post. The individual was then given a minimum of
24 hours to consider the information. Following this, the RA arranged to meet the participant at a place
of their choosing; in the majority of cases this was the participant’s own home. Some preferred to meet
within a mental health service or, if there were any possible risk issues, a meeting at a NHS site would be
arranged. Participants who were current inpatients were visited on the ward. The RA talked through the
PIS with the individual and ensured that the information was understood by asking the participant to
reflect it back to them. When both the RA and the participant were satisfied that all the information
about the trial had been provided and understood, the participant was asked to sign the consent form.
The RA then read through each point and the participant initialled the boxes provided if they agreed to
the information. Both the RA and the participant signed their names underneath.
The RA would then commence the baseline assessment. In the majority of cases, this was conducted
across two visits, but this was at the participant’s preference. On average, to complete all assessment
measures in full would take approximately 2 hours. The assessment would begin with the PANSS interview
and then move on to the self-report measures (outlined below). Each participant was also provided with a
personalised crisis card at the baseline assessment. This included contact details for their care team and
general practitioner (GP) as well as other helpline numbers, such as the Samaritans. Finally, participants
were compensated with £10 for their time and contribution to the research process.
Face-to-face follow-up assessments were completed at 9 and 21 months. The participant was contacted
by telephone and an appointment was arranged. Ongoing consent was confirmed with participants at each
follow-up. The RA conducted a PANSS interview and asked the participant to complete the self-report measures
METHODS
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at each of these time points. Participants were compensated £10 for their time and contribution to the research
process at these time points.
Follow-up assessments were completed by telephone at 3, 6, 13 and 17 months. These telephone
assessments focused only on obtaining health economics data – no clinical outcome data were collected.
The participants were sent £5 gift vouchers in the post on completion of these follow-ups. ‘Keeping in
touch’ cards were also posted to the participant on two occasions between these telephone calls.
Outcome measures
Primary outcome
Although there is considerable debate regarding the most appropriate or important outcome measures
(e.g. whether to focus on specific psychiatric symptoms or broader recovery and quality of life), the FOCUS trial
was funded as a result of a commissioned call that specified the PICO. The commissioned call specified the
important outcome as psychiatric symptoms and, therefore, PANSS,130 a reliable and valid, semistructured
interview to assess the severity of symptoms associated with psychosis, was chosen as the primary outcome.
It is widely used as the primary outcome measure in studies of treatments for people with a schizophrenia
diagnosis and research indicates that a 15-point change on the total PANSS score translates to minimal
clinical improvement.123 This allows comparison with other published trials and inclusion of these results in
any future systematic reviews and meta-analyses of treatment evidence. PANSS has 30 items that are scored
between 1 (absent) and 7 (extreme), and includes seven items that map on to the positive symptoms (such as
hallucinations and delusions), seven items relating to negative symptoms (such as blunted affect and emotional
withdrawal) and 16 items assessing general psychopathology (such as anxiety and depression). This three-factor
model of PANSS was originally proposed by Kay et al.130 However, multiple-factor structures have been
suggested for PANSS, including the original three-factor model, a four-factor model and, more commonly, a
five-factor model.131 Using confirmatory factor analysis on a large data set (n= 5769), van der Gaag et al.131
tested the fit of 25 published five-factor models; the results indicated that it was not possible to find a fit of
these models. Further analysis of the same data set using a 10-fold cross-validation identified a five-factor
model with the following subscales: (1) positive, (2) negative, (3) agitation–excitement, (4) depression–anxiety
and (5) cognitive.132 This model of PANSS was used for the FOCUS trial. As the PANSS has a 1 (absent) to
7 (severe) rating scale, each participant is allocated a minimum score of 30 even if they have no symptomology.
As noted by Leucht et al.,133 this poses a significant challenge to understanding percentage change on PANSS,
as percentage change is underestimated if 30 minimum points are not subtracted from the total score before
calculating percentage change. Therefore, for the analysis of PANSS percentage change for the FOCUS trial,
we rescaled the PANSS as recommended by Leucht et al.133 The commissioned call specified that the minimum
duration of follow-up should be 12 months. The primary outcome was therefore specified as PANSS total score
at 12-month follow-up from the end of the 9-month treatment window.
Secondary outcomes
Positive and negative symptoms
These were measured by PANSS as described in the preceding section.
Hallucinations and delusions
The PSYRATS134 is a semistructured interview consisting of 12 items assessing aspects of voice-hearing,
such as frequency, volume, distress and disruption caused, and six items assessing aspects of unusual
beliefs, such as preoccupation, distress and disruption. All items are scored from 0 to 4, with higher
scores indicating greater severity. Both sections include cognitive and emotional subscales, and the voices
section also includes a physical subscale.
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Recovery
The Process of Recovery Questionnaire (QPR) was developed in collaboration with service users to assess
recovery from psychosis.135 A shortened 15-item version was used here.136 Participants respond using a
five-point scale ranging from ‘disagree strongly’ to ‘agree strongly’. Items include ‘I feel better about
myself’ and relate to the preceding 7 days.
Social and occupational function
The Personal and Social Performance (PSP) scale137 assesses functioning in four key areas: (1) socially
useful activities, (2) personal and social relations, (3) self-care and (4) disturbing and aggressive behaviour.
A score is allocated out of 100, with higher scores indicating better functioning.
Depression
The CDSS138 is a structured interview measure with nine items. The items include assessment of
hopelessness, feelings of guilt and suicidal ideation. For each section, the assessor can score the client
between a score of zero (absent) and three (severe). Therefore, possible scores range from 0 to 27.
The measure was incorporated into the PANSS interview during the assessment of depression.
Anxiety
The Anxious Thoughts Inventory (AnTI)139 is a 22-item, self-report questionnaire designed to measure
aspects of worry. Each question is scored from one (almost never) to four (almost always). The measure has
a three-factor structure comprising (1) social worry, (2) health worry and (3) meta-worry. The seven-item
meta-worry scale only was included in the FOCUS trial. This subscale includes statements, such as ‘I worry
that I cannot control my thoughts as well as I would like to’.
Substance use
The Alcohol Use Disorders Identification Test (AUDIT) was developed by the World Health Organization
(WHO). It consists of 10 questions relating to alcohol use, with cut-off scores to identify hazardous
drinking levels. Scores range from 0 to 4 on each item, with total AUDIT scores ranging from 0 to 40.140
The higher the score, the more severe the alcohol use-related problems. AUDIT has been found to be
reliable when used with participants with first-episode psychosis.140
The Drug Abuse Screening Test (DAST)141 consists of 10 items relating to recent drug use. Participants are
asked to provide a dichotomous yes/no response to such questions as ‘Are you always able to stop using
drugs when you want to?’. DAST has been found to reliably identify substance abuse issues in participants
with first-episode psychosis.140
Clinical Global Impression
The CGI consists of three items, each scored on a seven-point scale. The RA was required to rate the
severity of the participant’s current difficulties from one (not at all ill) to seven (extremely ill). This was
completed at all time points. At 9 and 21 months only, the RA also rated change in the participant’s
presentation since baseline. This was rated from one (very much improved) to seven (very much worse).
In addition, at each time point, the participant was asked to rate the perceived severity of their own
difficulties from one (no mental health problems) to seven (very severe mental health problems).
Measurement of adverse events and effects
To ensure a thorough review of adverse events (AEs) and effects, we used a number of methods to
identify and report AEs including Health Research Authority (HRA) standard operating procedure (SOP),
guidance from our Trial Steering Committee (TSC) and Data Monitoring and Ethics Committee (DMEC)
and guidance recommended by Klingberg et al.126 and a bespoke patient-rated adverse effects measure,
developed for the FOCUS trial. Each will be outlined in more detail.
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The HRA requires all non-Clinical Trials of an Investigational Medicinal Product (CTIMPs) to report
the following AEs, when the chief investigator considers the event related and unexpected: death,
is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent
or significant disability or incapacity, consists of a congenital anomaly or birth defect and is otherwise
considered medically significant by the investigator. In addition to this list of AEs, our DMEC and TSC
advised that self-harm and harm to others also be included. All such events were reported by RAs and
therapists to the chief investigator. As per HRA policy, serious adverse events (SAEs) were reported to
the Research Ethics Committee (REC) if they were deemed by the chief investigator to be related to
trial proceedings and unexpected. To minimise the potential for bias, all AEs were also reviewed by an
independent clinician who was a member of the independent DMEC. If the independent clinician
considered the event both related and unexpected, then it was reported to the REC.
In addition to the above, for the purpose of the trial, we also defined adverse effects in the trial protocol in
line with Klingberg et al.125,126 as:
1. death caused by suicide
2. suicide attempt
3. suicidal crisis (explicit plan for serious suicidal activity without suicide attempt) as defined in CDSS,
item 8, rating 2)
4. severe symptomatic exacerbation, defined by the CGI, which includes ratings of illness severity, changes
in overall clinical status, and therapeutic effects. A rating of CGI 2 as six or more and CGI 1 as six or
more would be regarded as a severe AE.
In order to better evaluate the adverse effects of trial participation, the adverse effects measure was
developed for the FOCUS trial. Participants rated 27 statements on a five-point scale from ‘not at all’ to
‘very much’. Statements included ‘taking part took up too much time’ and ‘I did not like or feel I could
trust the FOCUS team members’. A free-text box was also provided for participants to record any
additional details about their experience of taking part in the FOCUS trial. This measure was either
provided following the final assessment, or at the point of withdrawal for participants who left the trial
early. The measure was completed anonymously and was optional.
Other measures including psychological processes
Appraisals of voices
The Interpretation of Voices Inventory (IVI)142 is a 26-item measure consisting of cognitive and
metacognitive appraisals of voice-hearing. The IVI has three subscales that relate to (1) positive beliefs
about voices, (2) metaphysical beliefs and (3) beliefs about loss of control. Participants respond on a
four-point scale from ‘not at all’ to ‘very much’ to indicate how much they endorse each belief. Items
include ‘they will take over my mind’ and ‘they are a sign that I am evil’.
Appraisals of paranoia
The Beliefs about Paranoia Scale143 contains 18 items relating to paranoia, such as ‘my paranoid thoughts
worry me’ and ‘paranoia is normal’. The scale has been found to have three subscales, namely (1) negative
beliefs about paranoia, (2) beliefs about paranoia as a survival strategy and (3) normalising beliefs. The
three-factor structure has been validated in a large clinical sample.144
Beliefs about self and others
The Brief Core Schema Scale (BCSS)145 is a 24-item measure assessing beliefs about self and others. It
consists of four subscales: (1) positive beliefs about self, (2) negative beliefs about self, (3) positive beliefs
about others and (4) negative beliefs about others. Participants respond ‘yes’ or ‘no’ to a question about
whether or not they endorse each belief and then, if they reply ‘yes’, state how much they believe this on
a scale from 1 (believe it slightly) to 4 (believe it totally).
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Working memory
The letter–number span (LNS)146 was completed at baseline and 9 months only and was read aloud to the
participant by the RA. In this test, a participant is presented with a string of letters and numbers and asked
to respond by reciting first the numbers in ascending numerical order and then the letters in alphabetical
order. The sequences provided begin with two items (e.g. D-6) and increase until they are seven items long
(e.g. C-7-G-4-Q-1-S). There are four sequences of each length and the test is stopped when the participant
answers all four of any one length incorrectly. The highest possible score is 24.
Attachment
The Psychosis Attachment Measure (PAM-SR)147 is a 16-item measure of adult attachment styles that was
developed specifically for use with individuals with psychosis. The PAM-SR has two subscales relating to
anxious attachment and avoidant attachment styles. It has been found to be a reliable and valid measure.147
Stigma
The Internalised Stigma of Mental Illness (ISMI) scale148 assesses the individual’s experience of stigma.
It consists of 29 items, each rated on a four-point scale between strongly disagree and strongly agree.
The measure includes items such as ‘others think that I can’t achieve much in life because I have a mental
illness’. It has five subscales – (1) alienation, (2) stereotype endorsement, (3) perceived discrimination,
(4) social withdrawal and (5) stigma resistance – and has been found to be reliable and valid.148
Childhood trauma
The Childhood Trauma Questionnaire (CTQ)149 was designed to retrospectively assess childhood trauma.
It has 28 items on a five-point scale, ranging from ‘never true’ to ‘very often true’. It consists of five
subscales – (1) physical abuse, (2) emotional abuse, (3) sexual abuse, (4) emotional neglect and (5) physical
neglect – and is thought to be a reliable and valid measure.149 This measure was administered at 9 months
only and delivered in line with a protocol developed in collaboration with members of a service user
reference group for managing any distress that could arise from completing this measure. Participants
were all offered a list of support services in relation to experience of abuse and offered a follow-up
telephone call for the next day.
Semistructured clinical interview for psychosis subgroups
The semistructured clinical interview for psychosis subgroups (SCIPS)150 assesses areas of life and events
before the onset of psychotic symptoms. The items cover psychosocial factors and comorbid conditions
that have been proven to be associated with psychosis to allow for the classification of a specified subgroup:
traumatic, drug related, anxiety or stress sensitivity. SCIPS was administered at 12-month follow-up
(21 months) for participants who reached this time point by October 2015; all other participants completed
SCIPS at the end-of-treatment assessment (9 months).
Demographic characteristics were captured for each participant at baseline. These included years in
full-time education, ethnicity, the participant’s estimate of their DI and duration of untreated psychosis (DUP).
Participants were also asked if they considered themselves to be experiencing mental health problems.
If they agreed with this, they were asked to rate the degree to which they felt their difficulties to be caused
by biological/genetic origins or by life stress/problems or experiences. At each assessment time point, a record
was taken of a participant’s current medication. This included dose and duration of time taking clozapine or
duration of time since discontinuation of clozapine and the reason for discontinuation. Augmentation with
a second antipsychotic was also recorded, as well as other medications for both mental and physical health.
Unless specified above, each outcome measure was administered at baseline and subsequently at 9 and
21 months by RAs who were trained in the use of all the instruments and scales.
Participants were offered choices regarding the length of the assessments, including the option of breaks
and multiple visits.
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Economic assessment
Health economics
At each face-to-face assessment, and additionally at assessment by telephone at 3, 6, 13 and 17 months,
an economic patient questionnaire (an assessment of health service receipt) was completed with each
participant. See Chapter 5 for more detail regarding this measure. For those participants who received
psychiatric inpatient care during the trial, a psychiatric hospital record was also completed by screening
their medical records for services received while hospitalised.
The EuroQoL-5 Dimensions (EQ-5D)151 health questionnaire assesses health outcomes and can be used
across a range of health conditions. Participants are asked to rate each item in relation to their health on
that day. The items rated are mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Participants then rate their health that day between 0 (the worst health imaginable) and 100 (the best
health imaginable). The EQ-5D has been found to have acceptable validity among participants with a
schizophrenia diagnosis.152
Trial interventions
The intervention to be assessed was CBT. This was delivered by appropriately qualified psychological
therapists over a 9-month period. Therapists were employed at NHS band 7, which is the starting point
for most psychological and nurse therapists and is representative of CBT delivered within NHS services.
Participants were offered up to 30 hours of CBT on an approximately weekly basis during the treatment
window. The sessions were provided on an individual basis. Most therapy appointments were delivered in
the participants’ own homes to help increase the acceptability and accessibility of the intervention.
The CBT was based on a specific cognitive model63 and was manualised.104 For a more detailed outline of
the intervention, see Pyle et al.127 The specific CBT interventions used were dependent on the individual
formulation, but had to be consistent with the intervention model. The range of permissible interventions
was provided in published treatment manuals.64,153 The therapy was flexible, but aimed to involve four
phases: (1) assessment, engagement and formulation, (2) change strategies, (3) longitudinal aspects and
(4) consolidation. Key milestones were included in each phase. The aims of CBT were to reduce distress
(particularly that associated with psychotic symptoms) and to improve quality of life, often by changing the
impact of psychotic experiences and beliefs. The CBT was delivered in a collaborative relationship between the
participant and therapist and addressed the problems and goals that were agreed between the participant
and therapist. Therefore, target of treatment could include positive symptoms of psychosis, social relational
issues and issues of comorbidity including anxiety and depression. Key therapeutic principles included
formulation, normalisation, collaboration and evaluation of the client’s appraisals of and responses to
psychological phenomena.
There was an emphasis on encouraging participants to undertake between-session practice, as research
evaluating components of CBT as mechanisms for change suggests that CBT is more effective if
between-session tasks are used.154
By the third session it was expected that there would be a shared list of problems and goals, and shared
formulation. It was expected that, by session 12, there would be a shared longitudinal formulation.
Milestones regarding formulation were important given the evidence to suggest that formulation is a core
component of CBT.154
Fidelity to the treatment manual
The therapists received weekly CBT-style clinical supervision from the central site to ensure fidelity to the
treatment protocol. Additional fortnightly clinical supervision was provided by clinical supervisors, or
research site leads, to deal with site-specific clinical issues and ensure that local governance arrangements
were followed. All central and local clinical supervisors had expertise and appropriate training in CBT.
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To ensure fidelity to the treatment protocol and assess the quality of the therapy delivered, trial therapists
regularly submitted audio-recordings of FOCUS trial therapy sessions. These sessions were rated on the
Cognitive Therapy Scale – Revised (CTS-R) by the therapist’s central supervisor and detailed feedback was
provided. Emphasis was placed on therapists submitting sessions across a range of participants, including
sessions that they may be finding difficult as a result of obstacles (e.g. thought disorder). At quarterly
therapist training days, group-based CTS-R therapy session ratings were carried out. Therapy sessions were
attended by trial therapists, clinical supervisors, the principal investigator and site leads. All trial therapists
received a group CTS-R rating at least once.
Fidelity to the treatment protocol was also monitored by analysing data on the content of the CBT
sessions. Following every CBT session, based on the treatment protocol, therapists completed a record
sheet designed to capture the key elements of CBT (e.g. agenda setting, homework setting/review) and
what specific CBT strategies were used with the client (e.g. developing a maintenance formulation, specific
cognitive, behavioural and meta-cognitive change strategies). Data were analysed to see if the milestones
in the treatment protocol were being met (e.g. a maintenance formulation by session 4) and to check for
any site differences in fidelity to the treatment protocol. At each therapist training day, the analysis of the
fidelity data were presented and discussed.
The control condition was TAU. Referrers were not asked to withhold any treatment. All participants were
required to have an allocated keyworker or care co-ordinator and, therefore, should have been receiving
regular outpatient follow-up from a multidisciplinary team within secondary mental health services or from
an inpatient setting.
Research assistant training and supervision
All RAs received initial training in the outcome measures from the FOCUS trial co-applicants and the
trial manager. Initial training on PANSS was delivered by a PANSS Institute certified trainer who was a
co-applicant on the FOCUS trial (Professor Thomas Barnes). RAs were required to complete role plays of
the PANSS interview and be observed by a senior clinician before conducting the PANSS interview with
participants. In addition, RAs were required to demonstrate a minimum interclass correlation co efficient
(ICC) of 0.80 on the PANSS gold standard rating provided by Professor Barnes. In addition to training on
the outcome measures, RAs were also given training from senior clinicians in clinical risk assessment, and
conducting clinical assessment and supporting service users who disclose trauma and abuse (given the use
of the CTQ at the end-of-treatment assessment). All RAs were required to complete Good Clinical Practice
training from NIHR.
All RAs were supervised by the trial manager on a weekly basis. As the FOCUS trial was a multisite RCT,
this supervision was done over the telephone, except in Manchester where it was completed face to face.
The agenda for trial management supervision had a specific focus on the recruitment and retention of
participants, data quality and assurance (in particular a check on the accuracy of PANSS scores) and a
review of blind breaks, withdrawals and SAEs. Trial management supervision provided an opportunity to
problem-solve recruitment and retention difficulties, assurance with data quality and systematic reporting
of blind breaks and evaluation of how to minimise future breaks and systematic reporting of withdrawals
and SAEs. All RAs attended a fortnightly group conference with the trial manager to share learning and
best practice regarding recruitment and to ensure consistency across the sites in scoring the primary
outcome measure. In addition, RAs received local clinical supervision from the principal investigator at
their site. This covered clinical assessment and risk management, compliance with local NHS policy and
procedure, and time management.
Research assistant PANSS consensus days were held on 14 occasions over the lifetime of the trial. At
PANSS consensus days, the RAs were required to independently rate a PANSS interview. The ICC across all
RAs’ ratings was calculated for each PANSS consensus day. The mean ICC was 0.83 [standard deviation
(SD) 0.06] using single measures and 0.96 (SD 0.04) using average measures, demonstrating a good level
of inter-rater reliability across the FOCUS trial assessors.
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Randomisation and blinding
Randomisation (at the individual level) was independent and concealed, using randomised permuted blocks
of random size (blocks of four or six) and stratified by site. The Centre for Healthcare Randomised Trials
(CHaRT), Health Services Research Unit, University of Aberdeen, a fully registered (registration number 007)
UK Clinical Research Collaboration Clinical Trials Unit (CTU), provided advice regarding the development of
the randomisation algorithms and was also consulted regarding the web-based technology. Randomisation
was undertaken using OpenCDMS (Open Clinical Data Management System), a web-based system developed
with the Mental Health Research Network that has been successfully used in several multisite trials. Utilising
this web-based technology ensured that randomisation was centralised, preventing the investigators who
were enrolling participants from predicting the randomisation sequence and, therefore, avoiding selection bias.
Assessors were blind to treatment allocation. Masking was maintained using a wide range of measures,
such as separate offices for therapists and researchers; protocols for answering phones, message taking and
secretarial support; separate diaries; and security for electronic randomisation information. When accidental
blind breaks did occur, these were reported to the trial manager, and, when possible, a second RA who
remained blind to allocation independently rated the assessment. The DMEC and TSC regularly monitored
blind breaks by each centre, and implemented corrective action if necessary. Outcome analyses were repeated,
excluding those participants for whom a blind break had occurred, to determine the robustness of the findings.
Following baseline assessment, eligible participants were randomised within 2 working days. Each randomised
allocation was made known to the trial manager (in order to monitor adherence to the randomisation
algorithm), the trial administrator and trial therapists by e-mail. The allocation was also made known to the
participant by letter, sent by the trial administrator. Blinding of the allocation code was maintained for RAs
until all outcome measures for all participants had been collected.
Patient and public involvement
Two co-applicant members of the trial management group are employed as user–researchers (SS and RB).
Both contributed to the development of the study protocol, and to oversight of the study during the
lifetime of the trial through regular attendance at trial management meetings and involvement with
training staff. These two co-applicants also wrote the end-of-study information sheet for participants.
In addition, both the trial DMEC and TSC include a service user representative. All trial-specific materials,
such as PISs, were developed with patient and public input from the Psychosis Research Unit Service User
Reference Group (SURG), the members of which all have experience of psychosis. A key example of the
SURG members’ valuable contribution was the recommendation for a standardised protocol for managing
distress arising from sensitive disclosures during trial assessments. This included offering a telephone contact
within 48 hours of assessments to check on well-being. Along with the key patient and public involvement
(PPI) contributions described above, Rory Byrne and Suzy Syrett along with a third user-researcher
(Caroline Asher) also undertook an add-on qualitative study to evaluate trial participants’ experiences of
CBT. All qualitative interviews, transcriptions and analyses for this study were user led.
Change to the protocol
During the lifetime of the trial, some aspects of the original protocol were changed. All changes were
approved by the DMEC, TSC, funder and REC. A summary of these changes can be found in Table 1.
Statistical methods and trial analysis
Ground rules for the statistical analysis
The trial analysis followed a statistical analysis plan (SAP), which was agreed by the DMEC. The SAP was
published on the CTU’s website in advance of pre access to data and, therefore, pre analysis and can be
found at http://w3.abdn.ac.uk/hsru/chart/publicfiles/sapfocus.pdf (accessed 23 November 2018).
The main analyses were based on the intention-to-treat (ITT) (i.e. analyse as randomised) principle and took
place after full recruitment and follow-up. Baseline and follow-up data were summarised using appropriate
descriptive statistics and graphical summaries. Statistical significance was at the two-sided 5% level with
corresponding confidence intervals (CIs) derived. There was no adjustment for secondary outcome CIs for
multiple testing. All analysis was done using Stata® version 14 software (StataCorp LP, College Station, TX, USA).
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Sample size
The FOCUS trial was designed to estimate treatment effects across a range of outcomes, in addition to
psychiatric symptoms. Therefore, we powered the study to detect a generic ES of 0.33. A sample size of
194 participants per group was required to provide 90% power to detect a difference in means using a
t-test with a significance level of 5%. To allow a drop-out rate of 20%, 485 participants (97 per site)
were required.
TABLE 1 Details of the protocol amendments approved by NRES Committee North West – Lancaster
Details of the protocol amendment Protocol version
Date of approval
by the REC
Change of inclusion criteria specifically relating to clozapine augmentation
with another antipsychotic medication from ‘Treatment for ≤ 24 weeks at
a stable dose of ≥ 400mg of clozapine a day, unless the size of the dose
was limited by side effects, without remission of psychotic symptoms,
or have discontinued clozapine because of adverse reactions (including
agranulocytosis) or lack of efficacy in the past 24 months’ to ‘Treatment
of clozapine at a stable dose of ≥ 400mg or more (unless limited by
tolerability) for ≤ 12 weeks, or if currently augmented with a second
antipsychotic that this has been given for at least 12 weeks, without
remission of psychotic symptoms, or have discontinued clozapine because
of adverse reactions (including agranulocytosis) or lack of efficacy in
the past 24 months’. The number of items in the economic patient
questionnaire was reduced (time use items removed as these were not
necessary for the economic evaluation). The version of the EQ-5D was
updated to the most current five-point version and the QPR was reduced
to the 15-item version (following publication of a confirmatory factor
analysis indicating that the 15-item version was a better model for this
measure)
V2, 1 November 2012 4 December 2012
Changes to the protocol that related to (1) notifying teams of the
outcome of randomisation and (2) reflecting the change in the CTU from
Glasgow to Aberdeen
V3, 4 February 2013 21 March 2013
Inclusion of three measures: (1) CGI scale (patient and rater version),
(2) measure of memory (Maryland LNS) and (3) the adverse effects measure
(A and B for completers and early discontinuation). Addition of a nested
qualitative study in the trial to assess the acceptability of CBT
V4, 18 August 2013 2 September 2013
Addition of the SCIPS and £10 token of appreciation for the participants
who take part in the nested qualitative study
V5, 19 March 2014 9 May 2014
Removal of Heinrichs Quality-of-Life Scale. Owing to an administrative
error, when the battery of assessments was initially collated, the Heinrichs
Scale was taken from the appendix of the original publication, which only
contained four items, instead of 21 items. This mistake was not identified
and, therefore, at the time the amendment was submitted only four items
had been administered to FOCUS trial participants. There were a number
of other secondary outcome measures that related conceptually to quality
of life, including the Personal, Social and Performance Subscale, the QPR
and the EQ-5D. It was agreed with the independent DMEC, TSC and
funder that we should remove this measure. Change to the protocol also
included inviting participants at the end of the final assessment (21 months)
who were at the Manchester site to take part in an experimental study
looking at the impact of manipulating response styles on distress and
frequency of words detected in an ambiguous auditory task. In addition,
three self-report measures of perseverative thinking, rumination and
anxiety were added at the final assessment (21 months) for the Newcastle
upon Tyne site only
V6, 30 April 2015 20 May 2015
Addition of a nested qualitative study with the trial therapists to explore
the therapists’ experiences and views of delivering Cognitive Behavioural
Therapy for Psychosis (CBTp) on the FOCUS trial
V7, 27 June 2016 26 July 2016
V, version.
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Primary and secondary outcome analyses
The primary outcome, PANSS total score assessed at 21 months, was analysed using a linear model with
adjustment for prespecified baseline covariates (baseline score, sex and age) and including a random
effect for site. Treatment effects over time were explored using repeated-measures mixed-effects models.
A sensitivity analysis of missing PANSS data was conducted; these models explored the robustness of the
treatment estimates, imputing missing outcome data using multiple imputation.155 If baseline PANSS data
were missing, data were imputed with the centre specific mean.
Secondary outcomes were analysed in a similar way using a linear model and adjusted for prespecified
baseline covariates; for the CGI improvement score, no adjustment for baseline score was made as this
was not collected.
Planned subgroup analysis
Subgroup analyses explored the potential moderating effect of covariates through the use of treatment-by-
subgroup interactions. The subgroups explored were as follows:
l age
l sex
l positive and negative core beliefs from the BCSS
l working memory using the LNS
l trauma in childhood using CTQ collected at 9 months
l substance use from DAST
l alcohol use from AUDIT
l difficulty with abstract thinking using item N5 on the PANSS questionnaire
l conceptual disorganisation using item P2 on the PANSS questionnaire
l duration of illness
l duration of untreated psychosis
l age at onset of psychotic symptoms
l dose of clozapine
l number of antipsychotic drugs prescribed
l attachment using the attachment avoidance subscale taken from PAM-SR
l psychosis subgroups.
All subgroups were captured at baseline unless otherwise stated.
Risk modelling
We modelled response to treatment, defined as change in PANSS total score from baseline to 21 months,
using a general linear model. The baseline covariates included age, age at onset, DI, duration of untreated
psychosis, number of antipsychotics, dose of clozapine, PANSS items on conceptual disorganisation and
difficulty in abstract thinking, sex, memory and treatment allocation. We explored the impact of missing
data at 21 months using a range of strategies, for example using 9-month data if available and multiple
imputation based on observed covariates.
Complier-average causal effect analysis
We used instrumental variable methods to estimate the complier-average causal effect (CACE) to explore
the impact of compliance with allocated treatment on effect estimates. We considered six or more sessions
as a measure of compliance. Randomisation was used as the instrumental variable.
Timing and frequency of analysis
A single principal analysis was carried out when the final participant reached the 21-month time point.
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Economic evaluation methods
Aims and objectives
The economic evaluation was a within-trial analysis using patient-level data collected during baseline and
follow-up FOCUS trial time points. The aim was to estimate the cost-effectiveness of usual care plus CBT,
relative to usual care alone, for people unable to tolerate, or with an inadequate response to, clozapine,
in a UK secondary care setting.
Using the patient-level data available from the trial, the objectives for the economic evaluation were to:
l estimate the costs of health and social care in the intervention and TAU groups and assess whether or
not there were differences between groups
l estimate the QALYs of participants in the intervention and TAU groups and assess whether or not there
were differences between groups
l assess whether or not any additional benefit is worth any additional cost.
Descriptive analysis and data manipulation was conducted using IBM SPSS (Statistical Product and Service
Solutions) Statistics version 23 (IBM Corporation, Armonk, NY, USA). The main statistical analyses and
estimation of net benefit statistics and cost-effectiveness analysis were conducted using Stata® version 13.
Intervention and comparator, study sample, time horizon and perspective
The study sample comprised all of the participants randomised in the trial. The time horizon of the economic
evaluation was 21 months (in line with the final trial follow-up). Costs, QALYs and the secondary outcome
measures were estimated from baseline to the end of the scheduled follow-up, to estimate the incremental
cost-effectiveness of the CBT intervention. The perspectives for the primary analysis were health and social
care service providers (costs) and service users (health benefits). Costs and outcomes were discounted at a
rate of 3.5%, in line with UK guidelines.156
Measure of health benefit
Quality-adjusted life-years were the measure of health benefit used in the primary analysis, on the premise
that the intervention and comparator would have a differential impact on participants’ overall health status.
QALYs were estimated from the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), and associated utility
tariffs157 completed at baseline, 9 months and end of scheduled follow-up (21 months). Resulting health
status profiles were converted to utility values using the most recently published utility tariffs for the EQ-5D-5L
for a UK population.157 These utility values represent the weight of preference for each health state of a
sample of 912 adults in England.
The EQ-5D has been shown to be a valid and responsive measure of health in people with psychosis.152,158
The QALY and the EQ-5D are the measures recommended for economic evaluations by NICE.156 However,
the EQ-5D is not a condition-specific measure, and so may miss differences in symptoms that are important to
service users. Accordingly, the measure of health benefit was varied in the sensitivity analysis.
Total QALYs were estimated as follows:
QALY = Σ ½(Ui + Ui+1)/2 × (ti+1 − ti). (1)
Here, U = utility value and t = time between assessments. The time between assessments is the time
from baseline data collection to 21-month follow-up; this varied by participant. QALY calculations also
accounted for mortality during the trial period.
Resource use and costs
Direct costs of health-care services used by trial participants were estimated for the primary analysis.
The total direct costs of service use for each trial arm were estimated by summing the costs of each
METHODS
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resource used to provide health and social care. Data on the resources used for each participant were
collected using a tailored service use questionnaire at baseline and follow-up (3, 6, 9, 13, 17 and
21 months). The questionnaire was adapted from those used successfully in previous large mental
health-based integrated clinical and economic trials, including two trials of first- and second-generation
antipsychotic drugs in people with severe schizophrenia.159,160 In addition, it was anticipated that use of
psychiatric inpatient care would be a key component of total cost. Accordingly, data on psychiatric hospital
admissions were also collected by case note review. When there were discrepancies between case note
and patient reports on admission or length of stay, the case note review data were used. This was based
on the assumption that the patient report data may be subject to problems of participant recall.
Services covered by the questionnaire included hospital inpatient stays (psychiatric and non-psychiatric),
hospital outpatient visits, primary care services (e.g. GP), community care services (e.g. CMHT) and accident
and emergency services.
The cost of providing CBT in the intervention arm was added to the costs of other services used by
participants to estimate the total costs of TAU plus CBT. The number of CBT sessions attended by each
participant was recorded. The protocol specified that participants would receive up to 30 hours of CBT
(rather than a set number of sessions) as shorter sessions may be more appropriate for some people. CBT
sessions were usually delivered at home; thus, the cost of a home-based CBT session was applied to the
number of sessions to calculate a per-participant cost of CBT.
The unit costs of NHS and social care services were derived from national average unit cost data. These unit
costs are published annually in the NHS reference costs database,161 and in the Unit Costs of Health and
Social Care document published by the Personal Social Services Research Unit (PSSRU), University of Kent.162–164
The price year was 2016 and costs are presented in Great British pounds (GBP).
Missing data
Analysis of the economic data was based on ITT principles, namely that outcome data for all trial
participants were included in the analysis regardless of whether or not the participant completed the
planned treatment. Missing data occurred as a result of both loss to follow-up and incomplete
data collection.
Single imputation was used to impute values for missing baseline data.165 Multiple imputation (MI) was
used to impute missing cost and utility data and passively calculate missing total cost and QALYs for each
participant. MI was used for the primary and sensitivity economic analyses. MI of both costs and QALYs is
increasingly recognised as an appropriate approach to deal with missing observation and missing follow-up
data.166 Missing cost and utility data were treated as missing at random. Missing values were imputed
for each time point, rather than as total values covering the whole follow-up period. To ensure that all
available data were used, we imputed values by health-care category for costs (inpatient, outpatient and
primary/community care) and utility, rather than as total costs or QALYs.
Imputations were conducted in Stata® version 13, using predictive mean matching and sequential chained
equations. The choice of independent variables for the imputation regression models was based on initial
descriptive analyses and regression analyses. These were used to identify key baseline and follow-up variables
(e.g. age, sex, PANSS score) that were significantly associated with either costs or outcomes. These initial
analyses were informed by published literature.159,160
Primary analysis
The incremental cost-effectiveness ratio (ICER) was the primary measure of interest for the economic
evaluation. Rather than considering costs and health outcomes separately, the ICER is a joint measure of
both. It is calculated by dividing the difference in costs (net costs) by the difference in QALYs (net QALYs)
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between any two interventions. For this analysis, the ICER represents the additional cost of CBT per
additional QALY gained compared with usual care.
ICER =
CostCBT – CostTAU
UtilityCBT – UtilityTAU
. (2)
Regression analysis was used to estimate the net costs and QALYs of CBT. Key covariates were included in
the regression models to control for factors that may influence costs or QALYs. The covariates for these
analyses were identified using the approach outlined for the MI described in Missing data.
The estimates of net costs and health outcomes from the regression were bootstrapped156 to simulate
10,000 pairs of incremental cost and QALY outcomes of the FOCUS trial intervention. This captures the
relationship between costs and QALYs and looks at how the pairs of net costs and QALYs are distributed
on the cost-effectiveness plane. This allowed parameter uncertainty to be captured in our economic
evaluation and enabled the undertaking of cost-effectiveness acceptability analysis, which is recommended
by NICE for health technology appraisals.156
The ICER measures the cost per QALY gained by an intervention, which then raises the question of whether
or not the additional cost to service providers of a QALY is economically acceptable. To help address this,
the ICER can be compared with benchmark or threshold values of how much decision-makers may be willing
to pay to gain 1 additional QALY. This is analogous to placing a monetary value on 1 QALY. However,
in the UK there is no universally agreed cost-effectiveness threshold value. One commonly reported threshold
in the UK, from NICE, is approximately £20,000 to £30,000 per QALY.156 However, some argue that this
may have decreased in recent years as expenditure has been constrained.167 In 2013, the threshold was
re-estimated to be £18,317 per QALY (taking into account expenditure breakdown and mortality), although
this was noted to be variable depending on other factors (e.g. disease category and primary care trust).168
In February 2015, this estimate was revised to ≈£13,000 per QALY.169 Recognising this lack of consensus,
the monetary value of our simulated QALYs used a mid-estimate threshold value of £15,000 per QALY
gained. This was varied from £0 to £30,000 to reflect a range of hypothetical thresholds for decision-makers’
willingness-to-pay for an additional QALY [willingness-to-pay thresholds (WTPTs)], from nothing (i.e. they are
interested only in the lowest-cost option) to £30,000.
Each of the net QALY estimates from the bootstrap simulation results was revalued by multiplying it by a
WTPT. Using these revalued QALY estimates, a net benefit statistic for each pair of simulated net costs and
net outcomes was produced as:
Net benefit = (O ×WTPT) – C, (3)
where O is the net outcome score and C is the net cost. This process was repeated for the WTPT values of
interest to generate a cost-effectiveness acceptability curve. For the simulated net cost and QALY pairs, the
cost-effectiveness acceptability curve shows the probability that the intervention is cost-effective for each
WTPT value (i.e. provides a positive net benefit). This probability varies at different ICER threshold values.
For example, if decision-makers are willing to pay more for an additional QALY, the additional health
benefits from an intervention would become more valuable. A cost-effectiveness acceptability curve was
used to plot the proportion of bootstrapped simulations in which the net benefit of an intervention is
equal to or greater than zero for each WTPT value.
Sensitivity analysis
Sensitivity analyses were used to test the impact of the study design on the ICER and results of the
cost-effectiveness acceptability analysis. Table 2 details these.
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TABLE 2 Variables assessed in the sensitivity analysis
Parameters Rationale Measure
Complete-case
analysis
If the level of missing observations for the cost and
QALY measures is high (> 10%), then MI to estimate
these data is more open to bias and imprecision.
Complete-case analysis may also be biased and the
subsample may not be representative of all trial
participants. These factors make it important to analyse
both sets of data and assess whether or not the results
indicate similar conclusions
Costs and QALYs for participants with
complete data at 21-month follow-up
Time horizon It was anticipated that results may vary at different
time horizons, depending on when (if any) effect of
CBT occurred and how long this was sustained for
Baseline to 9 months costs and QALYs
Measure of health
benefits
The EQ-5D-5L is a general measure of health,
recommended for use in economic evaluations to
calculate a generate QALY. However, there is debate
about whether or not this is sensitive to clinically
relevant changes in mental health. Accordingly, the
impact on the results of using mental health-specific
measures was assessed. The alternative health benefit
measures used were clinically relevant improvements
on the PANSS and QPR. The PANSS is a commonly
used scale for measuring symptoms in schizophrenia,
and the primary outcome of the trial. The QPR
captures items of recovery that are important to people
with a psychosis diagnosis
The PANSS and QPR were used to
estimate whether or not participants
had a clinically relevant improvement in
symptoms or recovery at the 25% and
50% levels129
Utility value set to
estimate QALYs
Until recently, utility scores for the EQ-5D-5L were
calculated using a crosswalk method that mapped
values from the three-level version (van Hout et al.170).
In 2016, a new value set, specific to the five-level
version, was released (Devlin et al.157) and was used for
the primary analysis. The crosswalk value set provides a
link between the three- and five-level versions of the
EQ-5D, allowing some comparison between studies
The crosswalk value set was used to
estimate QALYs (van Hout et al.170)
Inclusion of indirect
costs/benefits of
employment
Health measures may not fully reflect the impact of
treatment on non-health aspects that are of benefit to
participants or society. Employment and productive
activity is one such area. To minimise participant
burden, limited information was collected at follow-up
about whether the participant was employed, engaged
in other productive activity or unemployed. Detailed
information about type of paid or unpaid employment
or time spent in different productive activities was not
collected. Accordingly, a measure of whether or not
the participant was engaged in any productive activity
was used to estimate the net cost per person
employed
Whether or not the participant was in
paid or unpaid employment, education
or training at the 21-month follow-up
assessment
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Chapter 3 Baseline results
Reliability of outcome measures
The reliability of all outcome measures (total scores and subscales) at baseline were assessed using
Cronbach’s alpha reliability statistic. The reliability statistics can be seen in Table 3. The reliability of all
measures was acceptable (as indicated by α ≥ 0.7) except for PANSS positive, PANSS excitement, PANSS
emotional distress and ISMI scale stigma resistance.
TABLE 3 Reliability alpha
Measure α
PANSS total 0.78
PANSS positive 0.58
PANSS negative 0.73
PANSS disorganised 0.75
PANSS excitement 0.51
PANSS emotional distress 0.63
CDSS 0.77
AnTi 0.84
QPR 0.93
AUDIT 0.80
DAST 0.80
PSYRATS – delusion 0.86
PSYRATS – auditory hallucinations 0.95
PSYRATS unusual beliefs – cognitive 0.82
PSYRATS unusual beliefs – emotional 0.85
PSYRATS voices – cognitive 0.75
PSYRATS voices – emotional 0.94
PSYRATS voices – physical 0.94
PSYRATS voices – loudness 0.87
ISMI scale alienation 0.84
ISMI scale stereotype endorsement 0.73
ISMI scale discrimination experience 0.83
ISMI scale social withdrawal 0.87
ISMI scale stigma resistance 0.68
ISMI scale total 0.92
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Participant baseline characteristics
Trial recruitment
In total, 487 participants were recruited from five centres (Table 4): 242 were randomised to CBT and
245 were randomised to TAU. The referral pathway by the different service type for the participants
randomised overall and by centre is shown in Appendix 1. The highest recruiter across all centres was the
CMHTs, followed by the clozapine clinic. Participants were recruited to the trial between 1 January 2013
and 31 May 2015 and followed up to March 2017. The trajectory of recruitment from all centres is shown
in Figure 1.
TABLE 4 Recruitment by centre
Centre
Participants, n (%)
Eligible
(N= 565)
Ineligible
(N= 47)
Declined
(N= 31)
Randomised
(N= 487)
Randomised to
CBT (N= 242)
Randomised to
TAU (N= 245)
Manchester 129 (22.8) 11 (23.4) 10 (32.3) 108 (22.2) 54 (22.3) 54 (22.0)
Southampton 121 (21.4) 10 (21.3) 6 (19.4) 105 (21.6) 52 (21.5) 53 (21.6)
Newcastle 109 (19.3) 8 (17.0) 9 (29.0) 92 (18.9) 46 (19.0) 46 (18.8)
Edinburgh 100 (17.7) 6 (12.8) 2 (6.5) 92 (18.9) 46 (19.0) 46 (18.8)
Glasgow 106 (18.8) 12 (25.5) 4 (12.9) 90 (18.5) 44 (18.2) 46 (18.8)
0
50
100
150
200
250
300
350
400
450
500
N
u
m
b
er
 r
ec
ru
it
ed
Ja
n
u
ar
y 
20
13
M
ar
ch
 2
01
3
M
ay
 2
01
3
Ju
ly
 2
01
3
Se
p
te
m
b
er
 2
01
3
N
o
ve
m
b
er
 2
01
3
Ja
n
u
ar
y 
20
14
M
ar
ch
 2
01
4
M
ay
 2
01
4
Ju
ly
 2
01
4
Se
p
te
m
b
er
 2
01
4
N
o
ve
m
b
er
 2
01
4
Ja
n
u
ar
y 
20
15
M
ar
ch
 2
01
5
M
ay
 2
01
5
Ju
ly
 2
01
5
Month and year
FIGURE 1 Recruitment over time.
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Participant flow
Figure 2 shows the Consolidated Standards of Reporting Trials (CONSORT) flow diagram for the trial.
Of the patients, 898 were identified as potentially eligible for inclusion in the trial and were referred, and
of these 565 were found to be eligible at the referral stage. Of the 78 patients excluded from the trial,
47 were found to be ineligible and 31 declined. Details of the reasons for patients being ineligible at the
referral stage and before randomisation are shown in Appendix 1. All randomised participants completed
the baseline questionnaires. In the CBT arm, 230 participants received treatment; further detail on the
number of sessions attended is in Chapter 5. At 21 months, 425 participants (87.2%) were included in the
primary analysis: there were 10 deaths, 36 participants withdrew from the trial and declined to provide
outcome data and a further six were not assessed as they were not contactable at follow-up.
Patients identified
(n = 898)
Eligible patients
(n = 565)
Randomised
(n = 487)
CBT
(n = 242)
TAU
(n = 245)
• Ineligible, n = 79
• Declined, n = 254
• Received CBT, n = 230
• Did not receive CBT, n = 12
9-month assessment 
• Responded, n = 220
• Non-response, n = 5
• Withdrawn, n = 14
• Deceased, n = 3
9-month assessment 
• Responded, n = 228
• Non-response, n = 4
• Withdrawn, n = 12
• Deceased, n = 1
21-month assessment 
• Responded, n = 216
• Non-response, n = 2
• Withdrawn, n = 18
• Deceased, n = 6
21-month assessment 
• Responded, n = 219
• Non-response, n = 4
• Withdrawn, n = 18
• Deceased, n = 4
• Ineligible, n = 47
• Declined, n = 31
Excluded
(n = 78)
Included in the analysis, n = 209 Included in the analysis, n = 216
FIGURE 2 The CONSORT flow diagram. Reprinted from Lancet Psychiatry, Volume 5, Morrison et al., Cognitive
behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial,
Pages 633–43, © 2019, with permission from Elsevier.171
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Baseline characteristics
Baseline characteristics are shown in Table 5. The treatment groups were well balanced. The mean age of
participants was 42 years in the CBT group and 43 years in the TAU group; > 70% of participants were
male, the majority were unemployed (203 participants in the CBT group and 204 in the TAU group) and
71% were living independently. The median duration of untreated psychosis was 9 months [interquartile
range (IQR) 1–24 months] in the CBT group and 18 months (IQR 2–48 months) in the TAU group, and
the median DI was 216 months (IQR 132–300 months) and 240 months (IQR 144–300 months) in the
CBT and TAU groups, respectively. The mean PANSS total score, the primary outcome, was 82.8 points
(SD 13.7 points) in the CBT group and 83.3 points (SD 14.0 points) in the TAU group. The PANSS positive
and negative scores were also similar in both groups.
TABLE 5 Baseline characteristics
Characteristic
Trial arm
CBT (N= 242) TAU (N= 245)
Age (to the closest year), mean (SD) 42.2 (10.7) 42.8 (10.4)
Sex, n (%)
Male 176 (72.7) 173 (70.6)
Female 66 (27.3) 72 (29.4)
Ethnicity, n (%)
White 222 (91.7) 222 (90.6)
Asian 9 (3.7) 4 (1.6)
Black 5 (2.1) 3 (1.2)
Mixed 4 (1.7) 12 (4.9)
Other 2 (0.8) 3 (1.2)
Refused to answer 0 (0.0) 1 (0.4)
Employment, n (%)
Paid (full or part time) 10 (4.1) 10 (4.1)
Voluntary 14 (5.8) 16 (6.5)
Education or training 9 (3.7) 5 (2.0)
Other unpaid activity 6 (2.5) 8 (3.3)
Unemployed 203 (83.9) 204 (83.3)
Missing 0 (0.0) 2 (0.8)
Residential status, n (%)
Inpatient 17 (7.0) 16 (6.5)
Rehabilitation ward 13 (5.4) 8 (3.3)
Support accommodation 39 (16.1) 45 (18.4)
Independent living 172 (71.1) 174 (71.0)
Missing 1 (0.4) 2 (0.8)
Years in full-time education, median
(25th, 75th percentile); n
12 (11, 14); 223 12 (11, 14); 229
Duration of untreated psychosis (months),
median (25th, 75th percentile); n
8 (1, 24); 195 18 (2, 48); 203
Duration of illness (months), median
(25th, 75th percentile); n
216 (132, 300); 227 240 (144, 300); 231
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TABLE 5 Baseline characteristics (continued )
Characteristic
Trial arm
CBT (N= 242) TAU (N= 245)
Primary outcome, mean (SD)
PANSS total 82.8 (13.7) 83.3 (14.0)
Secondary outcomes, mean (SD); n
PANSS positive 24.7 (5.9); 242 25.2 (5.7); 245
PANSS negative 19.3 (6.1); 242 19.4 (6.4); 245
PANSS disorganised 24.7 (6.5); 242 24.8 (6.6); 245
PANSS excitement 18.0 (4.5); 242 17.9 (4.3); 245
PANSS emotional distress 27.0 (5.6); 242 27.4 (5.6); 245
CDSS 7.1 (4.8); 233 7.4 (4.7); 238
AnTI 18.2 (4.8); 226 18.9 (4.9); 236
PSYRATS – delusion 14.3 (5.7); 218 14.9 (5.3); 236
PSYRATS – auditory hallucinations 21.1 (14.1); 214 24.9 (12.6); 200
PSYRATS unusual beliefs – cognitive 9.6 (3.8); 221 9.9 (3.5); 240
PSYRATS unusual beliefs – emotional 4.7 (2.6); 227 5.0 (2.4); 238
PSYRATS voices – cognitive 3.9 (2.8); 224 4.5 (2.5); 213
PSYRATS voices – emotional 4.7 (3.1); 232 5.4 (2.8); 222
PSYRATS voices – physical 5.5 (3.8); 232 6.2 (3.4); 223
PSYRATS voices – loudness 2.5 (1.5); 229 2.6 (1.4); 239
PSP 49.2 (15.5); 242 48.3 (13.5); 245
QPR 48.5 (11.4); 216 47.4 (11.1); 228
AUDIT 4.3 (6.0); 230 3.5 (5.4); 234
DAST 0.7 (1.4); 224 0.7 (1.5); 231
Severity CGI 4.8 (0.9); 158 4.8 (0.8); 162
Participant severity CGI 3.9 (1.4); 152 4.0 (1.6); 157
EQ-5D-5L utility 0.740 (0.201); 223 0.703 (0.225); 230
Diagnosis at baseline, n (%)
Schizophrenia 209 (86.4) 218 (89.0)
Schizoaffective 28 (11.6) 20 (8.2)
Delusional disorder 2 (0.8) 5 (2.0)
Unspecified psychosis not attributable to a substance or
known physiological condition
2 (0.8) 1 (0.4)
Missing 1 (0.4) 1 (0.4)
Note
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Table 6 describes the baseline medication for the trial population; > 90% of participants in both arms were
prescribed clozapine. The length of time on clozapine was the same in both groups (median 60 months,
IQR 24–120 months). In the CBT group, 19 participants discontinued clozapine, and, in the TAU group,
24 discontinued it, with side effects given as the main reason in both groups. Other antipsychotic medication
was taken by 106 participants (43.8%) in the CBT group and 103 (42.0%) in the TAU group. Participants
also took other medication, listed in Table 6.
TABLE 6 Baseline medication
Medication
Trial arm
CBT (N= 242) TAU (N= 245)
Prescribed clozapine, n (%) 223 (92.1) 221 (90.2)
Length of time on clozapine (months), median (25th, 75th percentile); n 60 (24, 120); 218 60 (24, 120); 216
Clozapine dose (mg), median (25th, 75th centile); n 400 (300, 525); 221 400 (300, 500); 221
Discontinued clozapine, n (%) 19 (7.9) 24 (9.8)
Length of time discontinued (months), median (IQR); n 9 (5–13); 19 13 (3–20); 24
Reasons for discontinuing clozapine, n (%)
Side effects 16 (84.2) 23 (95.8)
Lack of efficacy 3 (15.8) 1 (4.2)
Taking other antipsychotic medication, n (%)
None 136 (56.2) 142 (58.0)
One 99 (40.9) 95 (38.8)
Two 7 (2.9) 7 (2.9)
Three 0 (0.0) 1 (0.4)
Other medication,a n (%)
None 85 (35.1) 81 (33.1)
Antidepressants 113 (46.7) 129 (52.7)
Other mental health medication 52 (21.5) 35 (14.3)
Benzodiazepines 27 (11.2) 30 (12.2)
Medication for the side effects of antipsychotics 27 (11.2) 24 (9.8)
Unknown medication 2 (0.8) 2 (0.8)
a Not mutually exclusive.
Note
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Chapter 4 Outcome and results
Primary outcome
The PANSS total and subscale scores at each time point are described in Table 7. Figure 3 shows the
profile for the two treatment groups over the study period. Treatment effect estimates are also included in
Table 7, based on 425 participants for whom at least one follow-up measurement was available. At 9 months,
the total PANSS score was lower in the CBT arm (mean –2.40, 95% CI –4.79 to –0.02; p= 0.049), with a
standardised ES of 0.16. The mean difference at 21 months was –0.89 (95% CI –3.32 to 1.55; p= 0.475),
with a standardised ES of 0.06. At 9 months, the subscale PANSS positive score was lower in the CBT arm
(mean –1.56, 95% CI –2.53 to –0.59; p = 0.002), with a standardised ES of 0.24; PANSS excitement was
lower in the CBT arm (mean –1.18, 95% CI –1.85 to 0.50; p= 0.001), with a standardised ES of 0.28, and
PANSS emotional distress was lower in the CBT arm (mean –1.08, 95% CI –2.02 to –0.13; p = 0.025), with a
TABLE 7 The PANSS outcomea
Time point
Trial arm, mean (SD); n
Mean difference 95% CI p-value
Cronbach’s
alphaCBT (N= 242) TAU (N= 245)
PANSS total
Baseline 82.8 (13.7); 242 83.3 (14.0); 245
9 months 75.2 (15.5); 218 77.8 (14.6); 224 –2.40 –4.79 to –0.02 0.049 0.16
21 months 73.0 (16.7); 209 74.1 (14.8); 216 –0.89 –3.32 to 1.55 0.475 0.06
PANSS positive
Baseline 24.7 (5.9); 242 25.2 (5.7); 245
9 months 21.7 (6.6); 218 23.6 (6.2); 225 –1.56 –2.53 to –0.59 0.002 0.24
21 months 21.3 (7.0); 209 22.5 (6.1); 216 –0.85 –1.84 to 0.15 0.095 0.13
PANSS negative
Baseline 19.3 (6.1); 242 19.4 (6.4); 245
9 months 18.1 (7.0); 220 18.6 (6.7); 227 –0.49 –1.48 to 0.49 0.327 0.07
21 months 17.8 (6.8); 211 17.5 (6.1); 216 0.29 –0.72 to 1.29 0.578 0.05
PANSS disorganised
Baseline 24.7 (6.5); 242 24.8 (6.6); 245
9 months 23.2 (6.4); 218 23.1 (6.0); 225 –0.01 –0.91 to 0.88 0.975 0.00
21 months 22.7 (6.6); 210 22.4 (6.2); 216 0.14 –0.78 to 1.05 0.770 0.02
PANSS excitement
Baseline 18.0 (4.5); 242 17.9 (4.3); 245
9 months 16.2 (4.1); 220 17.4 (4.2); 228 –1.18 –1.85 to –0.50 0.001 0.28
21 months 15.4 (3.9); 210 15.9 (4.0); 216 –0.57 –1.26 to 0.12 0.106 0.15
PANSS emotional distress
Baseline 27.0 (5.6); 242 27.4 (5.6); 245
9 months 24.1 (6.2); 220 25.4 (6.3); 228 –1.08 –2.02 to –0.13 0.025 0.17
21 months 23.4 (6.6); 210 24.0 (6.0); 216 –0.27 –1.24 to 0.70 0.583 0.04
a Adjusted for baseline score, sex, age and centre.
Note
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standardised ES of 0.17. For PANSS negative and PANSS disorganised, there was no evidence of a difference
at either time point. Sensitivity analysis using MI gave similar results (see Appendix 2). Figure 4 shows the site
difference and within-site differences for total PANSS score at 9 and 21 months. At 21 months, the Manchester
site recorded a greater effect in total PANSS score in favour of CBT.
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FIGURE 3 Profile of PANSS total scores.
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FIGURE 4 Site differences for PANSS total scores. (a) 9 months; and (b) 21 months. (continued )
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At the 9-month assessment, a total of 51 blind breaks had occurred. However, 23 of these cases were
transferred to a new, independent assessor, meaning that 28 assessments were unblind at the 9-month
assessment. At the 21-month assessment, the number of breaks that had occurred was 55. However,
35 of these cases were transferred to a new, independent assessor, meaning that 20 assessments were
unblind at the 21-month assessment. Outcome analyses for PANSS were repeated excluding those
participants for whom a blind break had occurred; the results are presented in Table 8.
The percentage of improvement in PANSS total is shown in Table 9. At 9 months, 16 participants (6.6%)
in the CBT arm and 11 (4.5%) in the TAU arm had > 50% improvement; the number needed to treat
(NNT) was 42. At 21 months, 28 participants (11.6%) in the CBT arm and 14 (5.7%) in the TAU arm had
> 50% improvement, and the NNT was 15.
Table 10 shows the effect of time on PANSS total for the sample as a whole. The analysis was adjusted for
randomised treatment, age, sex and centre. Table 10 shows a reduction in PANSS total score of 5.26 at
9 months compared with baseline and a reduction in PANSS total score of 9.1 at 21 months compared
with baseline.
– 12
Mean 3.67 (95% CI – 3.94 to 11.28); p = 0.345
Favours TAU
(b)
Favours CBT
Mean 4.35 (95% CI – 3.36 to 12.07); p = 0.269
Mean 2.86 (95% CI – 4.91 to 10.63); p = 0.470
Mean 4.82 (95% CI – 2.41 to 12.04); p = 0.191
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Southampton
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Overall
– 8 – 4 0 4
FIGURE 4 Site differences for PANSS total scores. (a) 9 months; and (b) 21 months.
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Secondary outcomes
The PSYRATS subscales at 9 and 21 months are shown in Table 11. At 9 months there was a mean difference
in favour of CBT for auditory hallucinations (–2.56, 95% CI –4.87 to –0.26; p = 0.029) and physical voices
(–0.58, 95% CI –1.11 to –0.04; p = 0.034). Both subscales were similar in both groups at 21 months.
At 21 months the mean difference between groups on emotional unusual beliefs was –0.53 (95% CI –1.05
to –0.00; p = 0.049). For the remainder of the PSYRATS subscales, there was no evidence of a difference
between the two treatments at 9 or 21 months. Other secondary outcomes were similar with the exceptions
of QPR and CGI (Table 12).
As indicated in Table 13, chi-squared analysis did not indicate any significant difference between the
groups regarding access to education, employment or training at either 9 or 21 months.
TABLE 9 Improvement in PANSS total scoresa
Improvement
Trial arm, n (%)
NNT 95% CICBT (N= 242) TAU (N= 245)
> 25%
9 months 68 (28.1) 57 (23.3) 18 NNTH 37 to ∞ to NNTB 8
21 months 80 (33.1) 82 (33.5) 318 NNTH 11 to ∞ to NNTB 11
> 50%
9 months 16 (6.6) 11 (4.5) 42 NNTH 48 to ∞ to NNTB 15
21 months 28 (11.6) 14 (5.7) 15 NNTB 8 to NNTB 81
> 75%
9 months 2 (0.8) 2 (0.8) 4070 NNTH 57 to ∞ to NNTB 56
21 months 4 (1.7) 2 (0.8) 102 NNTH 78 to ∞ to NNTB 31
NNTB, number needed to treat (benefit); NNTH, number needed to treat (harm).
a PANSS rescaled.
TABLE 10 The PANSS total effect of time
Time point Effect estimate 95% CI p-value
9 months –5.26 –7.84 to –2.67 < 0.001
21 months –9.1 –11.71 to –6.48 < 0.001
TABLE 8 The PANSS total scores excluding participants for whom a blind break had occurred
Time point
Trial arm, mean (SD); n
Mean difference 95% CI p-valueCBT (N= 242) TAU (N= 245)
Baseline 82.8 (13.7); 242 83.3 (14.0); 245
9 months 75.6 (15.5); 194 77.7 (14.5); 222 –2.21 –4.66 to 0.24 0.078
21 months 73.4 (16.7); 193 73.8 (14.6); 214 –0.48 –2.96 to 2.00 0.704
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TABLE 11 The PSYRATS outcomes
Time point
Trial arm, mean (SD); n
Mean difference 95% CI p-valueCBT (N= 242) TAU (N= 245)
PSYRATS auditory hallucinations
Baseline 21.1 (14.1); 214 24.9 (12.6); 200
9 months 17.8 (14.2); 185 22.4 (13.4); 192 –2.56 –4.87 to –0.26 0.029
21 months 17.1 (14.2); 179 20.3 (14.4); 182 –1.38 –3.75 to 0.99 0.255
PSYRATS delusion
Baseline 14.3 (5.7); 218 14.9 (5.3); 236
9 months 12.2 (6.8); 200 13.2 (6.7); 216 –0.42 –1.61 to 0.77 0.493
21 months 11.4 (7.1); 193 12.7 (6.8); 203 –0.76 –1.98 to 0.46 0.224
PSYRATS unusual beliefs – cognitive
Baseline 9.6 (3.8); 221 9.9 (3.5); 240
9 months 8.2 (4.5); 201 8.8 (4.3); 216 –0.24 –1.01 to 0.54 0.551
21 months 7.8 (4.7); 194 8.5 (4.4); 205 –0.35 –1.14 to 0.44 0.385
PSYRATS unusual beliefs – emotional
Baseline 4.7 (2.6); 227 5.0 (2.4); 238
9 months 3.9 (2.9); 206 4.4 (2.9); 219 –0.29 –0.79 to 0.22 0.269
21 months 3.6 (3.0); 199 4.3 (2.9); 206 –0.53 –1.05 to –0.00 0.049
PSYRATS voices – cognitive
Baseline 3.9 (2.8); 224 4.5 (2.5); 213
9 months 3.4 (2.8); 193 4.0 (2.7); 204 –0.32 –0.82 to 0.17 0.195
21 months 3.3 (2.9); 187 3.8 (2.8); 187 –0.17 –0.68 to 0.34 0.514
PSYRATS voices – emotional
Baseline 4.7 (3.1); 232 5.4 (2.8); 222
9 months 4.2 (3.3); 202 5.0 (3.0); 208 –0.43 –0.95 to 0.08 0.101
21 months 4.1 (3.3); 199 4.6 (3.3); 197 –0.03 –0.55 to 0.50 0.914
PSYRATS voices – physical
Baseline 5.5 (3.8); 232 6.2 (3.4); 223
9 months 4.7 (3.8); 208 5.7 (3.6); 209 –0.58 –1.11 to –0.04 0.034
21 months 4.4 (3.6); 201 5.1 (3.8); 198 –0.30 –0.85 to 0.24 0.279
PSYRATS voices – loudness
Baseline 2.5 (1.5); 229 2.6 (1.4); 239
9 months 2.0 (1.6); 206 2.3 (1.6); 219 –0.22 –0.50 to 0.06 0.120
21 months 1.9 (1.7); 199 2.3 (1.6); 206 –0.28 –0.57 to 0.01 0.056
Note
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TABLE 12 Other secondary outcomes
Time point
Trial arm, mean (SD); n
Mean difference 95% CI p-valueCBT (N= 242) TAU (N= 245)
CDSS
Baseline 7.1 (4.8); 233 7.4 (4.7); 238
9 months 6.3 (4.5); 210 6.8 (4.8); 215 –0.54 –1.31 to 0.23 0.168
21 months 6.0 (4.4); 202 6.6 (5.1); 205 –0.50 –1.28 to 0.29 0.212
AnTI
Baseline 18.2 (4.8); 226 18.9 (4.9); 236
9 months 17.5 (5.2); 189 18.0 (5.0); 206 –0.07 –0.88 to 0.73 0.856
21 months 16.9 (5.1); 180 18.1 (5.0); 193 –0.60 –1.44 to 0.24 0.160
PSP
Baseline 49.2 (15.5); 242 48.3 (13.5); 245
9 months 53.2 (14.6); 213 50.9 (13.9); 224 1.90 –0.31 to 4.11 0.093
21 months 51.5 (15.2); 206 51.4 (14.7); 214 0.18 –2.07 to 2.44 0.872
QPR
Baseline 48.5 (11.4); 216 47.4 (11.1); 228
9 months 50.9 (11.6); 181 48.7 (11.1); 194 1.88 –0.03 to 3.79 0.053
21 months 52.0 (9.6); 165 49.1 (11.7); 185 2.03 0.04 to 4.01 0.045
AUDIT
Baseline 4.3 (6.0); 230 3.5 (5.4); 234
9 months 4.4 (6.0); 194 3.5 (5.7); 209 0.69 –0.17 to 1.56 0.116
21 months 4.6 (6.5); 190 3.2 (5.0); 193 0.80 –0.09 to 1.69 0.079
DAST
Baseline 0.7 (1.4); 224 0.7 (1.5); 231
9 months 0.7 (1.7); 153 0.9 (1.7); 173 –0.13 –0.43 to 0.18 0.409
21 months 0.6 (1.3); 170 0.6 (1.3); 181 0.12 –0.17 to 0.41 0.417
Condition improvement CGIa
9 months 3.3 (1.1); 141 3.3 (1.1); 157 –0.04 –0.50 to 0.42 0.822
21 months 3.2 (0.9); 131 3.5 (1.0); 147 –0.33 –0.54 to -0.11 0.013
Severity CGI
Baseline 4.8 (0.9); 158 4.8 (0.8); 162
9 months 4.2 (1.0); 207 4.3 (1.1); 213 –0.09 –0.30 to 0.12 0.395
21 months 4.1 (1.0); 208 4.2 (1.0); 212 –0.03 –0.24 to 0.18 0.772
Participant severity CGI
Baseline 3.9 (1.4); 152 4.0 (1.6); 157
9 months 3.6 (1.7); 197 3.7 (1.5); 186 0.06 –0.27 to 0.39 0.729
21 months 3.7 (1.5); 193 3.7 (1.6); 210 0.12 –0.22 to 0.46 0.483
EQ-5D-5L utility
Baseline 0.740 (0.201); 223 0.703 (0.225); 230
9 months 0.760 (0.223); 187 0.721 (0.254); 205 0.035 –0.004 to 0.073 0.079
21 months 0.773 (0.204); 180 0.730 (0.223); 189 0.028 –0.012 to 0.068 0.170
a Analysised separately at 9 and 21 months as baseline score was not collected.
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Compliance with treatment
The median number of CBT sessions attended was 23, and 213 out of 242 participants (88%) attended at
least six sessions, which was the minimum number of sessions needed to be classified as having received
CBT (Table 14). Treatment effects from a CACE analysis, adjusting for compliance at 9 months and the
primary and secondary outcomes, are shown in Appendix 2. We repeated this analysis using the actual
number of sessions attended; results are presented in Table 15 for 9 months and Table 16 for 21 months.
For every extra session attended, the PANSS total score resulted in a difference of –0.12 (95% CI –0.24
to 0.00; p = 0.059) at 9 months, which suggests that attending more CBT sessions was beneficial in the
short term.
Session record data were analysed to determine if therapy milestones were achieved. The percentage of
participants allocated to CBT with whom therapy milestones were achieved is shown in Table 17.
Fidelity to the CBT model was evaluated using 57 audio-recordings of therapy sessions. Table 18 provides
descriptive statistics for the total fidelity ratings.
TABLE 13 Employment status
Employment status
Trial arm, n (%)
p-valueCBT (N= 242) TAU (N= 245)
9 months
NEET 180 (74.4) 186 (75.9)
EET 41 (16.9) 42 (17.1) 0.774
21 months
NEET 162 (66.9) 175 (71.4)
EET 50 (12.4) 41 (16.7) 0.499
EET, in education, employment, volunteering and training; NEET, not in education, employment, volunteering and training.
TABLE 14 Number of sessions attended for those randomised to CBT
Number of sessions CBT arm (N= 242), n (%)
0 12 (5.0)
1–5 17 (7.0)
6–10 20 (8.3)
11–20 48 (19.8)
21–30 124 (51.2)
> 31 21 (8.7)
Median 23
25th centile 13
75th centile 28
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TABLE 15 Complier-average causal effect analysis of the actual number of sessions at 9 months
Outcome Mean difference 95% CI p-value
PANSS total –0.12 –0.24 to 0.00 0.059
PANSS positive –0.02 –0.08 to 0.03 0.347
PANSS negative –0.08 –0.13 to –0.03 0.001
PANSS disorganised –0.00 –0.05 to 0.05 0.997
PANSS excitement –0.06 –0.10 to –0.02 0.001
PANSS emotional distress –0.06 –0.10 to –0.01 0.028
CDSS –0.13 –0.25 to –0.01 0.040
AnTI –0.02 –0.08 to 0.04 0.506
PSYRATS – auditory hallucinations –0.01 –0.05 to 0.03 0.566
PSYRATS – delusion –0.01 –0.04 to 0.01 0.283
PSYRATS unusual beliefs – cognitive –0.02 –0.04 to 0.01 0.206
PSYRATS unusual beliefs – emotional –0.02 –0.05 to 0.01 0.114
PSYRATS voices – cognitive –0.03 –0.06 to –0.00 0.038
PSYRATS voices – emotional –0.01 –0.03 to 0.00 0.112
PSYRATS voices – physical –0.03 –0.07 to 0.01 0.151
PSYRATS voices – loudness –0.00 –0.04 to 0.04 0.942
PSP 0.10 –0.02 to 0.21 0.091
QPR 0.10 –0.00 to 0.19 0.061
AUDIT 0.03 –0.01 to 0.08 0.127
DAST –0.01 –0.02 to 0.01 0.415
Severity CGI –0.00 –0.02 to 0.01 0.417
Participant severity CGI 0.00 –0.01 to 0.02 0.669
Condition improvement CGI –0.02 –0.03 to –0.01 0.003
EQ-5D-5L 0.002 –0.000 to 0.004 0.094
TABLE 16 Complier-average causal effect analysis of the actual number of sessions at 21 months
Instrument Mean difference 95% CI p-value
PANSS total –0.04 –0.16 to 0.08 0.547
PANSS positive 0.02 –0.03 to 0.06 0.527
PANSS negative –0.04 –0.09 to 0.01 0.101
PANSS disorganised 0.01 –0.04 to 0.05 0.745
PANSS excitement –0.02 –0.06 to 0.01 0.145
PANSS emotional distress –0.01 –0.06 to 0.03 0.565
CDSS –0.02 –0.06 to 0.02 0.263
AnTI –0.03 –0.07 to 0.01 0.156
PSYRATS – auditory hallucinations –0.06 –0.17 to 0.05 0.310
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TABLE 16 Complier-average causal effect analysis of the actual number of sessions at 21 months (continued )
Instrument Mean difference 95% CI p-value
PSYRATS – delusion –0.03 –0.09 to 0.02 0.231
PSYRATS unusual beliefs – cognitive –0.02 –0.05 to 0.02 0.396
PSYRATS unusual beliefs – emotional –0.02 –0.05 to 0.00 0.050
PSYRATS voices – cognitive –0.01 –0.03 to 0.02 0.551
PSYRATS voices – emotional –0.00 –0.03 to 0.02 0.969
PSYRATS voices – physical –0.01 –0.04 to 0.01 0.267
PSYRATS voices – loudness –0.01 –0.03 to 0.00 0.057
PSP –0.00 –0.12 to 0.11 0.941
QPR 0.09 0.01 to 0.18 0.036
AUDIT 0.03 –0.01 to 0.08 0.107
DAST 0.00 –0.01 to 0.02 0.488
Severity CGI –0.00 –0.01 to 0.01 0.752
Participant severity CGI 0.01 –0.01 to 0.02 0.502
Condition improvement CGI –0.00 –0.01 to 0.01 0.757
EQ-5D-5L 0.00 –0.00 to 0.00 0.152
TABLE 17 Therapy data
Milestones CBT, n/N (%)
Problem and goals identified during sessions 1–4 221/242 (91.3)
Maintenance formulation developed during sessions 1–4 185/242 (76.4)
If maintenance formulation was not developed during sessions 1–4, it was developed after 26/57 (45.6)
Longitudinal formulation developed during sessions 1–16 111/242 (45.9)
If longitudinal formulation was not developed during sessions 1–16, it was developed after 21/131 (16.0)
Change strategies were used during sessions 1–5 200/242 (82.6)
If change strategies were not used during sessions 1–5, they were used in sessions 6–10 15/42 (35.7)
Homework set during sessions 1–5 219/242 (90.5)
If homework was set during sessions 1–5, it was completed 181/219 (82.6)
TABLE 18 Fidelity ratings
Fidelity indicator
CTS-R fidelity
(N= 57)
Mean (SD) 43.11 (7.56)
Range 29.75–60.50
Number (%) achieving a pass on the CTS-R 45 (78.9)
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Subgroup analyses
Results from the subgroup analysis are reported in Figures 5 and 6 for PANSS total. Results from the
subgroup analysis for the secondary outcomes QPR, PSP and PSYRATS – auditory hallucinations are in
Appendix 2. There was no evidence that the treatment effect was moderated by any of the specified
subgroups. Sensitivity analysis for the subgroup LNS including participants who refused at least one
question is shown in Appendix 2. Overall, there was no evidence of a statistical difference for any of the
subgroups on PANSS total at either time point.
For subgroup analyses of QPR (see Appendix 2), there was evidence of a significant interaction effect at
9 months for the BCSS subscale ‘negative others’, which scored < 7.2, with those subscales that scored
≥ 7.2 (interaction effect –4.96, 95% CI –8.94 to –0.98; p = 0.015). All other subgroups showed no
evidence of a difference. Appendix 2 shows the subgroup analysis for PSP. There was evidence of a
significant interaction effect for participants with a DI of ≥ 31 years with participants with a DI of
0–15 years at 9 months (interaction effect –9.03, 95% CI –16.62 to –1.98; p = 0.013). For the CTQ
physical abuse subscale, there was evidence of a difference at 9 months for participants scoring ≥ 8 with
those scoring ≤ 7 (interaction effect 6.29, 95% CI 0.80 to 11.78; p = 0.025).
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FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset
and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years),
DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual
disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months;
(g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment
avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months;
and (l) BCSS at 21 months. (continued )
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FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset
and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years),
DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual
disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months;
(g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment
avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months;
and (l) BCSS at 21 months. (continued )
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FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset
and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years),
DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual
disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months;
(g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment
avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months;
and (l) BCSS at 21 months. (continued )
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Mean – 1.14 (95% CI – 6.17 to 3.89); p = 0.658
 
 
Mean – 2.27 (95% CI – 7.41 to 2.87); p = 0.387
 
 
Mean – 1.27 (95% CI – 6.96 to 4.42); p = 0.661
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FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset
and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years),
DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual
disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months;
(g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment
avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months;
and (l) BCSS at 21 months. (continued )
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Mean 4.57 (95% CI – 0.56 to 9.71); p = 0.081
 
 
Mean 2.37 (95% CI – 2.92 to 7.65); p = 0.380
 
 
Mean – 0.83 (95% CI – 6.73 to 5.07); p = 0.783
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FIGURE 5 Comparison of CBT and TAU by subgroups. (a) Age, age of onset and sex at 9 months; (b) age, age of onset
and sex at 21 months; (c) DI (years), DUP (years), antipsychotic and clozapine daily dose at 9 months; (d) DI (years),
DUP (years), antipsychotic and clozapine daily dose at 21 months; (e) difficulty with abstract thinking and conceptual
disorganisation at 9 months; (f) difficulty with abstract thinking and conceptual disorganisation at 21 months;
(g) childhood trauma at 9 months; (h) childhood trauma at 21 months; (i) AUDIT, DAST and PAM-SR attachment
avoidance at 9 months; (j) AUDIT, DAST and PAM-SR attachment avoidance at 21 months; (k) BCSS at 9 months;
and (l) BCSS at 21 months.
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FIGURE 6 Comparison of CBT and TAU by psychosis subgroup. (a) 9 months; and (b) 21 months. (continued )
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In the subgroup analyses for PSYRATS – auditory hallucinations (see Appendix 2), there was evidence of a
difference for participants with a DI of between 16 and 30 years and those with a DI of between 0 and
15 years at 9 months (interaction effect –7.33, 95% CI –12.41 to –2.25; p = 0.005). For AUDIT, these was
evidence of a difference for participants with a score of ≤ 12 and for those with a score of ≤ 12 (interaction)
(interaction effect –9.76, 95% CI –18.40 to –1.12; p = 0.027). Furthermore, there was evidence of a difference
for PAM-SR attachment avoidance at 9 months for those who scored 17–24 compared with those who
scored 1–9 in favour of TAU (interaction effect 8.56, 95% CI 0.73 to 16.30; p= 0.032).
Adverse events and potential unwanted side effects of trial participation
In total, three participants experienced an AE that was deemed to be related to the trial or unclear if
related; these AEs were reported to the National Research Ethics Committee (Table 19). Two of the
affected participants were in the CBT arm (unclear if related or not) and one was in the TAU arm (related);
one AE was categorised as life-threatening and resulted in self-harm, one was an involuntary hospitalisation
to a psychiatric hospital and one was self-harm that required treatment at an accident and emergency
department.
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Drug related
Stress sensitivity
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Mean 3.94 (95% CI – 2.24 to 10.13); p = 0.212
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FIGURE 6 Comparison of CBT and TAU by psychosis subgroup. (a) 9 months; and (b) 21 months.
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TABLE 19 Adverse events and effects
Adverse events and effects
Trial arm, n (%)
Odds
ratio 95% CI p-valueCBT (N= 242) TAU (N= 245)
SAEs
Participants who had a trial-related SAE 2 (0.8) 1 (0.4)
Life-threatening/resulted in self-harm 1
Involuntary hospitalisation 1
Self-harm that required treatment at A&E 1
Any AEs
Participants who had an AE 107 (44.2) 104 (42.4) 1.09 0.81 to 1.46 0.58
Total number of AEs 143 120
Detailsa
Death 6 4
Voluntary hospitalisation 33 24
Involuntary hospitalisation 10 14
Prolongation of hospitalisation 4 2
Risk to others 2 0
Self-harm 27 6
Suicide attempt 2 3
Suicidal crisis (CDSS item 8, rating 2) (n/N)
9 months 12/215 (5.6) 14/224 (6.3) 0.90 0.40 to 1.10 0.79
21 months 9/209 (4.3) 7/214 (3.3) 1.35 0.49 to 3.73 0.56
Severe symptomatic exacerbation (n/N)
CGI severity ≥ 6
9 months 18/207 (8.7) 25/213 (11.7) 0.69 0.36 to 1.33 0.27
21 months 19/208 (9.1) 17/212 (8.0) 1.16 0.57 to 2.33 0.69
CGI improvement ≥ 6b
9 months 0/131 5/147 (3.4) 0.06
21 months 3/141 (2.1) 6/157 (3.8) 0.45 0.10 to 2.02 0.30
Deterioration in PANSS total (n/N)
> 25%
9 months 22/218 (10.1) 28/224 (12.5) 0.75 0.41 to 1.38 0.35
21 months 15/209 (7.2) 21/216 (9.7) 0.68 0.33 to 1.37 0.28
> 50%
9 months 6/218 (2.8) 7/224 (3.1) 0.77 0.25 to 2.43 0.66
21 months 8/209 (3.8) 8/216 (3.7) 0.90 0.32 to 2.55 0.84
> 75%
9 months 2/218 (0.9) 1/224 (0.4) 1.78 0.15 to 20.95 0.65
21 months 1/209 (0.5) 3/216 (1.4) 0.26 0.03 to 2.73 0.26
A&E, accident and emergency.
a Two participants had two involuntary hospitalisations, one participant had 22 self-harm events, one participant had two
self-harm events and nine participants had two voluntary hospitalisations.
b High scores indicate deterioration.
Note
Reprinted from Lancet Psychiatry, Volume 5, Morrison et al., Cognitive behavioural therapy in clozapine-resistant schizophrenia
(FOCUS): an assessor-blinded, randomised controlled trial, Pages 633–43, © 2019, with permission from Elsevier.171
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There were 107 participants (44.2%) in the CBT arm and 104 (42.4%) in the TAU arm who reported at
least one AE or adverse effect; there was no significant difference between the groups in the number of
people with at least one AE or adverse effect (p = 0.58) (see Table 19). The main reasons were voluntary
hospitalisation to a psychiatric hospital, self-harm, CGI severity of > 6 and > 25% deterioration on the
PANSS. In the CBT group, 22 of the 27 reported self-harm events were from the same participant. There
were six deaths in the CBT arm and four in the TAU arm; all were deemed to be unrelated to the study.
At 9 months, 22 participants (9%) in the CBT arm and 28 (11%) in the TAU arm had a deterioration in PANSS
total score of > 25%. The number of deteriorations at > 50% and > 75% was similar in both groups at 9 and
21 months.
The frequency of participants responding ‘quite a lot’ or ‘very much’ to each of the items on the bespoke
adverse effects measure developed for the FOCUS trial can be found in Appendix 2. There were no
significant differences between the groups for any of the 27 items in the adverse effects measure.
Internalised stigma of mental illness
Levels of ISMI subscales for the whole sample at baseline are reported in Table 20. For the ISMI alienation
scale, 201 participants (41%) had a severe level, and 225 participants (46%) had moderate levels of
stigma resistance.
Figure 7 shows the profile for the ISMI subscales for the two treatment groups over the study period and
Table 21 shows the treatment effects. At 9 months, ISMI discrimination experience was lower in the CBT
arm than the TAU arm (–0.13, 95% CI –0.25 to –0.01; p = 0.029). For the subgroup analysis on the PANSS
total, only stigma resistance at 9 months showed evidence of a significant interaction effect (Figure 8).
TABLE 20 Levels of ISMI reported in the group at baseline
ISMI subscales
Participants, n (%)
(N= 487)
ISMI scale levels, n (%)
Minimal Low Moderate Severe
ISMI alienation 435 (89.3) 65 (13.3) 95 (19.5) 126 (25.9) 201 (41.3)
ISMI stereotype endorsement 435 (89.3) 186 (38.2) 149 (30.6) 76 (15.6) 76 (15.6)
ISMI discrimination experience 434 (89.1) 104 (21.4) 99 (20.3) 155 (31.8) 129 (26.5)
ISMI social withdrawal 435 (89.3) 76 (15.6) 122 (25.1) 142 (29.2) 147 (30.2)
ISMI stigma resistance 433 (88.9) 46 (9.4) 85 (17.5) 225 (46.2) 131 (26.9)
4
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FIGURE 7 Profile of ISMI subscales. (a) ISMI alienation; (b) ISMI sterotype endorsement; (c) ISMI discrimination
experience; (d) ISMI social withdrawal; (e) ISMI stigma resistance; and (f) ISMI total. (continued )
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FIGURE 7 Profile of ISMI subscales. (a) ISMI alienation; (b) ISMI sterotype endorsement; (c) ISMI discrimination
experience; (d) ISMI social withdrawal; (e) ISMI stigma resistance; and (f) ISMI total. (continued )
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FIGURE 7 Profile of ISMI subscales. (a) ISMI alienation; (b) ISMI sterotype endorsement; (c) ISMI discrimination
experience; (d) ISMI social withdrawal; (e) ISMI stigma resistance; and (f) ISMI total.
TABLE 21 The ISMI outcomes
ISMI subscale
Trial arm, mean (SD); n
Mean difference 95% CI p-valueCBT (N= 242) TAU (N= 245)
Alienation
Baseline 2.76 (0.69); 218 2.84 (0.68); 217
9 months 2.68 (0.74); 179 2.79 (0.67); 198 –0.08 –0.19 to 0.03 0.169
21 months 2.68 (0.64); 164 2.80 (0.68); 180 –0.04 –0.16 to 0.08 0.513
Stereotype endorsement
Baseline 2.16 (0.51); 218 2.16 (0.54); 217
9 months 2.08 (0.59); 178 2.14 (0.55); 198 –0.06 –0.16 to 0.03 0.177
21 months 2.03 (0.53); 164 2.17 (0.54); 180 –0.08 –0.17 to 0.02 0.128
Discrimination experience
Baseline 2.52 (0.63); 218 2.60 (0.66); 216
9 months 2.34 (0.69); 177 2.50 (0.64); 197 –0.13 –0.25 to –0.01 0.029
21 months 2.36 (0.63); 163 2.52 (0.72); 180 –0.05 –0.18 to 0.07 0.397
Social withdrawal
Baseline 2.62 (0.65); 218 2.64 (0.69); 217
9 months 2.50 (0.74); 177 2.56 (0.65); 198 –0.07 –0.19 to 0.05 0.241
21 months 2.52 (0.63); 164 2.63 (0.70); 180 –0.10 –0.23 to 0.02 0.095
Stigma resistance
Baseline 2.77 (0.51); 217 2.68 (0.53); 216
9 months 2.78 (0.61); 177 2.74 (0.52); 198 0.02 –0.09 to 0.12 0.747
21 months 2.76 (0.53); 163 2.71 (0.56); 180 0.02 –0.09 to 0.13 0.681
Total
Baseline 2.46 (0.46); 218 2.50 (0.48); 217
9 months 2.36 (0.51); 179 2.44 (0.46); 198 –0.07 –0.14 to 0.01 0.090
21 months 2.37 (0.44); 165 2.48 (0.51); 180 –0.04 –0.12 to 0.04 0.303
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Alienation
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Minimal
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Minimal
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   Mean 7.09 (95% CI – 1.35 to 15.53); p = 0.099
   Mean 3.53 (95% CI – 4.56 to 11.62); p = 0.393
   Mean 6.75 (95% CI – 0.88 to 14.38); p = 0.083
 
 
   Mean 0.31 (95% CI – 5.40 to 6.01); p = 0.916
   Mean – 0.57 (95% CI – 7.64 to 6.49); p = 0.874
   Mean 3.22 (95% CI – 4.10 to 10.53); p = 0.389
 
 
   Mean 1.27 (95% CI – 6.02 to 8.57); p = 0.732
   Mean 2.51 (95% CI – 4.09 to 9.11); p = 0.455
   Mean 2.66 (95% CI – 4.38 to 9.70); p = 0.459
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   Mean –1.11 (95% CI – 9.86 to 7.64); p = 0.804
   Mean –2.52 (95% CI – 10.82 to 5.79); p = 0.553
   Mean 4.27 (95% CI – 3.60 to 12.15); p = 0.288
 
 
   Mean 3.68 (95% CI – 2.14 to 9.49); p = 0.216
   Mean 2.54 (95% CI – 4.69 to 9.76); p = 0.491
   Mean 6.95 (95% CI – 0.42 to 14.33); p = 0.065
 
 
   Mean 1.63 (95% CI – 5.81 to 9.07); p = 0.668
   Mean 3.49 (95% CI – 3.31 to 10.29); p = 0.314
   Mean 1.54 (95% CI – 5.60 to 8.69); p = 0.672
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   Mean – 3.13 (95% CI – 10.67 to 4.40); p = 0.415
   Mean 0.89 (95% CI – 6.46 to 8.23); p = 0.813
   Mean 2.84 (95% CI – 4.58 to 10.26); p = 0.454
 
    
   Mean 9.87 (95% CI 0.30 to 19.45); p = 0.043
   Mean 7.42 (95% CI – 1.04 to 15.89); p = 0.086
   Mean 7.03 (95% CI – 2.01 to 16.07); p = 0.127
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FIGURE 8 The PANSS total subgroups. (a) Alienation, stereotype endorsement and discrimination experience at
9 months; (b) alienation, stereotype endorsement and discrimination experience at 21 months; (c) social withdrawal
and stigma resistance at 9 months; and (d) social withdrawal and stigma resistance at 21 months. (continued )
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   Mean 9.87 (95% CI 0.30 to 19.45); p = 0.043
   Mean 7.42 (95% CI – 1.04 to 15.89); p = 0.086
   Mean 7.03 (95% CI – 2.01 to 16.07); p = 0.127
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FIGURE 8 The PANSS total subgroups. (a) Alienation, stereotype endorsement and discrimination experience at
9 months; (b) alienation, stereotype endorsement and discrimination experience at 21 months; (c) social withdrawal
and stigma resistance at 9 months; and (d) social withdrawal and stigma resistance at 21 months.
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Chapter 5 Economic evaluation results
Chapter overview
This chapter describes the results of the economic evaluation conducted as part of the FOCUS trial of CBT
compared with TAU for people who cannot tolerate or have had an inadequate response to clozapine. The
economic evaluation uses service use and health status data collected in the RCT to compare the costs and
QALYs of CBT with those of TAU, and estimate the cost per QALY gained. The analysis used the viewpoint
of NHS health and social care service providers (costs) and patients (health benefits) for the 21-month
follow-up period of the trial. Full methods are provided in Chapter 2.
Missing cost and utility data
Table 22 summarises the number of participants with complete cost or utility data at baseline and at
9- and 21-month follow-up. Overall, complete cost and QALY data at 9-month follow-up were available
for 126 out of 245 participants (51%) in the TAU arm, compared with 114 out of 242 participants (47%)
in the CBT group. At 21-month follow-up, complete cost and QALY data were available for 93 out of
245 participants (38%) in the TAU arm, compared with 76 out of 242 participants (31%) in the CBT group.
TABLE 22 Available cost and utility data at different assessments
Study follow-up
Available data, n (%)
CBT arm (N= 242) TAU arm (N= 245)
Cost Utility Cost Utility
Baseline overall 195 (81) 223 (92) 195 (80) 230 (94)
Hospital inpatient stay (psychiatric) 235 (97) Not relevant 236 (96) Not relevant
Hospital inpatient stay (other) 202 (83) Not relevant 205 (84) Not relevant
Hospital outpatient, day and A&E care 237 (98) Not relevant 239 (98) Not relevant
Primary, community and social care 232 (96) Not relevant 238 (97) Not relevant
Baseline to 9 months 135 (56) 187 (77) 144 (59) 205 (84)
Hospital inpatient stay (psychiatric) 214 (88) Not relevant 215 (88) Not relevant
Hospital inpatient stay (other) 150 (62) Not relevant 155 (63) Not relevant
Hospital outpatient, day and A&E care 178 (74) Not relevant 182 (74) Not relevant
Primary, community and social care 168 (69) Not relevant 175 (71) Not relevant
Baseline to 21 months 103 (43) 180 (74) 110 (45) 189 (77)
Hospital inpatient stay (psychiatric) 203 (84) Not relevant 195 (80) Not relevant
Hospital inpatient stay (other) 122 (50) Not relevant 120 (49) Not relevant
Hospital outpatient, day and A&E care 153 (63) Not relevant 145 (59) Not relevant
Primary, community and social care 139 (57) Not relevant 137 (56) Not relevant
A&E, accident and emergency.
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Baseline clinical and demographic characteristics
Sociodemographic characteristics for the participants were reported in Table 5. The data suggested that
the two groups were similar at baseline.
Table 23 reports key baseline demographic and clinical characteristics that are statistically significantly
associated with either baseline utility or baseline cost data (Kendall’s τ-coefficient).
Stepwise linear regression (SPSS version 22), using all the characteristics in Table 23, was used to identify
the key characteristics to include in the MI of missing data and as covariates for the primary and
sensitivity analyses.
Table 24 shows the results of the regression analyses for the characteristics that were statistically
associated with utility (p ≤ 0.10) and included as covariates in the analyses. QALYs are estimated from
baseline and follow-up utilities. The EuroQol Visual Analogue Scale (EQ VAS) score was used to adjust for
any differences in participants’ reported health status at baseline. The EQ VAS is included in the EQ-5D
instrument as an alternative measure of self-reported health. None of the baseline characteristics identified
in Table 24 was associated with baseline cost. The characteristics listed in Table 24 that were statistically
significantly associated with cost were included in the MI of missing data and as covariates for the
analyses. The baseline cost categories were also included in the MI models, whereas total baseline cost
was included as a covariate in the regression models to estimate net costs.159,160
TABLE 23 Baseline demographic and clinical characteristics associated with costs or utility
Demographic or clinical characteristic
Kendall’s τ-coefficient; p-value (n)
Cost Utility
EQ VAS NSS 0.346; < 0.001 (450)
Age NSS –0.177; < 0.001 (453)
Years of full-time education NSS 0.072; 0.043 (419)
Gender NSS –0.089; 0.022 (453)
Ethnicity (white British vs. non-white British) NSS 0.105; 0.007 (453)
Consider themselves to be experiencing mental health problems NSS –0.156; < 0.001 (444)
Duration of illness in months 0.083; 0.020 (366) –0.129; < 0.001 (426)
Impact of health on socially useful activities, including work and study NSS –0.143; < 0.001 (453)
Impact of health on personal and social relationships NSS –0.107; 0.006 (453)
Taking clozapine 0.131; 0.002 (390) –0.087; 0.024 (453)
Taking antidepressant medication NSS –0.150; < 0.001 (453)
Taking benzodiazepine medication NSS –0.077; 0.047 (453)
Total PSP score –0.070; 0.042 (390) 0.124; < 0.001 (453)
Total PANSS score NSS –0.189; < 0.001 (453)
Total QPR score NSS 0.328; < 0.001 (426)
Total CDSS score 0.113; 0.002 (376) –0.308; < 0.001 (439)
Study centre NSS 0.115; 0.001 (453)
EQ VAS, EuroQol Visual Analogue Scale; NSS, not statistically significant.
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Descriptive analysis of health status, utility, quality-adjusted life-years
and cost for participants with complete cost and quality-adjusted
life-year data
Health status, utility and quality-adjusted life-years
Table 25 reports the percentage of people with no problems on each of the EQ-5D health domains at
each follow-up assessment. A breakdown, reporting across all levels and domains of the EQ-5D-5L,
is provided in Appendix 3.
TABLE 24 Regression analyses of baseline utility and demographic and clinical characteristics
Baseline characteristic
Utility (n= 412, adjusted R2= 0.39, p< 0.001)
Coefficient, SE (95% CI) p-value
Age 0.004, 0.001 (–0.005 to –0.002) < 0.001
Number of benzodiazepine medications –0.053, 0.023 (–0.099 to –0.007) 0.023
PANSS –0.002, 0.001 (–0.003 to –0.001) 0.006
QPR 0.005, 0.001 (0.003 to 0.007) < 0.001
CDSS –0.008, 0.002 (–0.013 to –0.004) < 0.001
Taking clozapine –0.052, 0.030 (–0.110 to 0.006) 0.080
EQ VAS 0.002, < 0.001 (0.001 to 0.003) < 0.001
Constant 0.733, 0.079 (0.577 to 0.888) < 0.001
SE, standard error.
TABLE 25 People with no problem on EQ-5D domains for participants with complete cost and QALY data
EQ-5D health states
Trial arm, n (%)
CBT (N= 76) TAU (N= 93)
Baseline
No problem with mobility 55 (72) 50 (54)
No problem with self-care 48 (63) 64 (69)
No problem with usual activities 27 (26) 32 (34)
No problem with pain/discomfort 43 (57) 38 (41)
No problem with anxiety/depression 9 (12) 12 (13)
9-month assessment
No problem with mobility 54 (71) 47 (51)
No problem with self-care 55 (72) 60 (65)
No problem with usual activities 41 (54) 40 (43)
No problem with pain/discomfort 47 (62) 42 (45)
No problem with anxiety/depression 17 (22) 11 (12)
21-month assessment
No problem with mobility 50 (66) 49 (53)
No problem with self-care 55 (72) 51 (55)
No problem with usual activities 38 (50) 36 (39)
No problem with pain/discomfort 47 (62) 38 (41)
No problem with anxiety/depression 17 (22) 15 (16)
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Table 26 reports the EQ VAS scores and the EQ-5D-5L utility scores at each follow-up assessment. The utility
values are reported for the crosswalk system,170 developed to map the EQ-5D-5L to the EQ-5D, three-level
version and the new utility value set estimated specifically for the EQ-5D-5L.157 The new utility value set was
used for the primary analysis and the crosswalk system was included in one of the sensitivity analyses.
The length of follow-up (days) and QALYs (derived from the EQ-5D) are presented in Table 27 for
participants with complete cost and QALY data. The number of days of follow-up is similar in both
groups at both the 9- and 21-month follow-ups.
TABLE 26 The EQ-5D-5L utility scores and EQ VAS scores at each assessment for participants with complete cost
and QALY data
Measure
Trial arm, mean, SE (95% CI)
CBT (n= 76) TAU (n= 93)
EQ VAS values
Baseline 58, 2 (54 to 63) 59, 2 (55 to 64)
9-month assessment 65, 2 (60 to 69) 57, 2 (53 to 62)
21-month assessment 65, 2 (61 to 69) 58, 2 (53 to 62)
EQ-5D utility values, crosswalk system, sensitivity analysis
Baseline 0.647, 0.028 (0.592 to 0.703) 0.566, 0.030 (0.508 to 0.625)
9-month assessment 0.706, 0.028 (0.655 to 0.765) 0.597, 0.030 (0.538 to 0.657)
21-month assessment 0.717, 0.027 (0.665 to 0.772) 0.592, 0.028 (0.537 to 0.648)
EQ-5D utility values, new value set, primary analysis
Baseline 0.728, 0.024 (0.680 to 0.776) 0.668, 0.025 (0.619 to 0.7170)
9-month assessment 0.774, 0.024 (0.727 to 0.824) 0.686, 0.028 (0.630 to 0.741)
21-month assessment 0.780, 0.025 (0.731 to 0.831) 0.682, 0.026 (0.631 to 0.733)
SE, standard error.
TABLE 27 Days of follow-up and QALYs for participants with complete cost and QALY data: new utility value set
Assessment point
Trial arm, mean, SE (95% CI)
CBT (n= 76) TAU (n= 93)
Days of follow-up
Baseline to 9 months 288, 3 (282 to 294) 288, 3 (282 to 294)
Baseline to 21 months 647, 3 (642 to 653) 644, 2 (640 to 648)
QALYs
Baseline to 9 months 0.59, 0.02 (0.56 to 0.63) 0.53, 0.02 (0.49 to 0.57)
Baseline to 21 months
(discounted)
1.31, 0.04 (1.24 to 1.38) 1.16, 0.04 (1.08 to 1.24)
SE, standard error.
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Costs
Appendix 3 reports unit costs and costs of the different types of service used at each assessment point for
participants with complete cost and QALY data. Service use and costs for the 3 months prior to baseline,
from baseline to 9 months and from baseline to 21 months are summarised in Tables 28 and 29. Overall,
the large standard errors (SEs) and wide 95% CIs indicate that there is a relatively high level of variation in
costs between participants. There appear to be differences between the comparator and CBT groups at
9 and 21 months. However, the 95% CIs overlap, suggesting that any differences could be attributable to
chance rather than being statistically significantly different.
TABLE 28 Mean number of health and social care visits/admissions for participants with complete cost and QALY data
Service type
Trial arm, mean, SE (95% CI)
CBT (n= 76) TAU (n= 93)
3 months prior to baseline
Hospital inpatient admission (psychiatric) 0.01, 0.01 (< 0.001 to 0.04) 0.03, 0.02 (0 to 0.07)
Hospital inpatient admission (non-psychiatric) 0.03, 0.02 (< 0.001 to 0.06) 0.02, 0.02 (< 0.001 to 0.05)
Hospital outpatient, day and emergency care 0.97, 0.20 (0.58 to 1.37) 1.17, 0.23 (0.72 to 1.63)
Other community and social care 13.73, 1.52 (10.69 to 16.76) 15.97, 3.2 (9.61 to 22.32)
Baseline to 3 months
Hospital inpatient admission (psychiatric) 0 0
Hospital inpatient admission (non-psychiatric) 0.01, 0.01 (< 0.001 to 0.04) 0.02, 0.02 (< 0.001 to 0.06)
Hospital outpatient, day and emergency care 0.92, 0.17 (0.58 to 1.26) 1.32, 0.22 (0.88 to 1.77)
Other community and social care 12.88, 1.42 (10.06 to 15.70) 14.87, 3.24 (8.44 to 21.31)
3–6 months
Hospital inpatient admission (psychiatric) 0 0
Hospital inpatient admission (non-psychiatric) 0.01, 0.01 (< 0.001 to 0.04) 0.06, 0.03 (0.01 to 0.12)
Hospital outpatient, day and emergency care 0.91, 0.18 (0.55 to 1.26) 1.46, 0.25 (0.97 to 1.96)
Other community and social care 10.16, 1.13 (7.91 to 12.41) 14.25, 2.01 (10.25 to 18.25)
6–9 months
Hospital inpatient admission (psychiatric) 0 0
Hospital inpatient admission (non-psychiatric) 0.03, 0.03 (< 0.001 to 0.08) 0.05, 0.02 (0.01 to 0.10)
Hospital outpatient, day and emergency care 1.34, 0.31 (0.73 to 1.95) 1.28, 0.22 (0.85 to 1.71)
Other community and social care 10.68, 1.02 (8.66 to 12.71) 15.90, 2.60 (10.73 to 21.07)
9–13 months
Hospital inpatient admission (psychiatric) 0 0
Hospital inpatient admission (non-psychiatric) 0.03, 0.02 (< 0.001 to 0.06) 0.04, 0.03 (< 0.001 to 0.09)
Hospital outpatient, day and emergency care 1.24, 0.22 (0.79 to 1.68) 1.31, 0.20 (0.91 to 1.71)
Other community and social care 14.69, 1.72 (11.27 to 18.11) 16.40, 1.97 (12.48 to 20.32)
continued
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TABLE 29 Costs of health and social care, excluding costs of CBT intervention, for participants with complete cost
and QALY data
Costs of services used
Trial arm, mean cost (£), SE (95% CI)
CBT (n= 76) TAU (n= 93)
3 months prior to baseline
Hospital inpatient admission (psychiatric) 63, 63 (0 to 187) 308, 264 (0 to 829)
Hospital inpatient admission (non-psychiatric) 0 0
Hospital outpatient, day and emergency care 45, 17 (12 to 78) 62, 22 (19 to 104)
General practice, community and social 704, 89 (529 to 879) 616, 63 (491 to 741)
Total cost 718, 100 (521 to 915) 661, 68 (527 to 795)
Baseline to 9 months
Hospital inpatient admission (psychiatric) No cases using inpatient care No cases using inpatient care
Hospital inpatient admission (non-psychiatric) 234, 170 (0 to 610) 290, 123 (16 to 468)
Hospital outpatient, day and emergency care 125, 27 (67 to 173) 215, 42 (130 to 299)
General practice, community and social 1568, 135 (1260 to 1805) 1899, 195 (1511 to 2294)
Total cost 1927, 251 (1255 to 2184) 2404, 249 (1841 to 2827)
Baseline to 21 months
Hospital inpatient admission (psychiatric) No cases using inpatient care No cases using inpatient care
Hospital inpatient admission (non-psychiatric) 506, 216 (88 to 1034) 497, 178 (108 to 837)
Hospital outpatient, day and emergency care 295, 63 (152 to 406) 434, 80 (271 to 594)
General practice, community and social 3834, 424 (2886 to 4613) 4345, 484 (3383 to 5329)
Total cost 4635, 529 (3241 to 5204) 5277, 581 (4026 to 6417)
SE, standard error.
TABLE 28 Mean number of health and social care visits/admissions for participants with complete cost and QALY data
(continued )
Service type
Trial arm, mean, SE (95% CI)
CBT (n= 76) TAU (n= 93)
13–17 months
Hospital inpatient admission (psychiatric) 0 0
Hospital inpatient admission (non-psychiatric) 0 0.04, 0.02 (0 to 0.09)
Hospital outpatient, day and emergency care 1.37, 0.29 (0.78 to 1.95) 1.40, 0.22 (0.96 to 1.83)
Other community and social care 18.03, 2.62 (12.80 to 23.25) 17.42, 2.67 (12.11 to 22.73)
17–21 months
Hospital inpatient admission (psychiatric) 0 0
Hospital inpatient admission (non-psychiatric) 0.05, 0.03 (0 to 0.10) 0.05, 0.03 (0 to 0.11)
Hospital outpatient, day and emergency care 1.29, 0.22 (0.85 to 1.73) 2.02, 0.42 (1.19 to 2.85)
Other community and social care 17.22, 2.64 (11.96 to 22.49) 16.71, 2.19 (12.37 to 21.05)
SE, standard error.
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The mean use, length and costs of the CBT intervention are summarised in Table 30. In the intervention
arm, 230 out of 242 participants (95%) received treatment and provided data on the number of CBT
sessions attended. Some information on CBT session length was available for nearly half of participants
in the CBT arm (113/242; 47%); complete data on CBT session length for all attended sessions were
available for 14 out of 242 participants (6%). The unit cost per session for CBT reported by the PSSRU
(£97 per 55-minute session) was used to calculate the cost of CBT for each participant with data on the
number of sessions. Those participants allocated to the intervention group but who did not receive CBT
were allocated a CBT treatment cost of zero.
Table 31 summarises the total cost per person, including the costs of CBT for participants in the intervention
arm of the trial, for the 3 months prior to baseline, from baseline to 9 months and from baseline to 21 months.
Appendix 3 presents the total cost per person for each assessment point. Although the total costs from baseline
to 21-month follow-up appear higher for those participants in the CBT group, the variance is high and the
95% CIs overlap, suggesting that any apparent differences may be attributable to chance.
Descriptive analysis of utility, quality-adjusted life-years and cost for all
participants, using multiple imputation data
Table 32 reports the utility values and QALYs for all participants, using the MI data. As with the complete-
case analysis, utility increases from baseline to end of scheduled follow-up in both groups. The data in
Table 32 indicate that the number of QALYs is similar in each group at 9 months. There appears to be a
trend towards a difference in total QALYs between the two groups at 21 months. However, these data are
not adjusted for any differences in the characteristics or utility of participants at baseline. Although the
QALY estimates include baseline utility, this may not fully capture the impact of differences in baseline
utility on utility at follow-up.
TABLE 31 Total costs of health and social care, including costs of CBT intervention for participants with complete
cost and QALY data
Assessment
Trial arm, mean cost (£), SE (95% CI)
CBT (n= 76) TAU (n= 93)
3 months prior to baseline 718, 100 (521 to 915) 661, 68 (527 to 795)
Baseline to 9-month follow-up 4197, 254 (3485 to 4451) 2404, 249 (1841 to 2827)
Baseline to 21-month follow-up 7073, 527 (5478 to 7463) 5468, 581 (4026 to 6417)
TABLE 30 Mean use, length and costs of CBT intervention
Item Mean (SE) Range 95% CI
All participants receiving one or more CBT sessions (n/N = 230/242)
Number of sessions 21 (1) 1–46 20 to 23
Session length (minutes) (n/N = 113/242) 51 (1) 5–76 48 to 54
Average cost per participant receiving one or more CBT sessions (£) 2038 (58) 95–4370 1924 to 2152
Average cost per participant allocated to CBT (n/N = 242/242) (£) 1937 (62) 0–4370 1815 to 2059
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Costs
Appendix 3 reports the average costs by cost category at each assessment point estimated for all participants,
from the MI data. The costs by category are summarised in Table 33 for the 3 months prior to baseline, from
baseline to 9 months and from baseline to 21 months. One point to note is that the costs at follow-up are
higher in the MI data than in the complete-case data. This is mainly because complete cost and QALY data
at 21-month follow-up were not available for participants who were inpatients during scheduled follow-up.
In contrast, the mean costs estimated from the MI data do include the cost of inpatient stays in psychiatric
hospitals. The pooled available case data indicate that the mean cost of an inpatient psychiatric hospital
stay was £9525 (SE £1447, 95% CI £6681 to £12,368; n = 429) from baseline to 9-month follow-up and
TABLE 32 Utility and QALYs for all participants, using MI data
Utility and QALYs, all participants,
multiple imputation data
Trial arm, mean, SE (95% CI)
CBT (n= 242) TAU (n= 245)
Utility
Baseline (single imputation) 0.734, 0.013 (0.708 to 0.760) 0.704, 0.014 (0.675 to 0.732)
9 months 0.769, 0.014 (0.741 to 0.796) 0.723, 0.016 (0.691 to 0.755)
21 months 0.781, 0.013 (0.756 to 0.808) 0.740, 0.014 (0.712 to 0.768)
QALYs
Baseline to 9 months 0.61, 0.01 (0.59 to 0.63) 0.57, 0.01 (0.55 to 0.60)
Baseline to 21 months (discounted) 1.32, 0.02 (1.28 to 1.36) 1.24, 0.02 (1.19 to 1.28)
TABLE 33 Costs of health and social care from the MI data
Costs of services used
Trial arm, mean cost (£), SE (95% CI)
CBT (n= 242) TAU (n= 245)
3 months prior to baseline
Hospital inpatient admission (psychiatric) 2170, 515 (1158 to 3183) 2581, 553 (1494 to 3668)
Hospital inpatient admission (non-psychiatric) 48, 25 (0 to 97) 44, 24 (0 to 92)
Hospital outpatient, day and emergency care 95, 19 (57 to 133) 95, 21 (54 to 135)
General practice, community and social 796, 65 (668 to 924) 830, 78 (677 to 982)
Total cost 959, 69 (823 to 1095) 1011, 102 (810 to 1212)
Baseline to 9 months
Hospital inpatient admission (psychiatric) 9099, 1891 (5383 to 12,814) 8104, 1744 (4678 to 11,530)
Hospital inpatient admission (non-psychiatric) 182, 71 (42 to 322) 269, 84 (102 to 436)
Hospital outpatient, day and emergency care 178, 23 (133 to 224) 304, 44 (218 to 391)
General practice, community and social 1972, 180 (1619 to 2325) 2190, 160 (1874 to 2505)
Total cost (including CBT intervention) 13,368, 1884 (9667 to 17,069) 10,867, 1769 (7390 to 14,344)
Baseline to 21 months
Hospital inpatient admission (psychiatric) 17,492, 3587 (10,443 to 24,541) 15,482, 3340 (8919 to 22,045)
Hospital inpatient admission (non-psychiatric) 589, 140 (313 to 866) 573, 146 (287 to 860)
Hospital outpatient, day and emergency care 492, 72 (351 to 633) 601, 74 (456 to 746)
General practice, community and social 4882, 416 (4065 to 5698) 4842, 315 (4221 to 5462)
Total cost (including CBT intervention) 25,392, 3638 (18,244 to 32,540) 21,499, 3399 (14,820 to 28,178)
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£19,095 (SE £2962, 95% CI £13,271 to £24,919; n = 389) from baseline to 21-month follow-up.
However, participants for whom complete data were available at 21 months did not have a psychiatric
hospital inpatient stay. This suggests that the subsample of participants with complete data was not
representative of the full sample.
Overall, the MI results indicate some variation between participants and between the allocation groups in
total costs at 9- and 21-month follow-ups. The 95% CIs for the two groups overlap, suggesting that there
are no statistically significant differences in costs.
Primary analysis of incremental costs, quality-adjusted life-years and
incremental cost-effectiveness ratio
Table 34 shows the net costs and QALYs of CBT compared with TAU at 21 months of follow-up for the
primary and sensitivity analyses. Appendix 3 reports the full results of the regression analyses used to
adjust for baseline covariates. A linear regression model was used to estimate net QALYs and alternative
measures of health benefit and a generalised linear model with gamma log distribution was used for the
costs, to account for the skewed distribution of costs towards zero. The data from each of the primary and
sensitivity analyses were bootstrapped to generate 10,000 pairs of net cost and net QALY estimates.
The primary analysis indicates that CBT is associated with a net gain in QALYs and a net cost. The net
QALY gain is statistically significant. In contrast, the net cost is associated with a high level of variability
TABLE 34 Net costs and QALYs of CBT vs. TAU: primary and sensitivity analyses
Analysis Net cost (£), SE (95% CI); p-value Net QALYs, SE (95% CI); p-value
Primary analysis, n = 487 5378, 9382 (–13,010 to 23,766); 0.566 0.052, 0.025 (0.003 to 0.103); 0.038
Sensitivity analyses
Complete-case analysis,
n= 169
2531, 782 (998 to 4065); 0.001 0.153, 0.046 (0.062 to 0.243); 0.001
9-month time horizon,
n= 487
3851, 8977 (–13,744 to 21,447); 0.67 0.023, 0.013 (–0.003 to 0.049); 0.077
Crosswalk value set used to
estimate utility values
5378, 9382 (–13,010 to 23,766); 0.566 0.074, 0.028 (0.019 to 0.130) p; 0.009
Clinically relevant
improvement, PANSS (25%)
5378, 9382 (–13,010 to 23,766); 0.566 –0.066, 0.206 (–0.470 to 0.339); 0.750
Clinically relevant
improvement, PANSS (50%)
5378, 9382 (–13,010 to 23,766); 0.566 0.245, 0.277 (–0.298 to 0.788); 0.376
Clinically relevant
improvement, QPR (25%)
5378, 9382 (–13,010 to 23,766); 0.566 0.426, 0.272 (–0.107 to 0.958); 0.117
Clinically relevant
improvement, QPR (50%)
5378, 9382 (–13,010 to 23,766); 0.566 –0.104, 0.415 (–0.918 to 0.710); 0.802
Engaged in productive activity 5378, 9382 (–13,010 to 23,766); 0.566 0.318, 0.249 (–0.169 to 0.805); 0.201
Unless stated otherwise, all the results are based on the MI data set, estimated from the 10,000 bootstrap iterations, over a
time horizon of baseline to 21 months.
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and is not statistically significant. The additional net cost associated with CBT is attributable to the costs of
delivering the intervention and the higher costs of care overall. Excluding the cost of CBT, the net cost of
care for the intervention was £2123 (SE £4595, 95% CI –£6883 to £11,129; p = 0.644); however, the
difference in cost between CBT and TAU was not statistically significantly.
It is important to consider the joint uncertainty associated with the pairs of net cost and QALY estimates,
because these are combined to estimate the ICER, which is the overall outcome measure for the economic
evaluation. This uncertainty is illustrated in Figure 9 with a scatterplot of the 10,000 pairs of net cost and
QALYs, from the bootstrapped data, in the form of a cost-effectiveness plane. The cost-effectiveness plane
demonstrates that the majority of pairs of net cost and QALYs are to the right-hand side of the horizontal
axis, indicating that the CBT intervention is associated with a net gain in QALYs and health benefit.
However, the majority of pairs also lie in the top half of the vertical axis, indicating a net cost to CBT.
Table 35 reports the ICER, the likelihood that CBT is cost-effective at a WTPT of £15,000 and the estimated
net monetary benefit statistic of CBT, when compared with TAU. There is no universally agreed monetary
value to attach to QALYs. Therefore, the simulated net QALYs were revalued using a range of values that a
decision-maker may be willing to pay to gain 1 QALY, ranging from £0 to £30,000. This was based on the
range of willingness-to-pay values historically used in NICE decisions.167,172 This approach takes into account
uncertainty about the amount that decision-makers would be willing to pay to gain 1 additional QALY
from the CBT intervention. The impact of different WTPT values on the likelihood that CBT is cost-effective
is shown in the cost-effectiveness acceptability curve in Figure 10.
The primary analysis indicates that, although CBT is associated with higher health benefits than TAU in
terms of QALYs, the additional costs mean that it is unlikely to be cost-effective if decision-makers are
willing to pay £15,000 to gain 1 QALY. The probability that CBT is cost-effective (in this analysis of
10,000 net cost and QALY pair estimates) is 0.13, or 13% (see Table 35). If decision-makers are willing
to pay £30,000 to gain 1 QALY, the chance that CBT is cost-effective is < 50%, at 17% (see Figure 10).
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FIGURE 9 Cost-effectiveness plane of 10,000 pairs of net costs and QALYs: bootstrapped MI data.
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Sensitivity analyses of incremental costs, quality-adjusted life-years and
incremental cost-effectiveness ratio
The cost-effectiveness acceptability curves in Figures 11 and 12 show the sensitivity analyses for the
complete-case analysis, 9-month time horizon, QALYs estimated from crosswalk utility values (see Figure 11)
and the alternative health benefit measures (see Figure 12). These indicate that CBT has a likelihood of
being cost-effective of < 50%. This is the case for a WTPT of up to £30,000 per QALY gained (or, for the
alternative health benefit measures, a WTPT of up to £30,000 per person with a clinically relevant improvement
gained). The exception is the analysis using ≥ 25% improvement in QPR. In this case, CBT had a 54% chance
of being cost-effective.
TABLE 35 Cost-effectiveness of CBT when compared with usual care: primary and sensitivity analyses
Analysis ICER (£)
Probability that CBT
is cost-effective
(WTPT= £15,000 to
gain 1 QALY)
Net monetary benefit
statistic, mean (£), SE
(2.5th, 97.5th percentiles)
Primary analysis 103,423 0.13 –5414, 53 (–14,184, 3483)
Sensitivity analyses
Complete-case analysis 16,542 0.40 –280, 11 (–2700, 1775)
9-month time horizon 167,435 0.08 –3801, 36 (–8788, 1159)
Crosswalk value set used to estimate
utility values
72,676 0.14 –5093, 50 (–13,935, 3780)
Clinically relevant improvement,
PANSS (25%)
Dominated by TAU 0.09 –7236, 59 (–17,710, 2976)
Clinically relevant improvement,
PANSS (50%)
21,951 0.35 –2498, 89 (–20,636, –265)
Clinically relevant improvement,
QPR (25%)
12,624 0.54 392, 56 (–17,249, 3391)
Clinically relevant improvement,
QPR (50%)
Dominated by TAU 0.15 –7690, 59 (–28,345, –7709)
Engaged in productive activity 16,912 0.43 –1274, 68 (–18,547, 2147)
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FIGURE 10 Cost-effectiveness acceptability curve: primary analysis.
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The complete-case analysis suggests that there is a 40% chance that CBT is cost-effective if decision-makers
are willing to pay up to £15,000 to gain 1 QALY. This rises to an 89% chance of being cost-effective if
decision-makers are willing to pay up to £30,000 to gain 1 QALY. However, the complete-case analysis
consists of the subset of participants with complete data on costs and QALYs over the 21-month follow-up
period. These participants did not use inpatient psychiatric hospital care over the 21-month follow-up period.
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FIGURE 11 Cost-effectiveness acceptability curve: sensitivity analysis 1.
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Chapter 6 Discussion
Summary
The FOCUS trial is, to our knowledge, the first definitive RCT to evaluate the long-term clinical effectiveness
and cost-effectiveness of CBT in comparison with TAU for people who meet the criteria for CRS. In addition,
we utilised baseline data to develop a risk model of factors that may predict a good outcome from CBT.
The FOCUS trial was methodologically robust with a low risk of bias.
No effect on the primary outcome of PANSS total score was found at the 21-month assessment and the
CIs around estimated treatment effect rule out the hypothesised ES. Many of the secondary outcomes
were not found to be significant; however, there was a significant effect of CBT over TAU for the main
secondary outcome of PANSS total at the end of treatment (9-month assessment) and an encouraging NNT
for achieving a good outcome on the PANSS total score at 21 months. The results also indicated small
but significant effects of CBT over TAU for self-rated recovery, emotional distress associated with delusions
and CGI improvement at long-term follow-up, and at the end of treatment on PANSS total score, positive
symptoms, emotional distress and auditory hallucinations. With 88% of those who were allocated to CBT
having six sessions or more, it is clear that CBT is acceptable to the majority of those who are offered it.
We did not find a difference between CBT and TAU in reportable SAEs or in the number of participants
who had one or more AE. The number of reportable SAEs and the absence of any significant difference
between the groups on non-reportable AEs suggest that CBT is a safe treatment for this population.
The results of the risk modelling did not reveal any factors that predict a good response to CBT. There was
no evidence that the treatment effects of CBT varied over any of the subgroups investigated in the FOCUS
trial population for PANSS total score or the PANSS subscales.
Overall, CBT was associated with a net cost and net QALY gain compared with TAU. The additional cost for
the CBT group was the result of higher use of health and social care services by participant as well as the
additional cost of the CBT intervention. There was a high level of variance in the costs of different services
and total costs, and the differences in cost between the two groups were not statistically significant. This
indicates uncertainty about whether the CBT group incurred higher costs than the TAU group or whether
the difference found was attributable to chance. Nevertheless, the cost-effectiveness acceptability analysis
indicated a low likelihood that CBT was cost-effective, in the primary and sensitivity analyses (probability
of < 50%). There are a number of limitations that increase the uncertainty of the results, which are
discussed in Strengths and limitations.
Findings in context
The results of the FOCUS trial showed no lasting effect of CBT for people who meet the criteria for CRS on
total symptoms as measured by PANSS. However, there was a statistically significant impact on overall health
for those who received CBT in comparison with those who received TAU. Clinically significant improvement
on PANSS total score has been defined in meta-analyses of antipsychotic medication as ≥ 50% improvement
in the PANSS total score (rescaled) from baseline;32 our NNT for a good improvement in PANSS total score
was 15. A recent meta-analysis of all double-blind, placebo-controlled RCTs of antipsychotic medications,
except clozapine, found a NNT of eight for ≥ 50% improvement on PANSS.32 More specifically, for clozapine
the NNT has been reported as eight.47 However, the participants in the FOCUS trial had experienced a poor
response to treatment with both standard antipsychotic medication and clozapine and, therefore, our NNT of
15 is encouraging, particularly as this was at long-term follow-up.
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In addition, the effect of CBT at end of treatment on PANSS total, PANSS subscales (positive symptoms,
emotional distress and excitement) and auditory hallucinations demonstrates that CBT can change symptoms
of psychosis in the short term. The reasons for the short-term effect of CBT are unclear; however, given the
long DI experienced by our sample, it is possible that a greater number of CBT sessions or longer duration
of the treatment window may be required to yield a long-term benefit. It could also be argued that the
effects seen at the end of treatment are a result of the non-specific aspects of therapy, such as the therapeutic
relationship, rather than the active components of CBT. Therapeutic alliance has been shown to contribute
to both improvement and deterioration in PANSS scores for CBT and other psychological therapies, such as
supportive counselling.173 However, not all FOCUS trial participants completed CBT over the full 9-month
treatment window and, therefore, it is not possible to say with any confidence that the effects of CBT seen
at the end of treatment were indicative that it works only while treatment is ongoing.
The ES of CBT in this trial is similar to those reported by meta-analyses of CBT for psychosis trials that are
deemed to be methodically robust.67,69 The authors of the most current meta-analysis have proposed that
the field of CBT for psychosis research is lacking evidence from a large and methodologically robust trial.69
Prior to the FOCUS trial, there had been no definitive trials of CBT for CRS. The FOCUS trial has clearly
addressed this need for the CRS population and also addressed methodological limitations of previous
trials. Jauhar et al.69 reported an ES of 0.15 from trials at a low risk of masking bias and 0.62 from trials at
a high risk of bias. For the FOCUS trial, the risk of this particular bias is low, with only 6.17% of assessments
at 9 months (end of treatment) being conducted by an unmasked assessor and our ES at the end of treatment
being 0.16, consistent with the pooled estimate from low-risk trials reported by Jauhar et al.69
With regard to other outcomes, meta-analyses have shown very small ESs for trials with a low risk of bias
from masking for positive symptoms.67,69 Jauhar et al.69 found, at the end of treatment, an ES of 0.08 for
positive symptoms and concluded, therefore, that it is not justified to propose that CBT is effective for
positive symptoms. However, the end-of-treatment results for the FOCUS trial indicate an ES of 0.24 and,
although this is a small effect, this finding comes from a methodologically robust trial and is encouraging
as it indicates that for positive symptoms, CBT can have small short-term benefits for people who meet
criteria for CRS, while in receipt of treatment. This finding is particularly encouraging given that our
participants have experienced positive symptoms with a poor response to antipsychotic medication and
their DI, on average, was long. This finding also demonstrates, in line with psychological models of
psychosis, that hallucinations and delusions can change in response to consideration of the person’s
interpretation of these experiences and their associated behavioural responses.
Cognitive–behavioural models of psychosis and schizophrenia recognise the link between cognitions,
emotions and behaviours; the CBT delivered in this trial permitted work on emotional distress and
dysfunction, including prioritising depression and anxiety (if the participant prioritised this as part of their
problem list or goals for therapy). Given the role of emotion in psychosis, it has been argued that CBT for
psychosis trials should include emotional distress as a secondary outcome121 and the results of the FOCUS
trial indicate that CBT can have small but significant effects at the end of treatment for this important
secondary outcome.
There were also some small long-term treatment effects at the 21-month assessment, including for
self-rated recovery and an encouraging NNT of 15 to achieve a good response (> 50% improvement
on PANSS at 21 months). The primary health economics analysis also suggested that CBT is associated
with higher health benefits than TAU in terms of QALYs. Service users advocate that outcomes used in
research and clinical services should refocus to ones of personal recovery goals, rather than the reduction
or absence of symptoms, which has traditionally been the key outcome advocated by clinicians.118 UK
policy places an emphasis on recovery-orientated outcomes and services for people who experience psychosis
and schizophrenia30 and, for this reason, our finding that CBT can have a lasting effect on self-rated recovery
is arguably more important for service users and services.
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The primary health economics analysis uses the EQ-5D-5L and new value set rather than the earlier,
interim, crosswalk value set. The crosswalk value set mapped utility values from the older EQ-5D-3L
measure to the EQ-5D-5L.170 The new set of utility values157 is intended to replace the crosswalk system.
The data for the new value set were collected using a different methodology, at a different time and on a
different sample to the original utility value set used for the EQ-5D-3L and the crosswalk value set. This
means that differences in utility between the crosswalk and new value set may reflect differences in
methods, time and sample rather than underlying preferences and/or changes in preferences over time.
Thus, the crosswalk-derived values were used to facilitate comparison between utility values estimated
using the older three-level version of the EQ-5D and the more recent five-level version.
Table 36 compares the UK population norms for the EQ-5D-3L utility values and those of the FOCUS trial
participants using the EQ-5D-5L and crosswalk value set. This indicates that FOCUS trial participants have
lower utility values across all age group, and, overall, than the sample of the general population used to
generate the population norms.174
The utility values for FOCUS trial participants were similar to those reported in other studies. Barton et al.158
reported EQ-5D-3L baseline utility values of 0.657 (n = 32) to 0.693 (n = 36), whereas Crawford et al.175
reported EQ-5D-3L utility values of 0.664 to 0.699 (n = 409). The pooled baseline mean utility for participants
with severe schizophrenia requiring a change in management in the Cost Utility of the Latest Antipsychotic
Drugs in Schizophrenia Study (CUtLASS) (unpublished analysis of utility data from the CUtLASS trial) was 0.628
(SE 0.017, 95% CI 0.595 to 0.661; n= 361).159,160 Similarly, another large study,159 also using the EQ-5D-3L,
looked at the use of antipsychotics in a population with schizophrenia and found that the baseline mean
utility was 0.61 to 0.67 (SD 0.29 to 0.33; n= 118). Finally, a recent large study176 (n = 275) of schizophrenia
reported higher values using the EQ-5D-5L, with reported baseline utility values between 0.74 and 0.76.
There is limited evidence about the relative cost-effectiveness of CBT in people with psychosis and
schizophrenia. We identified three economic evaluations158,177,178 published since 2010 that used broadly
similar methods, in a UK setting. Barton et al.158 compared social recovery-orientated CBT with usual care
(defined as active case management), over 9 months’ follow-up. The authors concluded that social
recovery-orientated CBT was cost-effective in 54% of scenarios at a WTPT of £20,000 per QALY.158 A UK
evaluation of CBT combined with motivational care, using a societal perspective and a time frame of 18 months,
concluded that the probability of the intervention being cost-effective was 69%, even if decision-makers are not
willing to pay to gain a 1-point increase in the Global Assessment of Functioning.177 McCrone et al.178 evaluated
an early intervention service for people with psychosis, which included low-dose medication regimens, CBT,
family therapy and vocational rehabilitation. This study found that the intervention did not increase costs and
was likely to be cost-effective (probability of 76%) even if decision-makers are not willing to pay to gain an
additional person who makes a full or partial vocational recovery.178
A fourth study179 compared cognitive remediation therapy plus usual care with usual care alone and found
it likely to be cost-effective from a NHS and social care perspective but at a limited time horizon of
40 weeks.
Although using different time horizons and health benefit measures, the findings of these studies differ
from the findings of this study, which indicates that CBT is not likely to be cost-effective. All identified
studies had limitations, including missing data, small sample sizes and challenges controlling for other
medications/treatments received outside the trial intervention. In addition, the participants in this study
were people unable to tolerate, or with an inadequate response to, clozapine. This may mean that they
are less likely to respond to CBT than people who are not treatment resistant or treatment intolerant.
Although CBT was associated with a net gain in QALYs, the costs of CBT were not offset by reduced use
of other health and social care services; the participants in the CBT group used more services and had
higher costs than the TAU group. However, the greater use of health and social care services found in
the CBT group may reflect a desirable outcome for this population who typically have a high level of
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TABLE 36 Utility values, population norms (EQ-5D-3L and Time Trade Off values) and FOCUS trial participants (EQ-5D-5L and crosswalk values)
EQ-5D utility values
Age (years)
18–24 25–34 35–44 45–54 55–64 65–74 ≥ 75 All ages
Population norms, EQ-5D-3L
Mean 0.940 0.927 0.911 0.847 0.799 0.779 0.726 0.856
SE 0.007 0.006 0.007 0.011 0.012 0.012 0.015 0.004
25th percentile 0.97 0.85 0.85 0.80 0.73 0.69 0.66 0.8
75th percentile 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
95% CI Not available Not available Not available Not available Not available Not available Not available Not available
FOCUS trial participants, EQ–5D-5L and crosswalk values, n = 453
Mean 0.721 0.723 0.643 0.604 0.466 0.662 No cases 0.631
SE 0.057 0.019 0.018 0.025 0.040 0.065 No cases 0.012
25th percentile 0.62 0.63 0.54 0.46 0.20 0.56 No cases 0.50
75th percentile 0.88 0.85 0.82 0.82 0.70 0.76 No cases 0.84
95% CI 0.600 to 0.842 0.685 to 0.761 0.607 to 0.679 0.554 to 0.654 0.385 to 0.547 0.508 to 0.816 No cases 0.607 to 0.655
D
ISCU
SSIO
N
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
72
unidentified and unmet need for health and social care.180 There is evidence that the physical health needs
of this population are severely neglected, often as a result of discrimination by health-care providers.180,181
This can arise if health-care providers attribute physical sympyoms to a person’s mental health condition,
often referred to as ‘diagnostic overshadowing’.181 Moreover, the fear and shame associated with the
public stigmatisation of psychosis and schizophrenia often results in feelings of disempowerment and
avoidance of help-seeking for health-care needs.182 The reduction of stigma and discrimination has been
identified as a key target for improving the physical health care of people with a serious mental illness.183
The early mortality associated with these unmet needs indicates an area in which improvements in health
and social care are needed. It is suggested that one approach to making such improvements could be to
utilise interventions that encourage service users with serious mental illness, such as CRS, to become
empowered to seek support for their physical health care.183 The findings of this trial indicate that
participants who received CBT had greater use of the health-care services that people who meet the
criteria for CRS have an equal right to access. Increasing the overall level of physical and mental health
care for CRS patients may reduce the differences in costs between the TAU and CBT groups in this trial,
potentially improving the relative cost-effectiveness of CBT.
Strengths and limitations
The FOCUS trial provides high-quality evidence regarding the clinical effectiveness and cost-effectiveness of
CBT for this population, with a low risk of bias across a number of domains. Our trial was pre-registered
and our a priori SAP was published online and in the public domain. Compared with other trials that
have evaluated CBT, the FOCUS trial had many methodological strengths that reduced the potential for
bias: randomisation was implemented via a web-based platform centrally and independently, resulting in
concealed allocation; outcome assessors were blinded and there were few instances of unblinding; a high
proportion of participants received their allocated intervention; and there was low attrition for the primary
outcome. Furthermore, the FOCUS trial was adequately powered to detect a clinically meaningful difference
at 21-month follow-up. Data from the CONSORT diagram (see Figure 2) indicate a representative sample of
people who meet CRS criteria. Of people identified for the study, 72% agreed to meet with the research
team and, of those, 94.5% agreed to take part in the study. Although there is a subgroup of people who
met the CRS criteria who refused to meet with the study team, overall the majority of people referred
were engaged. Moreover, the services we recruited from were typical of services for CRS, that is CMHTs,
clozapine clinics, psychiatrists and inpatient settings.
The FOCUS trial had strong patient and public involvement (PPI) in the conception of the study design
and oversight of the study throughout, with PPI representation on the trial management committee, the
Trial Steering Committee and the Data Monitoring and Ethics Committee. The trial documentation was
reviewed by two co-applicants, who provided PPI representation, interpreted the results and wrote the
participant summary sheet.
The RAs and therapist received training before the trial commenced, or, if they were appointed during the
trial, received training before they started to see participants. They received regular supervision throughout
the lifetime of the trial to ensure that assessments were conducted reliably and CBT was delivered with
fidelity to the model. The small treatment effects should be routinely replicable in the NHS, because almost
all of our therapists were band 7, which is the lowest NHS band for psychological therapists. The frequency
with which FOCUS trial therapists received supervision is likely to be greater for FOCUS trial therapists than
in the NHS; however, it could be argued that for the CRS population, in whom there is a greater degree of
complexity, more frequent supervision may be indicated. One limitation to the design of the study was the
choice of TAU as the comparator. Although this was specified in the commissioned call by the funder as
the comparator, we recognise that a control group that does not include non-specific therapeutic factors,
such as contact time, does not allow us to exclude the possibility that any observed change was not
attributable to the non-specific therapeutic aspects of CBT.
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When placing the above findings in context, it is important to note that, although the effects at the end
of treatment and long-term follow-up were statistically significant, the changes observed on the outcome
measures are unlikely to reach a threshold of clinically significant change. The NNT of 15 to achieve a
good response on our primary outcome, a 50% reduction in PANSS score, at 21 months is encouraging.
NNT is reported for 25%, 50% and 75% change in PANSS score from baseline and it is widely accepted
that a 50% improvement in PANSS score is a good outcome.32 Clinicians consider NNT to be a useful way
to interpret the findings of trials.184 However, there are limitations to representing the outcome data for
this trial as NNT; the amount of change on PANSS from baseline is dependent on the starting point, that
is the baseline score, and the use of percentage change to generate the NNT ignores the absolute benefit.
The NNT should be presented with CIs; however, when there is no treatment effect, generating an
accurate CI is problematic.185 In the case of the FOCUS trial, the treatment effect on PANSS at 21 months
was limited. Therefore, although NNT has been reported here to aid interpretation by clinicians, who
regularly use this statistic, its interpretation should be undertaken with caution, with the caveat that the
most efficient and least biased way to analyse the trial data is using our primary analysis of a linear mixed
model adjusting for baseline. It should also be noted that NNT is one of a number of statistical tests carried out,
and multiple hypothesis testing may lead to type I error, inflating the chance of finding a positive result.
The economic analysis was subject to the same strengths and limitations discussed for the clinical
evaluation of effectiveness in terms of trial design, trial sample and length of follow-up.
In line with NICE recommendations,156 the measure of health benefit used for the primary analysis was the
QALY, estimated from the published EQ-5D utility values. This enables comparison between different
disorders, which is useful for policy-makers and commissioners, who have to consider the distribution of
limited budgets between different health-care services. However, the EQ-5D is a generic health status
measure that may not be sufficiently sensitive to identify important clinical changes in participants’ mental
health. The measure covers five domains (mobility, self-care, usual activity, pain and distress and anxiety
and depression), but does not include specific symptoms that may be important to service users. This
means that the measure could underestimate the benefits of a successful intervention. The descriptive
analyses indicated that the EQ-5D health status measure and associated utility index correlated well with
the clinical measures used in the trial (see Appendix 3). In addition, the sensitivity analyses using clinical
measures of improvement in mental health symptoms (PANSS) and indicators of recovery (QPR) also found
that CBT was not likely to be cost-effective.
As planned prior to the end of data collection, the new value set was used to estimate utility values from
the EQ-5D-5L. More recently, however, NICE advised that the crosswalk mapping system, developed as
an interim method of estimating utility values, should be used.186 This is to allow time for further work
to explore and understand differences between two approaches before the NICE methods guidance is
updated. Accordingly, we re-estimated the results using the older crosswalk system as one of the sensitivity
analyses. The results of this did not differ substantially from the primary analysis.
There were differences between the CBT and TAU groups in utility scores at baseline, although these
differences were not statistically significant. The lower score in TAU participants may reflect the lower
overall health status of people in the TAU group. This was accounted for, to some extent, by including
the baseline utility value in the calculation of total QALYs between baseline and the end of follow-up.
In addition, the EQ-5D thermometer or EQ VAS score at baseline was included as a covariate in the analyses
to account for possible differences in overall health and utility between the groups.
The proportion of participants with complete-case data (34%) makes imputation of missing data essential
but difficult. In addition, none of the participants for whom complete cost and QALY data were available at
21-month follow-up had psychiatric inpatient stays. In contrast, the available case data at each assessment
indicated that this service was used by participants. This suggests that the group of participants with
complete cost and QALY data may not be representative of the study sample as a whole. To strengthen
the robustness of the results, available data were used at each assessment point to impute cost categories
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and EQ-5D domains and passively impute total costs and QALYs. The level of missing data for psychiatric
inpatient stays was ≤ 20% at baseline and at 9- and 21-month follow-up, which, in part, reflects the use
of hospital case note review for participants reporting any psychiatric hospital inpatient stay. Psychiatric
inpatient stay was the key cost component of the total cost. In the available and multiple imputation data,
it accounted for approximately 70% of the total cost.
With the exception of non-psychiatric hospital stay, the level of missing data for the other cost categories
at baseline and 9-month follow-up was ≈30%. However, it was higher (37–44%) at 21-month follow-up.
Constraints on researcher time meant that it was not feasible to review primary and community care or
non-psychiatric hospital case notes. The level of missing utility data was lower: < 10% at baseline and
< 30% at 21-month follow-up.
The greater number of complete data for each cost category means that our approach of imputing cost
categories for each assessment point mitigates the overall impact of missing data to some extent (in terms
of both bias and imprecision). Nevertheless, the large number of missing cost data at 21-month follow-up
means that the results must be interpreted with caution. The extensive uncertainty around estimates from
all analysis reflects this.
The primary analysis for the economic evaluation was limited to direct costs, from NHS and social care
perspectives. In this population, effective interventions may also affect whether or not a person is
employed and the subsequent earnings and benefits they receive. The trial design needed to balance
complete and detailed assessment of outcomes and service use with minimisation of participant burden
when possible. It was felt to be important to collect detailed service use data at 3-monthly intervals to
minimise problems with participant recall. Accordingly, limited information was collected about paid and
unpaid work and activities. This covered whether the participant was participating in paid or unpaid/
voluntary employment, education or training, other productive activity or was unemployed. The data
suggested that there were no statistically significant differences between groups in the proportion of
participants engaged in any productive activity or participating in paid employment.
If CBT improves overall health and/or mental health symptoms and recovery, then this may reduce the need
for informal carers (e.g. family members), potentially offsetting some of the costs of formal care and CBT.
Experience in previous trials indicated a number of barriers to collecting data about the use of informal
carers and the time spent by carers. These included incomplete reporting of whether or not participants
had family members or friends who they considered to be informal carers. In addition, informed consent
was required from participants to contact any informal carers identified, and from informal carers to collect
this information. The data collected from informal carers were also incomplete in a number of cases. These
factors meant that complete data were available only for a small proportion of participants.159,160 Combined
with the need to collect detailed formal care-use data, it was felt to be outside the scope of this trial to
collect information about the use of informal care. This means that, if CBT reduced or increased the use of
informal care, our estimates would underestimate or overestimate the relative cost-effectiveness of CBT.
The economic evaluation was limited to the choice of intervention and comparator included within the
trial. Although this leads to a robust comparison, it may not reflect the full range of interventions that are
available within a clinical setting. For example, other economic evaluations identified looked at a wider
range of psychological therapies in a population with schizophrenia, including cognitive remediation
therapy, group art therapy and body psychotherapy.179,187,188 A modelling study, informed by a network
meta-analysis of trial data, would have the potential to compare costs and outcomes across a wider range
of interventions. However, in this treatment-resistant population there are likely to be limited data to
inform the model structure and populate the model.
Although PANSS is commonly used as a primary outcome measure in treatment trials for people who
meet criteria for a schizophrenia diagnosis (both pharmacological and psychological), it may not have been
the most appropriate outcome for this trial for a number of reasons. Although PANSS has been rated
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favourably by service users,116 the same study also found that, overall, service users have a preference
for self-rated measures. In addition, it has been argued that distinctions between pharmacological and
psychological interventions should be made clearer in that psychological interventions, such as CBT,
are not a quasi-neuroleptic. Therefore, outcome measures should reflect the target of the specific
intervention.121 For CBT this could be positive symptoms,67 but it may be more appropriate to consider
the reduction of emotional distress given that this is a primary aim of CBT, or self-rated recovery,
given the emphasis in CBT on working with the client’s own problem list and goals.
The analysis adjusting for the measure of working memory at baseline needs to be interpreted with caution
for two reasons. First, the response rate at baseline was poor because the assessment was introduced
9 months into the recruitment window; a small proportion of data was expected to be missing given that
the working-memory assessment was introduced 9 months into the recruitment window. Burden may also
explain missing data for this measure. There were a relatively high number of measures in the assessment
battery; more specifically, in relation to the working-memory measure, the participant was required to recall
and reorder sequences of letters and numbers from a string length of two to seven, and this may have
been too burdensome. Second, we proposed a sensitivity analysis using our own algorithm for scoring the
measure that was not described by the author.
Although the RAs were blind to allocation, it is not possible to blind participants from the treatment
allocation and mask the receipt of CBT when the control is TAU. It could be argued, therefore, that the
treatment effect, because it was so small, might be an artefact of the design.
Our inclusion criteria for CRS had been employed in a previous study of clozapine augmentation with a
second antipsychotic.52 This did not include tests to determine, for each potential participant, whether
or not there were any periods of less than full clozapine adherence, that an adequate plasma clozapine
level (350 ng/ml) had been achieved consistently for an adequate time or substance use (that may have
adversely influenced the effectiveness of the clozapine treatment). It could be argued that such tests were
necessary to establish clozapine unresponsiveness; however, given the existing precedent for our inclusion
criteria, it was considered unrealistic and impracticable to apply criteria relating to the adequacy of the
clozapine trial for each patient being screened for eligibility, which involved checks and investigations that
are not routinely done in clinical practice and which, for many patients, could prove to be difficult if not
impossible to definitively establish whether or not they were met.
Implications for public health/treatment services
The results of the FOCUS trial suggest that CBT should not be offered routinely with the aim of achieving
lasting symptom reduction in people who meet the criteria for CRS. However, the finding that CBT has
short-term effects for symptoms and long-term effects for self-recovery, and had a NNT of 15 for good
response on our primary outcome, suggests that services could consider offering CBT as a pragmatic
individual trial. This may be particularly indicated when the service user’s goals relate to acutely distressing
positive symptoms and voices or longer-term recovery-orientated goals. The economic evaluation indicates
that participants in the CBT group had a net gain in overall health as measured by QALYs. The CBT group
also used more services over the course of the trial. Whether this was attributable to chance or to the
intervention is unclear. The economic analysis of the participants with complete cost and QALY data also
indicates that there may be participants for whom CBT is more likely to be cost-effective. One feature of
those with complete cost and QALY data was that they had lower costs in the 3 months prior to the
baseline assessment. As outlined, it was not possible to identify any subgroups of participants who had a
good outcome from CBT and, therefore, if offering a pragmatic trial of CBT, it should be considered for all
service users who meet the criteria for CRS. In addition, the uptake of CBT by FOCUS trial participants
provides an optimistic message for the ability to engage people whose experiences are considered
‘treatment resistant’.
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A commonly used approach to the treatment of CRS is to augment clozapine with a second
antipsychotic.53 The treatment ES for augmentation with a second antipsychotic has been shown to be in
the small but significant range. The ESs found in the FOCUS trial for CBT are also very similar to those
found for pharmacological augmentation with a second antipsychotic.55 However, the FOCUS trial provides
a more rigorous test of the effects of a treatment for CRS, with a lower risk of bias than the few, small,
short-duration, low-quality trials that contribute to the meta-analyses of augmentation with antipsychotics.
In addition to the methodological limitations of the clozapine augmentation trials, the current evidence
base cannot provide a clear indication from the literature to indicate which clozapine combination strategy
is superior.58 The adverse effect profile for CBT is also likely to be favourable when compared with the
likely cardiovascular risks associated with multiple antipsychotic medications. Therefore, for service users
who are reluctant to consider pharmacological augmentation because of the likely side effect burden of
polypharmacy, the provision of CBT may be indicated.
A pragmatic trial of CBT may be more effective if offered earlier in the course of clozapine use, when
treatment resistance is first established and when DI is shorter, given the personal and social functioning
subgroup analysis, which indicated that participants with a shorter DI had greater benefits from CBT in
this domain. This may be particularly important as entrenched symptoms may persist for longer and
respond more slowly to CBT, which is similar to the use of medication. A person may need to attend more
sessions of CBT to derive maximum benefit, given that results of the CACE analysis indicated a potential
dose response: for every session of CBT attended, there was a 0.11 reduction in the PANSS total score.
The FOCUS trial recruited people who met the criteria for CRS and, for this reason, the small and short-term
effect on symptoms does not mean that CBT will not have stronger effects for less severe or earlier psychosis
populations. The NICE guideline for the treatment of psychosis and schizophrenia30 recommends that EIP
services routinely offer CBT and family intervention for people with a first episode of psychosis, and meta-
analysis of the effects of CBT for this population has demonstrated that it can reduce symptom severity.189
Finally, it is important to note that the FOCUS trial has an optimistic message for people who meet the
criteria for CRS: both the CBT and TAU groups recovered during the trial period to a degree that, on
average, approaches clinical significance. Given the DI, poor response to medication and lack of social
opportunities (such as employment) among FOCUS trial participants, the finding that, on average,
each group had a 10-point improvement in PANSS total scores is a positive one.
Implications for future research
Clearly, this is a population of people who have significant unmet need in relation to their physical and
mental health and, therefore, future research to develop and evaluate more effective interventions is
required. This could include pharmacological (although issues of physical health and side effects are likely
to be important) and other new interventions of either a psychological or social nature. Given the current
criticism of CBT for psychosis trials, future RCTs of psychological or social interventions for this population
should also demonstrate high methodological rigour and a low risk of bias, as this will help to identify
populations most likely to benefit from this intervention.
More specifically, in relation to CBT for this population, approaches to analysis, such as trajectory analysis,
may identify responders to CBT; however, it was not possible to use this analytical approach in the FOCUS
trial because of the limited number of time points at which our data were collected. There is no research
to date to indicate whether or not there are any active ingredients of CBT for the CRS population, and, in
the FOCUS trial, a number of techniques were utilised within therapy. Therefore, from the FOCUS trial
data, it should be explored if there are any specific therapeutic techniques that result in a good outcome
from CBT. Previous research indicates that there is a greater treatment effect from CBT for people
considered at risk of developing psychosis if therapy involves between-session tasks and formulation,154
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and mediation analyses of the FOCUS trial data may reveal components of therapy as predictors
of response.
The mean health and social care costs for the 3 months prior to the baseline assessment were lower in
the analysis of participants with complete cost and QALY data (£686, 95% CI £572 to £801; n = 169)
than the MI analysis of all participants (£985, 95% CI £863 to £1107; n = 487). This indicates that, for
whatever reason, these participants were making less use of services. In addition, the analysis indicated
that participants in the CBT group used more health and social care services than those in the TAU group,
particularly towards the end of the follow-up period. Future research could explore the reasons for high
and low service use and whether it indicates higher need for care, or whether CBT helps participants
and/or health-care professionals better recognise the need for care.
The economic evaluation was limited to the choice of intervention and comparator included within the
trial. Although this leads to a robust comparison, it may not reflect the full range of interventions that are
available within a clinical setting. A modelling study, informed by a network meta-analysis of trial data,
would have the potential to compare costs and outcomes across a wider range of interventions. This
could include comparisons of TAU plus CBT with TAU plus other forms of counselling, supportive care or
psychosocial therapy interventions or with TAU plus pharmacological augmentation. However, in this
treatment-resistant population, there are likely to be limited data to inform the model structure and
populate the model.
Conclusions
Cognitive–behavioural therapy for people who meet the criteria for CRS has small but significant
improvements for symptoms of psychosis in the short term, but there is not a lasting effect in the long
term (except in relation to self-rated recovery). CBT is a highly acceptable treatment with little evidence
of adverse effects for this population. Finally, psychotic symptoms in CRS improved in both groups to a
clinically significant extent over 21 months, suggesting that long-term recovery is possible.
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Appendix 1 Recruitment information
TABLE 37 Referral pathway of participants randomised
Service setting
Centre, n (%)
All (N= 487)
Manchester
(N= 108)
Southampton
(N= 105)
Newcastle
(N= 92)
Edinburgh
(N= 92)
Glasgow
(N= 90)
CMHT 224 (46.0) 24 (22.2) 69 (65.7) 69 (75.0) 24 (26.1) 38 (42.2)
Clozapine clinic 129 (26.5) 20 (18.5) 19 (18.1) 8 (8.7) 39 (42.4) 43 (47.8)
MHRN 46 (9.4) 44 (40.7) 2 (1.9) 0.00 0.00 0.00
Inpatient unit 42 (8.6) 4 (3.7) 1 (1.0) 7 (7.6) 24 (26.1) 6 (6.7)
Research trial 9 (1.8) 2 (1.9) 4 (3.8) 0.00 3 (3.3) 0.00
EIP 8 (1.6) 3 (2.8) 1 (1.0) 4 (4.3) 0.00 0.00
Supported accommodation 8 (1.6) 2 (1.9) 4 (3.8) 0.00 1 (1.1) 1 (1.1)
Psychiatrist 8 (1.6) 6 (5.6) 1 (1.0) 1 (1.1) 0.00 0.00
Assertive outreach 6 (1.2) 0.00 3 (2.9) 2 (2.2) 0.00 1 (1.1)
Forensic services 2 (0.4) 0.00 0.00 1 (1.1) 0.00 1 (1.1)
Psychologist 2 (0.4) 2 (1.9) 0.00 0.00 0.00 0.00
Voluntary/third sector 2 (0.4) 1 (0.9) 0.00 0.00 1 (1.1) 0.00
Older adults’ mental health
service
1 (0.2) 0.00 1 (1.0) 0.00 0.00 0.00
MHRN, Mental Health Research Network.
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TABLE 38 Ineligible reasons
Ineligible reasons n (%)
After patients identified N = 79
No current positive symptoms of psychosis or problems 21 (26.6)
Dose of clozapine < 400mg and not limited because of side effects 16 (20.3)
Lacking capacity to consent 9 (11.4)
Current CBT or CBT in previous year 8 (10.1)
Never taken clozapine 7 (8.9)
Diagnosis not schizophrenia spectrum 7 (8.9)
Discontinued clozapine > 2 years ago 6 (7.6)
Moved out of area 2 (2.5)
Diagnosis of a developmental disability 1 (1.3)
Not English speaking 1 (1.3)
Deceased before consented 1 (1.3)
After patients found to be eligible N = 47
Below threshold on PANSS 40 (85.1)
Diagnosis not schizophrenia spectrum 2 (4.3)
Lacking capacity to consent 2 (4.3)
Dose of clozapine < 400mg and not limited because of side effects 1 (2.1)
No current positive symptoms of psychosis or problems 1 (2.1)
Unable to complete the baseline assessment 1 (2.1)
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Appendix 2 Additional analyses
TABLE 39 The PANSS outcome using MI
PANSS subscale Mean difference 95% CI p-value
PANSS total
9 months –2.50 –4.98 to –0.02 0.048
21 months –0.63 –3.22 to 1.96 0.634
PANSS positive
9 months –1.64 –2.65 to –0.63 0.002
21 months –0.74 –1.80 to 0.33 0.174
PANSS negative
9 months –0.43 –1.44 to 0.59 0.408
21 months 0.28 –0.77 to 1.32 0.604
PANSS disorganised
9 months 0.05 –0.88 to 0.98 0.915
21 months 0.22 –0.75 to 1.19 0.657
PANSS excitement
9 months –1.14 –1.84 to –0.44 0.001
21 months –0.51 –1.25 to 0.23 0.176
PANSS emotional distress
9 months –1.04 –2.02 to –0.05 0.040
21 months –0.10 –1.14 to 0.94 0.853
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TABLE 40 Complier-average causal effect analysis estimates, using a minimum of six sessions of CBT attendance at
9 months
Mean difference 95% CI p-value
PANSS
Total –2.50 –5.10 to 0.11 0.060
Positive –0.52 –1.60 to 0.56 0.348
Negative –1.67 –2.68 to –0.67 0.001
Disorganised –0.00 –0.97 to 0.97 0.997
Excitement –1.28 –2.05 to –0.50 0.001
Emotional distress –1.17 –2.21 to –0.13 0.028
CDSS –0.59 –1.41 to 0.22 0.152
AnTI –0.03 –0.90 to 0.83 0.942
PSYRATS
Delusion –0.42 –1.67 to 0.82 0.506
Auditory hallucinations –2.62 –5.12 to –0.12 0.040
Unusual beliefs – cognitive –0.24 –1.05 to 0.58 0.566
Unusual beliefs – emotional –0.29 –0.83 to 0.24 0.283
Voices – cognitive –0.34 –0.87 to 0.19 0.205
Voices – emotional –0.45 –1.01 to 0.11 0.114
Voices – physical –0.63 –1.23 to –0.04 0.038
Voices – loudness –0.24 –0.54 to 0.06 0.112
PSP 2.05 –0.33 to 4.43 0.091
QPR 2.02 –0.10 to 4.14 0.062
AUDIT 0.72 –0.20 to 1.64 0.127
DAST –0.15 –0.53 to 0.22 0.414
Severity CGI –0.09 –0.32 to 0.13 0.418
Participant severity CGI 0.08 –0.27 to 0.42 0.669
Condition improvement CGI –0.35 –0.58 to –0.11 0.004
EQ-5D-5L 0.036 –0.006 to 0.078 0.094
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
TABLE 41 Complier-average causal effect analysis estimates, using a minimum of six sessions of CBT attendance at
21 months
Mean difference 95% CI p-value
PANSS
Total –0.87 –3.69 to 1.96 0.548
Positive 0.36 –0.76 to 1.48 0.527
Negative –0.95 –2.10 to 0.19 0.102
Disorganised 0.17 –0.87 to 1.22 0.745
Excitement –0.56 –1.32 to 0.20 0.146
Emotional distress –0.33 –1.47 to 0.80 0.565
CDSS –0.51 –1.41 to 0.38 0.263
AnTI –0.68 –1.61 to 0.26 0.155
PSYRATS
Delusion –0.84 –2.22 to 0.54 0.232
Auditory hallucinations –1.37 –4.01 to 1.27 0.310
Unusual beliefs – cognitive –0.39 –1.28 to 0.51 0.397
Unusual beliefs – emotional –0.58 –1.16 to 0.00 0.050
Voices – cognitive –0.17 –0.75 to 0.40 0.551
Voices – emotional –0.01 –0.60 to 0.58 0.969
Voices – physical –0.33 –0.91 to 0.25 0.267
Voices – loudness –0.32 –0.64 to 0.01 0.057
PSP –0.10 –2.85 to 2.64 0.941
QPR 2.27 0.15 to 4.39 0.036
AUDIT 0.84 –0.18 to 1.87 0.107
DAST 0.10 –0.18 to 0.38 0.488
Severity CGI –0.04 –0.26 to 0.19 0.752
Participant severity CGI 0.12 –0.23 to 0.48 0.502
Condition improvement CGI –0.04 –0.32 to 0.23 0.757
EQ-5D-5L 0.03 –0.01 to 0.07 0.151
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TABLE 42 Questionnaire about the Process of Recovery: age, age at onset and sex
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Age (years)
9 months
16–32 53.3 (12.1); 40 50.6 (9.6); 40 0.41 –3.67 to 4.50 0.842 –2.33 –7.16 to 2.51 0.345
33–49 51.1 (10.1); 97 48.7 (10.8); 105 2.74 0.16 to 5.33 0.038
≥ 50 48.3 (13.8); 44 47.0 (12.9); 49 1.23 –2.70 to 5.16 0.540 –1.51 –6.22 to 3.19 0.528
21 months
16–32 52.5 (8.4); 92 49.4 (11.0); 104 2.52 –0.10 to 5.14 0.059
33–49 54.6 (9.2); 38 50.9 (11.9); 32 0.80 –3.66 to 5.26 0.724 –1.72 –6.89 to 3.45 0.514
≥ 50 47.9 (11.8); 35 47.2 (12.7); 49 1.78 –2.39 to 5.94 0.403 –0.74 –5.67 to 4.18 0.767
Age at onset (years)
9 months
≤ 35 52.2 (10.8); 148 49.0 (10.9); 169 2.45 0.40 to 4.51 0.019
≥ 36 46.7 (14.3); 22 43.0 (12.8); 16 2.96 –3.24 to 9.16 0.349 0.51 –6.02 to 7.05 0.878
21 months
≤ 35 52.6 (9.0); 141 49.4 (11.5); 159 1.71 –0.41 to 3.83 0.114
≥ 36 47.7 (14.5); 15 42.1 (12.5); 15 6.01 –0.60 to 12.61 0.075 4.30 –2.65 to 11.24 0.226
Sex
9 months
Female 52.2 (12.1); 51 46.8 (12.9); 59 4.82 1.27 to 8.37 0.008
Male 50.3 (11.4); 130 49.5 (10.2); 135 0.70 –1.56 to 2.95 0.546 –4.13 –8.33 to 0.08 0.054
21 months
Female 51.6 (10.2); 48 50.0 (11.7); 53 0.92 –2.80 to 4.64 0.628
Male 52.1 (9.4); 117 48.7 (11.7); 132 2.45 0.12 to 4.79 0.039 1.53 –2.85 to 5.92 0.493
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TABLE 43 Questionnaire about the Process of Recovery: DI, DUP and clozapine
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
DI (years)
9 months
0–15 51.8 (12.2); 79 48.8 (11.3); 68 2.20 –0.81 to 5.22 0.153
16–30 50.7 (10.8); 75 48.8 (10.5); 89 1.60 –1.27 to 4.47 0.275 –0.60 –4.77 to 3.56 0.777
≥ 31 53.7 (10.2); 16 47.3 (13.3); 28 6.51 0.66 to 12.35 0.029 4.30 –2.27 to 10.87 0.199
21 months
0–15 52.5 (10.3); 75 47.7 (12.6); 59 2.52 –0.66 to 5.70 0.120
16–30 52.1 (8.8); 68 49.2 (11.0); 85 2.45 –0.53 to 5.42 0.107 –0.08 –4.43 to 4.28 0.972
≥ 31 50.4 (11.5); 13 49.7 (12.4); 30 0.49 –5.60 to 6.59 0.874 –2.03 –8.89 to 4.83 0.562
DUP (years)
9 months
0–2 51.6 (11.4); 99 48.2 (10.5); 79 2.00 –0.76 to 4.76 0.156
2–5 51.7 (8.6); 28 48.8 (11.8); 59 1.33 –3.01 to 5.66 0.548 –0.67 –5.80 to 4.47 0.799
≥ 6 49.5 (11.8); 23 47.3 (11.9); 27 4.97 –0.27 to 10.21 0.063 2.97 –2.96 to 8.90 0.326
21 months
0–2 52.7 (9.5); 90 48.0 (11.7); 76 2.27 –0.60 to 5.15 0.121
2–5 52.9 (10.4); 28 49.7 (12.0); 54 1.65 –2.68 to 5.97 0.456 –0.63 –5.82 to 4.56 0.812
≥ 6 51.3 (9.1); 20 47.5 (11.1); 23 6.26 0.65 to 11.87 0.029 3.99 –2.33 to 10.30 0.216
continued
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TABLE 43 Questionnaire about the Process of Recovery: DI, DUP and clozapine (continued )
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Number of antipsychotic drugs at baseline
9 months
One or less 51.9 (11.0); 109 48.2 (11.5); 123 2.52 0.07 to 4.98 0.044
Two or more 49.3 (12.3); 72 49.6 (10.6); 71 0.98 –2.07 to 4.04 0.528 –1.54 –5.47 to 2.39 0.442
21 months
One or less 53.2 (9.1); 97 49.6 (11.8); 114 1.82 –0.76 to 4.40 0.167
Two or more 50.3 (10.1); 68 48.3 (11.5); 71 2.51 –0.59 to 5.60 0.113 0.69 –3.34 to 4.72 0.738
Clozapine daily dose (mg)
9 months
None 50.3 (10.4); 15 47.9 (12.7); 17 5.01 –1.41 to 11.42 0.126
< 300 54.5 (8.2); 25 47.7 (10.0); 41 5.23 0.52 to 9.93 0.030 0.22 –7.75 to 8.19 0.957
300–600 49.8 (12.5); 106 49.4 (11.1); 103 0.41 –2.15 to 2.98 0.752 –4.59 –11.50 to 2.31 0.192
≥ 600 51.7 (11.3); 35 47.9 (12.1); 33 2.15 –2.22 to 6.51 0.335 –2.86 –10.62 to 4.90 0.470
21 months
None 50.0 (14.8); 15 51.0 (13.7); 15 0.50 –6.02 to 7.01 0.882
< 300 55.0 (7.7); 24 49.1 (12.6); 43 4.12 –0.61 to 8.85 0.088 3.62 –4.43 to 11.68 0.378
300–600 51.3 (9.2); 94 49.2 (11.5); 97 1.18 –1.49 to 3.85 0.386 0.69 –6.36 to 7.73 0.849
≥ 600 52.7 (9.0); 32 47.9 (10.0); 30 3.65 –1.00 to 8.31 0.124 3.16 –4.85 to 11.17 0.440
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TABLE 44 Positive and Negative Syndrome Scale: difficulty with abstract thinking, conceptual disorganisation and LNS
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Difficulty with abstract thinking (PANSS)
9 months
0–4 51.6 (10.9); 114 48.7 (11.6); 124 2.18 –0.20 to 4.57 0.073
≥ 4 49.7 (12.8); 67 48.7 (10.4); 70 1.32 –1.88 to 4.52 0.418 –0.86 –4.86 to 3.14 0.673
21 months
0–4 52.7 (9.7); 103 49.0 (11.2); 121 2.61 0.12 to 5.09 0.040
≥ 4 50.8 (9.4); 62 49.3 (12.5); 64 0.89 –2.41 to 4.19 0.597 –1.72 –5.85 to 2.42 0.416
Conceptual disorganisation (PANSS)
9 months
0–4 50.3 (11.6); 153 48.0 (11.0); 159 2.19 0.10 to 4.27 0.040
≥ 4 53.9 (11.3); 28 51.9 (11.2); 35 0.43 –4.38 to 5.25 0.860 –1.75 –7.00 to 3.50 0.513
21 months
0–4 51.8 (9.7); 138 48.7 (11.8); 151 2.00 –0.17 to 4.18 0.071
≥ 4 53.1 (9.6); 27 50.7 (11.2); 34 1.96 –2.88 to 6.81 0.427 –0.04 –5.35 to 5.27 0.988
LN
9 months
≤ 8 52.4 (11.9); 23 44.6 (14.6); 17 5.42 –0.59 to 11.44 0.077
≥ 9 54.6 (9.9); 14 50.9 (14.1); 11 3.02 –4.34 to 10.38 0.421 –2.40 –11.86 to 7.05 0.618
21 months
≤ 8 51.0 (8.6); 20 51.3 (9.5); 15 –1.11 –7.51 to 5.28 0.733
≥ 9 51.7 (9.6); 13 52.1 (10.4); 12 –0.58 –7.94 to 6.78 0.877 0.53 –9.19 to 10.26 0.914
D
O
I:10.3310/hta23070
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.7
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
M
orrison
et
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,Southam
pton
SO
16
7N
S,U
K
.
103
TABLE 45 Questionnaire about the Process of Recovery: childhood trauma
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Emotional abuse
9 months
≤ 9 49.2 (11.9); 80 48.6 (10.8); 83 1.54 –1.35 to 4.43 0.296
≥ 10 52.5 (11.7); 55 46.8 (11.2); 67 3.46 0.03 to 6.88 0.048 1.92 –2.57 to 6.40 0.402
21 months
≤ 9 50.7 (9.2); 75 49.5 (11.0); 76 1.62 –1.37 to 4.61 0.289
≥ 10 53.2 (9.9); 48 47.5 (12.0); 65 3.07 –0.45 to 6.60 0.087 1.46 –3.17 to 6.08 0.537
Emotional neglect
9 months
≤ 14 51.2 (11.6); 104 49.8 (9.9); 106 2.04 –0.48 to 4.57 0.112
≥ 15 47.7 (12.7); 34 42.6 (12.3); 40 2.66 –1.71 to 7.04 0.233 0.62 –4.43 to 5.67 0.810
21 months
≤ 14 52.0 (9.2); 97 50.7 (10.7); 96 1.83 –0.78 to 4.44 0.170
≥ 15 50.3 (10.6); 27 42.8 (11.6); 41 4.20 –0.40 to 8.79 0.074 2.37 –2.92 to 7.66 0.380
Physical abuse
9 months
≤ 7 51.0 (11.5); 93 48.5 (10.8); 92 2.92 0.19 to 5.64 0.036
≥ 8 49.6 (13.5); 42 46.4 (11.3); 56 2.20 –1.67 to 6.07 0.265 –0.72 –5.46 to 4.02 0.767
21 months
≤ 7 51.7 (8.6); 85 49.7 (11.0); 92 2.11 –0.65 to 4.88 0.134
≥ 8 51.7 (11.1); 39 45.8 (12.0); 47 3.64 –0.46 to 7.75 0.082 1.53 –3.43 to 6.48 0.546
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Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Physical neglect
9 months
≤ 7 49.9 (11.7); 72 47.6 (11.0); 72 2.63 –0.50 to 5.75 0.100
≥ 8 50.9 (12.4); 64 47.9 (11.0); 79 2.37 –0.81 to 5.55 0.144 –0.26 –4.72 to 4.21 0.911
21 months
≤ 7 50.6 (8.1); 64 49.2 (11.8); 70 1.04 –2.18 to 4.27 0.526
≥ 8 52.9 (10.6); 58 47.9 (11.2); 72 4.15 0.87 to 7.43 0.013 3.11 –1.49 to 7.70 0.186
Sexual abuse
9 months
≤ 7 50.4 (11.8); 102 48.2 (10.1); 110 2.25 –0.31 to 4.81 0.085
≥ 8 50.6 (13.1); 31 46.9 (13.3); 40 3.75 –0.75 to 8.25 0.103 1.50 –3.68 to 6.68 0.571
21 months
≤ 7 52.1 (9.0); 94 48.9 (11.0); 104 3.01 0.38 to 5.64 0.025
≥ 8 50.3 (11.3); 29 47.1 (12.6); 37 1.36 –3.29 to 6.01 0.568 –1.66 –7.00 to 3.69 0.544
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TABLE 46 Questionnaire about the Process of Recovery: AUDIT, DAST and PAM-SR attachment avoidance
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
AUDIT
9 months
≤ 12 51.3 (11.8); 160 48.5 (11.1); 177 2.03 0.03 to 4.03 0.047
≥ 13 46.1 (10.6); 17 48.5 (13.7); 11 0.83 –6.07 to 7.73 0.813 –1.20 –8.38 to 5.99 0.744
21 months
≤ 12 52.1 (9.9); 147 48.8 (11.8); 166 1.76 –0.31 to 3.83 0.095
≥ 13 51.5 (6.8); 13 51.7 (12.0); 14 1.14 –5.71 to 8.00 0.744 –0.61 –7.77 to 6.54 0.866
DAST
9 months
1–2 51.1 (11.6); 160 48.3 (10.9); 175 1.89 –0.08 to 3.87 0.060
≥ 3 52.0 (5.8); 9 49.8 (16.2); 11 4.92 –3.64 to 13.48 0.260 3.02 –5.77 to 11.81 0.501
21 months
1–2 52.2 (9.7); 146 48.4 (11.6); 168 2.45 0.40 to 4.49 0.019
≥ 3 49.7 (11.0); 7 56.9 (10.2); 9 –5.60 –14.93 to 3.74 0.240 –8.06 –17.63 to 1.51 0.099
PAM-SR attachment avoidance
9 months
< 9 54.3 (10.2); 116 51.3 (9.9); 113 2.96 0.58 to 5.34 0.015
9–16 43.5 (12.0); 49 43.7 (11.5); 66 –0.47 –3.92 to 2.98 0.788 –3.43 –7.62 to 0.76 0.109
17–24 48.7 (9.4); 16 50.5 (11.8); 15 –1.03 –8.10 to 6.05 0.776 –3.99 –11.45 to 3.48 0.295
21 months
< 9 54.3 (9.0); 106 51.2 (10.6); 109 2.89 0.44 to 5.33 0.021
9–16 46.0 (9.6); 42 44.5 (13.0); 62 0.16 –3.46 to 3.78 0.931 –2.73 –7.10 to 1.65 0.222
17–24 52.5 (7.7); 17 52.8 (6.9); 14 0.52 –7.02 to 8.06 0.892 –2.36 –10.29 to 5.56 0.559
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TABLE 47 Questionnaire about the Process of Recovery: BCSS
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Negative others
9 months
< 7.2 54.0 (10.4); 93 48.6 (10.0); 79 4.42 1.65 to 7.18 0.002
≥ 7.2 47.0 (12.0); 72 48.5 (11.9); 103 –0.54 –3.39 to 2.31 0.709 –4.96 –8.94 to –0.98 0.015
21 months
< 7.2 53.4 (9.4); 87 49.5 (11.3); 71 2.78 –0.10 to 5.66 0.059
≥ 7.2 50.2 (10.1); 66 48.4 (12.4); 101 1.79 –1.14 to 4.73 0.231 –0.98 –5.10 to 3.13 0.639
Negative self
9 months
< 7.2 54.5 (10.1); 106 50.8 (9.7); 111 2.61 0.17 to 5.04 0.036
≥ 7.2 45.4 (11.4); 61 44.7 (12.1); 72 1.61 –1.61 to 4.83 0.327 –1.00 –5.04 to 3.05 0.629
21 months
< 7.2 55.0 (8.4); 99 51.7 (10.4); 107 2.38 –0.11 to 4.88 0.061
≥ 7.2 46.6 (9.5); 51 44.5 (12.7); 68 1.86 –1.54 to 5.25 0.284 –0.53 –4.75 to 3.69 0.806
Positive others
9 months
< 7.2 46.5 (11.2); 36 45.1 (11.7); 59 0.77 –3.08 to 4.62 0.694
≥ 7.2 52.1 (11.5); 130 50.2 (10.4); 124 2.11 –0.16 to 4.39 0.068 1.34 –3.13 to 5.81 0.557
21 months
< 7.2 47.3 (11.6); 29 46.3 (12.5); 63 0.97 –3.14 to 5.07 0.644
≥ 7.2 53.0 (9.2); 121 50.4 (11.2); 111 2.06 –0.32 to 4.43 0.089 1.09 –3.64 to 5.83 0.651
continued
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TABLE 47 Questionnaire about the Process of Recovery: BCSS (continued )
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Positive self
9 months
< 7.2 45.9 (12.4); 68 44.2 (11.4); 86 2.72 –0.22 to 5.66 0.069
≥ 7.2 54.6 (9.6); 97 52.2 (9.4); 96 1.64 –0.98 to 4.27 0.219 –1.08 –5.03 to 2.87 0.592
21 months
< 7.2 47.2 (10.1); 63 45.0 (11.7); 81 2.45 –0.58 to 5.48 0.114
≥ 7.2 55.2 (8.3); 88 52.0 (11.1); 90 1.92 –0.81 to 4.65 0.168 –0.53 –4.61 to 3.56 0.801
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TABLE 48 Questionnaire about the Process of Recovery: psychosis
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
9 months
Stress sensitivity 51.1 (11.7); 62 47.7 (9.5); 67 3.18 0.00 to 6.36 0.050
Drug related 51.5 (10.1); 57 49.8 (10.0); 48 1.62 –1.85 to 5.09 0.359 –1.56 –6.27 to 3.15 0.517
Trauma 47.7 (15.2); 7 55.5 (15.9); 4 –12.90 –24.96 to –0.84 0.036 –16.08 –28.56 to –3.61 0.012
Anxiety 47.3 (14.9); 20 47.6 (12.7); 32 1.13 –4.08 to 6.34 0.671 –2.05 –8.16 to 4.05 0.510
Drug and trauma 40.3 (8.0); 3 36.0 (21.5); 4 11.84 –2.00 to 25.68 0.094 11.84 –2.00 to 25.68 0.094
21 months
Stress sensitivity 52.4 (9.0); 61 48.6 (10.2); 68 2.44 –0.75 to 5.63 0.134
Drug related 52.6 (9.3); 52 51.2 (9.9); 46 1.77 –1.82 to 5.36 0.335 –0.67 –5.48 to 4.13 0.783
Trauma 46.0 (9.6); 7 47.6 (25.0); 5 –9.26 –20.23 to 1.70 0.098 –11.71 –23.12 to –0.29 0.044
Anxiety 50.5 (12.7); 17 47.1 (13.9); 31 4.99 –0.54 to 10.52 0.077 2.55 –3.84 to 8.94 0.434
Drug and trauma 37.5 (14.8); 2 49.8 (8.4); 4 –2.00 –17.23 to 13.23 0.797 –4.44 –20.02 to 11.14 0.576
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TABLE 49 Personal and Social Performance: age, age at onset and sex
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Age (years)
9 months
16–32 57.0 (13.0); 48 50.6 (14.3); 41 5.86 0.94 to 10.77 0.019 4.21 –1.55 to 9.96 0.152
33–49 53.8 (14.9); 114 51.7 (13.2); 124 1.65 –1.35 to 4.65 0.281
≥ 50 48.3 (14.2); 51 49.6 (15.1); 59 –0.66 –5.09 to 3.77 0.770 –2.31 –7.67 to 3.05 0.399
21 months
16–32 52.2 (15.5); 109 52.1 (15.2); 120 –0.10 –3.15 to 2.96 0.951
33–49 53.5 (15.3); 47 54.7 (13.3); 38 –0.60 –5.65 to 4.44 0.815 –0.51 –6.41 to 5.39 0.866
≥ 50 47.8 (14.3); 50 47.8 (14.0); 56 1.25 –3.26 to 5.76 0.588 1.34 –4.11 to 6.80 0.629
Age at onset (years)
9 months
≤ 35 53.8 (14.6); 178 51.5 (13.7); 191 1.89 –0.53 to 4.31 0.126
≥ 36 52.0 (13.9); 23 44.8 (14.5); 20 4.13 –3.04 to 11.29 0.259 2.24 –5.33 to 9.81 0.562
21 months
≤ 35 52.1 (15.4); 169 52.3 (14.5); 181 –0.21 –2.69 to 2.27 0.869
≥ 36 47.9 (14.5); 24 44.5 (15.3); 20 1.35 –5.73 to 8.43 0.709 1.56 –5.95 to 9.06 0.684
Sex
9 months
Female 56.5 (13.3); 59 53.9 (14.9); 64 2.66 –1.52 to 6.84 0.212
Male 52.0 (14.9); 154 49.7 (13.4); 160 1.59 –1.02 to 4.20 0.231 –1.07 –6.00 to 3.86 0.671
21 months
Female 54.8 (15.0); 58 56.2 (14.8); 62 –0.90 –5.13 to 3.34 0.678
Male 50.2 (15.2); 148 49.5 (14.2); 152 0.62 –2.05 to 3.29 0.647 1.52 –3.48 to 6.52 0.552
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TABLE 50 Personal and Social Performance: DI, DUP and clozapine
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
DI (years)
9 months
0–15 55.4 (13.4); 92 49.7 (13.8); 76 4.80 1.22 to 8.39 0.009
16–30 54.0 (15.2); 87 51.2 (14.0); 102 1.57 –1.81 to 4.94 0.363 –3.24 –8.17 to 1.69 0.198
≥ 31 44.0 (12.8); 22 52.5 (14.2); 33 –4.50 –10.87 to 1.88 0.167 –9.30 –16.62 to –1.98 0.013
21 months
0–15 53.0 (16.3); 91 51.3 (14.3); 73 1.28 –2.36 to 4.91 0.491
16–30 51.6 (14.2); 83 52.3 (15.8); 98 –1.16 –4.61 to 2.29 0.510 –2.44 –7.45 to 2.57 0.341
≥ 31 44.4 (13.7); 19 49.4 (12.7); 30 –1.58 –8.37 to 5.21 0.649 –2.85 –10.56 to 4.85 0.468
DUP (years)
9 months
0–2 53.1 (14.9); 112 50.8 (14.3); 94 1.76 –1.52 to 5.04 0.292
2–5 55.4 (15.2); 35 49.7 (13.9); 62 5.32 0.34 to 10.30 0.036 3.56 –2.41 to 9.52 0.243
≥ 6 51.2 (14.2); 26 51.5 (13.7); 31 0.93 –5.33 to 7.18 0.771 –0.84 –7.90 to 6.22 0.816
21 months
0–2 51.6 (15.6); 110 51.6 (15.0); 89 –0.33 –3.67 to 3.01 0.846
2–5 53.6 (16.5); 34 52.5 (14.1); 60 0.99 –4.06 to 6.05 0.700 1.32 –4.75 to 7.40 0.669
≥ 6 47.2 (13.4); 25 47.5 (13.6); 29 0.84 –5.58 to 7.26 0.798 1.17 –6.06 to 8.40 0.751
continued
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TABLE 50 Personal and Social Performance: DI, DUP and clozapine (continued )
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Number of antipsychotic drugs at baseline
9 months
One or less 52.1 (14.5); 134 50.6 (14.4); 142 1.57 –1.22 to 4.36 0.270
Two or more 55.1 (14.5); 79 51.4 (13.0); 82 2.45 –1.20 to 6.10 0.189 0.87 –3.73 to 5.48 0.710
21 months
One or less 50.4 (15.6); 129 51.5 (14.6); 136 –0.33 –3.18 to 2.53 0.823
Two or more 53.2 (14.5); 77 51.3 (14.9); 78 1.04 –2.67 to 4.76 0.582 1.37 –3.33 to 6.07 0.567
Clozapine daily dose (mg)
9 months
None 52.1 (11.4); 17 46.3 (14.4); 23 5.13 –2.23 to 12.49 0.172
< 300 56.4 (16.6); 31 53.2 (16.0); 46 0.80 –4.55 to 6.15 0.769 –4.32 –13.44 to 4.79 0.352
300–600 52.3 (14.5); 129 50.4 (13.3); 120 1.98 –0.93 to 4.89 0.182 –3.15 –11.06 to 4.77 0.436
≥ 600 54.4 (14.4); 36 52.7 (12.2); 35 1.93 –3.52 to 7.38 0.488 –3.20 –12.38 to 5.98 0.495
21 months
None 46.3 (13.7); 17 49.0 (16.5); 21 –2.27 –9.77 to 5.24 0.554
< 300 54.1 (18.4); 30 53.6 (16.5); 46 –1.98 –7.37 to 3.42 0.473 0.29 –8.97 to 9.54 0.951
300–600 50.0 (14.9); 124 50.6 (14.3); 113 0.11 –2.87 to 3.09 0.943 2.37 –5.70 to 10.45 0.565
≥ 600 56.9 (12.7); 35 52.6 (12.0); 34 4.94 –0.59 to 10.47 0.080 7.21 –2.14 to 16.55 0.131
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TABLE 51 Personal and Social Performance: difficulty with abstract thinking, conceptual disorganisation and LN
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Difficulty with abstract thinking (PANSS)
9 months
0–4 54.6 (14.4); 126 51.5 (13.5); 142 1.38 –1.46 to 4.21 0.341
≥ 4 51.3 (14.7); 87 49.9 (14.6); 82 2.72 –0.84 to 6.29 0.135 1.35 –3.22 to 5.91 0.564
21 months
0–4 53.8 (16.4); 122 51.9 (14.8); 135 0.60 –2.29 to 3.49 0.684
≥ 4 48.1 (12.7); 84 50.6 (14.5); 79 –0.40 –4.04 to 3.24 0.830 –1.00 –5.66 to 3.66 0.674
Conceptual disorganisation (PANSS)
9 months
0–4 53.9 (14.1); 178 52.6 (13.1); 182 1.49 –0.94 to 3.92 0.230
≥ 4 49.6 (16.4); 35 43.5 (14.9); 42 3.66 –1.63 to 8.94 0.175 2.17 –3.66 to 8.00 0.466
21 months
0–4 52.9 (15.2); 170 52.7 (14.4); 177 0.73 –1.75 to 3.21 0.563
≥ 4 44.8 (13.7); 36 45.4 (14.9); 37 –2.27 –7.68 to 3.14 0.410 –3.00 –8.97 to 2.96 0.323
LN
9 months
≤ 8 50.9 (12.2); 25 44.6 (14.8); 23 7.05 0.27 to 13.82 0.041
≥ 9 50.7 (16.4); 17 56.2 (12.8); 11 –7.48 –16.49 to 1.54 0.104 –14.52 –25.75 to –3.29 0.011
21 months
≤ 8 47.2 (12.2); 24 51.6 (14.3); 23 –3.03 –9.91 to 3.85 0.388
≥ 9 56.5 (16.3); 15 57.9 (18.5); 11 –2.46 –11.70 to 6.77 0.601 0.57 –10.90 to 12.04 0.922
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TABLE 52 Personal and Social Performance: childhood trauma
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Emotional abuse
9 months
≤ 9 55.0 (14.3); 89 50.6 (13.5); 88 2.77 –0.70 to 6.25 0.118
≥ 10 53.0 (15.2); 63 51.7 (15.3); 75 3.33 –0.63 to 7.30 0.100 0.56 –4.73 to 5.85 0.836
21 months
≤ 9 52.8 (15.5); 84 51.5 (15.1); 88 –0.34 –3.86 to 3.19 0.851
≥ 10 50.4 (14.3); 59 52.8 (15.7); 75 –0.46 –4.51 to 3.58 0.823 –0.13 –5.51 to 5.25 0.964
Emotional neglect
9 months
≤ 14 54.1 (14.8); 113 52.7 (13.2); 114 1.67 –1.39 to 4.73 0.285
≥ 15 53.5 (14.0); 39 48.2 (16.4); 47 4.90 –0.11 to 9.92 0.055 3.23 –2.64 to 9.11 0.281
21 months
≤ 14 52.0 (15.3); 109 53.8 (15.6); 114 –1.39 –4.48 to 1.70 0.379
≥ 15 51.0 (14.2); 35 49.5 (15.4); 46 1.35 –3.85 to 6.55 0.610 2.74 –3.31 to 8.79 0.375
Physical abuse
9 months
≤ 7 53.1 (14.4); 102 52.9 (13.2); 103 0.49 –2.72 to 3.71 0.765
≥ 8 55.1 (14.7); 49 48.9 (15.4); 60 6.78 2.34 to 11.23 0.003 6.29 0.80 to 11.78 0.025
21 months
≤ 7 51.6 (14.7); 97 53.0 (15.7); 103 –1.03 –4.28 to 2.23 0.536
≥ 8 50.6 (15.3); 46 51.4 (15.0); 59 –0.30 –4.85 to 4.24 0.896 0.72 –4.87 to 6.32 0.800
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Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Physical neglect
9 months
≤ 7 55.5 (13.8); 77 53.1 (13.6); 75 3.47 –0.29 to 7.23 0.071
≥ 8 52.2 (15.3); 73 49.6 (14.7); 91 2.12 –1.52 to 5.76 0.254 –1.35 –6.59 to 3.89 0.614
21 months
≤ 7 53.1 (14.5); 74 53.3 (15.1); 78 0.60 –3.16 to 4.36 0.755
≥ 8 50.5 (15.5); 68 51.3 (15.8); 87 –0.94 –4.69 to 2.81 0.622 –1.54 –6.85 to 3.77 0.570
Sexual abuse
9 months
≤ 7 53.5 (14.8); 114 52.0 (14.8); 115 1.61 –1.40 to 4.62 0.293
≥ 8 55.7 (14.6); 34 48.7 (12.0); 48 6.53 1.42 to 11.63 0.012 4.91 –1.01 to 10.84 0.104
21 months
≤ 7 52.1 (14.2); 109 53.5 (15.2); 116 –1.08 –4.12 to 1.96 0.486
≥ 8 51.1 (15.9); 32 48.5 (15.4); 46 1.70 –3.55 to 6.95 0.525 2.78 –3.28 to 8.85 0.368
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TABLE 53 Personal and Social Performance: AUDIT, DAST and PAM-SR attachment avoidance
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
AUDIT
9 months
≤ 12 53.6 (14.6); 185 50.9 (13.8); 202 2.64 0.30 to 4.98 0.027
≥ 13 52.8 (13.1); 20 47.9 (13.7); 14 –0.45 –8.48 to 7.58 0.912 –3.09 –11.46 to 5.28 0.469
21 months
≤ 12 51.6 (15.7); 176 51.8 (14.7); 192 0.19 –2.21 to 2.59 0.874
≥ 13 51.4 (11.7); 19 47.3 (13.3); 15 –0.56 –8.52 to 7.39 0.890 –0.76 –9.07 to 7.56 0.858
DAST
9 months
1–2 53.8 (14.4); 185 50.9 (13.8); 197 2.22 –0.12 to 4.57 0.063
≥ 3 48.2 (17.1); 12 46.4 (13.4); 16 0.98 –7.80 to 9.75 0.827 –1.25 –10.34 to 7.85 0.788
21 months
1–2 52.1 (15.2); 178 51.3 (14.9); 189 0.73 –1.67 to 3.13 0.550
≥ 3 46.1 (14.9); 11 50.2 (13.0); 14 –4.35 –13.62 to 4.91 0.357 –5.08 –14.66 to 4.49 0.298
PAM-SR attachment avoidance
9 months
< 9 55.5 (14.4); 128 53.9 (13.5); 126 0.91 –1.93 to 3.75 0.529
9–16 50.7 (13.8); 59 46.9 (13.2); 75 3.75 –0.20 to 7.70 0.063 2.84 –2.04 to 7.71 0.254
17–24 47.8 (15.3); 26 47.7 (14.8); 23 0.41 –6.07 to 6.89 0.901 –0.50 –7.58 to 6.58 0.889
21 months
< 9 54.4 (15.4); 125 54.9 (14.5); 124 –0.88 –3.76 to 1.99 0.547
9–16 46.3 (14.0); 54 46.8 (14.1); 70 –0.16 –4.27 to 3.96 0.940 0.72 –4.30 to 5.75 0.778
17–24 48.0 (13.8); 27 46.0 (11.8); 20 3.91 –2.78 to 10.60 0.252 4.79 –2.49 to 12.08 0.197
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TABLE 54 Personal and Social Performance: BCSS
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Negative others
9 months
< 7.2 55.4 (14.3); 104 53.3 (13.7); 88 0.91 –2.43 to 4.26 0.592
≥ 7.2 51.5 (14.7); 84 50.0 (13.7); 117 2.22 –1.09 to 5.52 0.189 1.30 –3.41 to 6.01 0.588
21 months
< 7.2 54.4 (15.0); 99 52.5 (15.8); 84 0.66 –2.76 to 4.08 0.705
≥ 7.2 48.5 (15.4); 85 51.5 (14.2); 111 –1.66 –4.99 to 1.68 0.330 –2.32 –7.10 to 2.47 0.343
Negative self
9 months
< 7.2 54.6 (14.8); 121 52.2 (14.7); 125 0.57 –2.36 to 3.50 0.702
≥ 7.2 50.8 (13.0); 68 49.7 (12.0); 81 3.42 –0.36 to 7.21 0.076 2.85 –1.94 to 7.65 0.244
21 months
< 7.2 54.6 (15.8); 116 53.2 (15.0); 121 0.02 –2.96 to 3.00 0.990
≥ 7.2 46.1 (13.1); 66 49.1 (14.2); 76 –0.55 –4.43 to 3.32 0.780 –0.57 –5.47 to 4.33 0.819
Positive others
9 months
< 7.2 50.3 (15.6); 44 47.6 (13.3); 69 2.22 –2.19 to 6.62 0.324
≥ 7.2 54.1 (13.8); 144 53.3 (13.7); 136 0.87 –1.85 to 3.59 0.530 –1.35 –6.54 to 3.84 0.611
21 months
< 7.2 48.0 (15.7); 39 47.4 (14.5); 69 –0.27 –4.85 to 4.30 0.906
≥ 7.2 52.5 (15.4); 144 54.6 (14.4); 128 –1.44 –4.20 to 1.32 0.306 –1.17 –6.52 to 4.19 0.669
continued
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TABLE 54 Personal and Social Performance: BCSS (continued )
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Positive self
9 months
< 7.2 49.6 (14.0); 81 49.4 (13.3); 96 –0.38 –3.86 to 3.10 0.831
≥ 7.2 56.2 (14.3); 108 53.0 (14.1); 108 3.07 –0.06 to 6.20 0.054 3.45 –1.24 to 8.14 0.149
21 months
< 7.2 48.8 (15.0); 76 50.2 (14.8); 92 –2.07 –5.65 to 1.51 0.257
≥ 7.2 53.4 (15.7); 106 53.3 (14.8); 103 0.61 –2.57 to 3.79 0.705 2.69 –2.11 to 7.48 0.273
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TABLE 55 Personal and Social Performance: psychosis
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
9 months
Stress sensitivity 54.3 (14.3); 74 49.9 (14.6); 76 3.74 0.01 to 7.47 0.049
Drug related 54.8 (14.0); 61 51.4 (12.6); 53 0.59 –3.70 to 4.89 0.786 –3.15 –8.83 to 2.53 0.277
Trauma 46.9 (17.4); 10 42.6 (14.4); 7 7.17 –4.09 to 18.44 0.212 3.43 –8.45 to 15.31 0.571
Anxiety 53.5 (14.9); 22 54.7 (15.3); 36 1.59 –4.61 to 7.78 0.616 –2.16 –9.39 to 5.07 0.559
Drug and trauma 44.3 (11.0); 3 54.5 (5.7); 4 –3.15 –21.04 to 14.74 0.730 –3.15 –21.04 to 14.74 0.730
21 months
Stress sensitivity 53.8 (14.4); 72 51.9 (15.1); 75 1.24 –2.53 to 5.01 0.519
Drug related 53.3 (16.3); 60 51.2 (13.7); 54 –0.48 –4.77 to 3.80 0.825 –1.72 –7.43 to 3.98 0.553
Trauma 41.8 (14.5); 8 45.6 (20.9); 7 –1.39 –13.23 to 10.45 0.818 –2.63 –15.07 to 9.81 0.678
Anxiety 51.9 (15.0); 24 52.7 (15.9); 35 2.86 –3.20 to 8.93 0.354 1.62 –5.51 to 8.76 0.655
Drug and trauma 32.7 (7.5); 3 53.0 (7.0); 4 –9.57 –27.06 to 7.92 0.284 –10.81 –28.71 to 7.09 0.236
D
O
I:10.3310/hta23070
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.7
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.This
w
ork
w
as
produced
by
M
orrison
et
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,Southam
pton
SO
16
7N
S,U
K
.
119
TABLE 56 Psychotic Symptom Rating Scale – auditory hallucinations: age, age at onset and sex
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Age (years)
9 months
16–32 17.8 (13.5); 41 22.0 (13.8); 37 –1.66 –6.72 to 3.41 0.522 0.88 –5.02 to 6.78 0.770
33–49 17.5 (14.7); 102 23.0 (13.0); 105 –2.54 –5.59 to 0.52 0.104
≥ 50 18.2 (14.2); 42 21.5 (14.1); 50 –3.43 –8.24 to 1.38 0.162 –0.90 –6.60 to 4.81 0.758
21 months
16–32 16.8 (14.5); 98 20.0 (14.7); 105 –1.11 –4.22 to 2.01 0.485
33–49 15.8 (12.8); 41 19.4 (13.4); 29 0.71 –4.73 to 6.15 0.798 1.82 –4.44 to 8.08 0.569
≥ 50 19.3 (14.6); 40 21.5 (14.4); 48 –3.46 –8.37 to 1.45 0.167 –2.35 –8.17 to 3.46 0.428
Age at onset (years)
9 months
≤ 35 17.4 (14.2); 157 22.7 (13.3); 163 –2.95 –5.46 to –0.44 0.021
≥ 36 17.3 (14.0); 19 21.8 (14.8); 18 –3.16 –10.90 to 4.58 0.423 –0.21 –8.37 to 7.94 0.959
21 months
≤ 35 17.0 (14.1); 153 20.7 (14.1); 153 –1.02 –3.60 to 1.56 0.438
≥ 36 16.5 (14.9); 19 19.3 (14.9); 18 –5.56 –13.28 to 2.16 0.158 –4.54 –12.70 to 3.61 0.275
Sex
9 months
Female 19.1 (15.2); 54 25.4 (12.5); 54 –3.54 –7.69 to 0.61 0.095
Male 17.2 (13.8); 131 21.3 (13.6); 138 –2.15 –4.89 to 0.60 0.125 1.39 –3.57 to 6.35 0.583
21 months
Female 16.5 (15.6); 51 22.0 (14.0); 54 –3.87 –8.12 to 0.38 0.074
Male 17.4 (13.6); 128 19.6 (14.5); 128 –0.28 –3.11 to 2.55 0.846 3.59 –1.51 to 8.68 0.167
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TABLE 57 Psychotic Symptom Rating Scale – auditory hallucinations: DI, DUP and clozapine
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
DI (years)
9 months
0–15 19.1 (13.5); 79 20.2 (13.8); 65 1.08 –2.67 to 4.83 0.573
16–30 15.2 (14.7); 80 25.3 (12.3); 90 –6.25 –9.70 to –2.80 < 0.001 –7.33 –12.41 to –2.25 0.005
≥ 31 19.9 (13.9); 17 19.8 (14.5); 26 –4.13 –10.77 to 2.51 0.223 –5.21 –12.84 to 2.42 0.181
21 months
0–15 16.4 (13.8); 78 18.7 (13.9); 60 0.09 –3.75 to 3.94 0.962
16–30 16.9 (14.8); 78 22.1 (13.9); 87 –1.99 –5.52 to 1.55 0.272 –2.08 –7.29 to 3.13 0.434
≥ 31 19.2 (13.1); 16 19.5 (15.4); 24 –4.56 –11.54 to 2.41 0.199 –4.66 –12.62 to 3.30 0.251
DUP (years)
9 months
0–2 18.7 (14.1); 97 22.1 (14.3); 86 –1.36 –4.62 to 1.89 0.412
2–5 11.3 (12.1); 33 22.9 (12.9); 52 –7.06 –11.93 to –2.19 0.005 –5.69 –11.53 to 0.14 0.056
≥ 6 16.4 (14.6); 25 23.8 (13.1); 28 –8.17 –14.29 to –2.05 0.009 –6.81 –13.72 to 0.11 0.054
21 months
0–2 16.7 (13.9); 95 21.0 (14.3); 78 –1.69 –5.05 to 1.67 0.325
2–5 11.5 (13.4); 29 20.0 (14.2); 49 –6.20 –11.32 to –1.07 0.018 –4.51 –10.62 to 1.61 0.149
≥ 6 18.3 (14.4); 25 22.8 (13.8); 27 –3.27 –9.58 to 3.05 0.311 –1.58 –8.71 to 5.55 0.665
continued
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TABLE 57 Psychotic Symptom Rating Scale – auditory hallucinations: DI, DUP and clozapine (continued )
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Number of antipsychotic drugs at baseline
9 months
One or less 15.8 (14.1); 109 21.4 (13.6); 114 –2.75 –5.74 to 0.24 0.071
Two or more 20.6 (14.0); 76 23.9 (13.1); 78 –2.49 –6.01 to 1.04 0.167 0.26 –4.36 to 4.89 0.911
21 months
One or less 15.1 (14.0); 108 18.8 (14.3); 113 –0.56 –3.59 to 2.47 0.718
Two or more 20.1 (14.0); 71 22.8 (14.1); 69 –2.92 –6.65 to 0.82 0.126 –2.36 –7.17 to 2.46 0.338
Clozapine daily dose (mg)
9 months
None 19.1 (15.7); 15 23.3 (14.6); 21 –1.94 –9.37 to 5.50 0.610
< 300 10.9 (13.8); 23 22.3 (13.4); 39 –6.92 –12.71 to –1.13 0.019 –4.98 –14.38 to 4.42 0.299
300–600 18.2 (14.1); 113 22.3 (13.2); 99 –3.03 –6.05 to –0.01 0.049 –1.10 –9.11 to 6.92 0.788
≥ 600 20.2 (13.6); 34 22.4 (13.8); 33 1.70 –3.82 to 7.23 0.546 3.64 –5.62 to 12.89 0.441
21 months
None 20.3 (15.3); 16 23.5 (13.4); 20 –1.98 –9.40 to 5.44 0.601
< 300 11.6 (11.9); 24 21.1 (13.9); 37 –4.81 –10.55 to 0.94 0.101 –2.83 –12.18 to 6.53 0.554
300–600 17.6 (14.5); 109 20.1 (14.5); 94 –1.05 –4.18 to 2.08 0.511 0.93 –7.11 to 8.98 0.820
≥ 600 18.2 (13.7); 30 18.1 (15.2); 31 1.19 –4.64 to 7.02 0.689 3.17 –6.27 to 12.61 0.510
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TABLE 58 Psychotic Symptom Rating Scale – auditory hallucinations: difficulty with abstract thinking, conceptual disorganisation and LN
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Difficulty with abstract thinking (PANSS)
9 months
0–4 16.9 (14.5); 112 21.2 (13.5); 126 –2.38 –5.27 to 0.51 0.106
≥ 4 19.1 (13.8); 73 24.7 (13.0); 66 –2.77 –6.60 to 1.06 0.156 –0.39 –5.18 to 4.40 0.874
21 months
0–4 16.5 (14.4); 109 19.8 (14.1); 120 –2.04 –4.99 to 0.92 0.177
≥ 4 18.1 (13.8); 70 21.4 (14.8); 62 –0.00 –3.97 to 3.96 0.998 2.03 –2.91 to 6.97 0.420
Conceptual disorganisation (PANSS)
9 months
0–4 18.2 (14.3); 160 22.6 (13.3); 160 –2.53 –5.02 to –0.03 0.047
≥ 4 15.0 (14.1); 25 21.3 (13.9); 32 –2.94 –8.90 to 3.03 0.335 –0.41 –6.87 to 6.05 0.901
21 months
0–4 17.7 (14.3); 150 20.6 (14.3); 153 –1.43 –4.02 to 1.16 0.280
≥ 4 14.3 (13.4); 29 18.8 (15.0); 29 –1.08 –6.91 to 4.75 0.717 0.35 –6.03 to 6.73 0.914
LN
9 months
≤ 8 17.7 (13.1); 23 24.4 (14.0); 19 –1.01 –7.41 to 5.38 0.756
≥ 9 17.8 (14.9); 16 22.4 (9.9); 9 –4.80 –14.43 to 4.83 0.328 –3.79 –15.22 to 7.64 0.516
21 months
≤ 8 19.5 (14.0); 21 21.5 (15.4); 17 3.51 –3.10 to 10.13 0.298
≥ 9 20.1 (13.2); 16 23.3 (9.9); 9 –3.04 –12.08 to 6.00 0.510 –6.55 –17.65 to 4.55 0.247
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TABLE 59 Psychotic Symptom Rating Scale – auditory hallucinations: childhood trauma
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Emotional abuse
9 months
≤ 9 17.2 (14.5); 79 23.5 (12.7); 75 –3.88 –7.39 to –0.37 0.030
≥ 10 18.8 (14.6); 53 24.3 (12.2); 67 –1.49 –5.55 to 2.56 0.470 2.39 –2.98 to 7.75 0.383
21 months
≤ 9 17.2 (13.7); 78 19.1 (14.3); 74 0.30 –3.25 to 3.84 0.870
≥ 10 19.2 (14.6); 52 23.4 (13.4); 64 –2.16 –6.28 to 1.96 0.304 –2.46 –7.90 to 2.98 0.376
Emotional neglect
9 months
≤ 14 18.0 (14.7); 96 23.0 (12.5); 98 –3.60 –6.75 to –0.46 0.025
≥ 15 16.1 (14.5); 36 25.6 (12.3); 43 –1.55 –6.59 to 3.49 0.546 2.05 –3.86 to 7.97 0.497
21 months
≤ 14 17.7 (13.7); 97 19.8 (13.9); 95 –0.71 –3.88 to 2.46 0.660
≥ 15 16.5 (15.5); 32 24.7 (13.0); 42 –2.93 –8.17 to 2.30 0.273 –2.22 –8.33 to 3.89 0.476
Physical abuse
9 months
≤ 7 16.8 (14.7); 87 23.4 (12.4); 93 –4.04 –7.36 to –0.72 0.017
≥ 8 18.0 (15.0); 44 25.3 (12.7); 50 –2.08 –6.61 to 2.45 0.367 1.96 –3.63 to 7.55 0.492
21 months
≤ 7 16.8 (14.0); 87 19.7 (14.0); 90 –0.69 –4.06 to 2.68 0.689
≥ 8 17.9 (14.8); 41 24.3 (13.2); 48 –2.91 –7.55 to 1.73 0.219 –2.22 –7.94 to 3.49 0.446
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Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Physical neglect
9 months
≤ 7 17.0 (15.1); 65 24.6 (12.0); 67 –5.13 –8.93 to –1.34 0.008
≥ 8 17.5 (14.0); 65 23.9 (12.7); 76 –1.88 –5.61 to 1.86 0.325 3.26 –2.04 to 8.55 0.228
21 months
≤ 7 17.5 (14.4); 66 21.0 (13.3); 67 –0.98 –4.80 to 2.83 0.613
≥ 8 17.2 (14.1); 61 21.8 (14.4); 73 –2.27 –6.08 to 1.55 0.244 –1.28 –6.66 to 4.09 0.640
Sexual abuse
9 months
≤ 7 16.7 (14.3); 96 23.4 (12.7); 100 –3.85 –7.02 to –0.68 0.017
≥ 8 19.7 (15.1); 32 25.3 (11.9); 43 –2.04 –7.12 to 3.05 0.433 1.81 –4.16 to 7.79 0.552
21 months
≤ 7 16.8 (14.1); 97 19.4 (14.1); 99 –0.42 –3.61 to 2.76 0.795
≥ 8 18.9 (13.8); 29 26.0 (12.4); 39 –4.58 –10.00 to 0.84 0.098 –4.15 –10.43 to 2.12 0.194
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TABLE 60 Psychotic Symptom Rating Scale – auditory hallucinations: AUDIT, DAST and PAM-SR attachment avoidance
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
AUDIT
9 months
≤ 12 18.2 (14.4); 160 21.9 (13.6); 173 –1.88 –4.33 to 0.57 0.132
≥ 13 16.2 (12.8); 18 31.4 (5.9); 12 –11.64 –19.93 to –3.35 0.006 –9.76 –18.40 to –1.12 0.027
21 months
≤ 12 17.8 (14.2); 155 20.0 (14.3); 164 –0.75 –3.26 to 1.76 0.558
≥ 13 15.2 (12.8); 16 26.8 (12.9); 12 –7.76 –16.34 to 0.82 0.076 –7.01 –15.95 to 1.92 0.124
DAST
9 months
1–2 17.5 (14.3); 161 23.0 (13.1); 171 –3.59 –6.03 to –1.16 0.004
≥ 3 19.6 (10.6); 10 20.0 (15.7); 12 4.83 –4.73 to 14.39 0.322 8.42 –1.43 to 18.27 0.094
21 months
1–2 17.3 (14.0); 156 21.0 (14.2); 160 –2.05 –4.55 to 0.44 0.107
≥ 3 15.2 (12.5); 9 19.5 (16.1); 12 –0.77 –11.27 to 9.73 0.885 1.28 –9.50 to 12.06 0.816
PAM-SR attachment avoidance
9 months
< 9 14.9 (13.9); 114 21.5 (12.7); 108 –4.21 –7.19 to –1.23 0.006
9–16 23.8 (13.0); 50 26.3 (12.3); 68 –0.97 –4.94 to 3.00 0.632 3.24 –1.72 to 8.21 0.201
17–24 19.0 (14.8); 21 12.4 (16.8); 16 4.35 –2.88 to 11.58 0.239 8.56 0.73 to 16.39 0.032
21 months
< 9 15.3 (13.6); 114 19.6 (13.6); 104 –2.06 –5.08 to 0.96 0.181
9–16 23.9 (13.7); 43 23.6 (14.4); 62 0.13 –4.15 to 4.42 0.951 2.20 –3.05 to 7.44 0.412
17–24 13.5 (14.2); 22 12.3 (16.0); 16 1.62 –5.59 to 8.83 0.660 3.68 –4.14 to 11.51 0.356
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TABLE 61 Psychotic Symptom Rating Scale – auditory hallucinations: BCSS
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Negative others
9 months
< 7.2 15.7 (14.0); 90 23.4 (12.0); 72 –4.55 –8.19 to –0.92 0.014
≥ 7.2 20.5 (13.6); 75 23.1 (13.5); 104 –1.75 –5.15 to 1.66 0.314 2.80 –2.19 to 7.80 0.271
21 months
< 7.2 16.6 (13.8); 89 21.9 (13.3); 69 –2.48 –6.17 to 1.20 0.186
≥ 7.2 18.7 (14.4); 73 19.9 (14.7); 96 –0.91 –4.46 to 2.64 0.616 1.57 –3.55 to 6.70 0.547
Negative self
9 months
< 7.2 16.4 (13.9); 105 21.5 (12.8); 105 –1.47 –4.66 to 1.71 0.365
≥ 7.2 20.0 (14.2); 60 25.3 (13.1); 74 –5.36 –9.16 to –1.57 0.006 –3.89 –8.86 to 1.07 0.125
21 months
< 7.2 15.4 (13.4); 100 19.7 (13.7); 99 –1.34 –4.59 to 1.92 0.422
≥ 7.2 20.8 (14.4); 59 22.7 (14.6); 68 –1.86 –5.80 to 2.08 0.355 –0.53 –5.65 to 4.59 0.840
Positive others
9 months
< 7.2 16.6 (14.9); 38 24.2 (13.2); 59 –1.97 –6.68 to 2.73 0.411
≥ 7.2 18.4 (13.9); 127 22.5 (12.8); 118 –3.42 –6.31 to –0.52 0.021 –1.44 –6.96 to 4.07 0.608
21 months
< 7.2 15.5 (13.9); 35 22.5 (14.9); 60 –3.28 –8.10 to 1.53 0.182
≥ 7.2 18.2 (14.0); 125 19.7 (13.6); 108 –0.38 –3.38 to 2.62 0.804 2.90 –2.76 to 8.57 0.315
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TABLE 61 Psychotic Symptom Rating Scale – auditory hallucinations: BCSS (continued )
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
Positive self
9 months
< 7.2 19.2 (15.1); 67 23.6 (13.5); 85 –3.06 –6.71 to 0.58 0.099
≥ 7.2 17.1 (13.3); 98 22.3 (12.7); 92 –2.95 –6.25 to 0.34 0.079 0.11 –4.80 to 5.02 0.965
21 months
< 7.2 18.7 (14.5); 71 21.5 (14.3); 81 –2.24 –5.89 to 1.41 0.229
≥ 7.2 17.1 (13.7); 89 20.1 (13.9); 85 –0.44 –3.92 to 3.04 0.805 1.80 –3.24 to 6.85 0.484
A
PPEN
D
IX
2
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
128
TABLE 62 Psychotic Symptom Rating Scale – auditory hallucinations: psychosis
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
9 months
Stress sensitivity 16.1 (14.2); 60 23.0 (13.3); 65 –4.17 –8.05 to –0.28 0.035
Drug related 15.8 (13.2); 56 22.7 (13.5); 44 –4.05 –8.57 to 0.48 0.079 0.12 –5.82 to 6.06 0.969
Trauma 31.1 (2.7); 9 18.9 (18.2); 7 6.81 –3.62 to 17.23 0.201 10.98 –0.18 to 22.13 0.054
Anxiety 12.9 (14.4); 22 21.4 (13.6); 33 –5.20 –11.33 to 0.93 0.096 –1.03 –8.27 to 6.20 0.779
Drug and trauma 33.0 (1.4); 2 25.3 (12.3); 3 19.71 0.45 to 38.98 0.045 19.71 0.45 to 38.98 0.045
21 months
Stress sensitivity 19.6 (13.8); 63 22.2 (14.4); 65 –0.56 –4.46 to 3.34 0.778
Drug related 14.5 (12.6); 57 18.8 (13.5); 44 –2.02 –6.50 to 2.47 0.378 –1.46 –7.38 to 4.46 0.629
Trauma 21.3 (16.8); 7 22.1 (15.9); 7 –5.11 –16.18 to 5.95 0.365 –4.55 –16.32 to 7.21 0.448
Anxiety 8.9 (13.6); 22 20.4 (14.4); 30 –8.60 –14.79 to –2.41 0.006 –8.04 –15.33 to –0.75 0.031
Drug and trauma 34.3 (7.5); 3 9.3 (18.5); 4 31.39 13.46 to 49.31 0.001 31.95 13.62 to 50.28 0.001
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TABLE 63 Sensitivity analysis of LN subgroup
Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
PANSS total
9 months
≤ 8 75.8 (13.9); 29 82.5 (15.0); 27 –2.31 –7.82 to 3.20 0.412
≥ 9 75.5 (17.0); 69 76.5 (14.2); 75 –2.34 –7.32 to 2.63 0.356 –0.04 –7.48 to 7.41 0.992
21 months
≤ 8 76.8 (18.4); 26 78.9 (16.4); 27 –1.12 –6.73 to 4.49 0.696
≥ 9 72.9 (18.2); 67 74.5 (14.7); 72 –2.37 –7.48 to 2.74 0.364 –1.25 –8.86 to 6.36 0.748
QPR
9 months
≤ 8 52.6 (11.7); 24 44.7 (13.7); 20 3.53 –0.76 to 7.81 0.107
≥ 9 50.9 (11.5); 55 49.5 (9.9); 64 1.32 –2.26 to 4.90 0.469 –2.21 –7.79 to 3.38 0.439
21 months
≤ 8 51.4 (8.7); 21 50.7 (8.8); 19 –0.04 –4.47 to 4.38 0.985
≥ 9 52.4 (10.4); 50 49.8 (11.1); 62 0.45 –3.25 to 4.16 0.811 0.50 –5.28 to 6.27 0.866
PSP
9 months
≤ 8 51.2 (12.1); 26 45.2 (14.2); 26 7.08 1.93 to 12.22 0.007
≥ 9 52.2 (15.2); 69 51.4 (14.4); 73 –1.90 –6.54 to 2.73 0.421 –8.98 –15.92 to –2.04 0.011
21 months
≤ 8 48.0 (12.6); 25 51.4 (13.5); 27 –0.11 –5.32 to 5.10 0.967
≥ 9 52.1 (15.6); 65 50.0 (15.6); 71 1.71 –3.02 to 6.44 0.479 1.82 –5.23 to 8.87 0.613
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Trial arm, mean (SD); n
Mean difference 95% CI p-value Interaction effect 95% CI p-valueCBT (N= 242) TAU (N= 245)
PSYRATS – auditory hallucination
9 months
≤ 8 16.9 (13.3); 24 23.8 (14.1); 22 –0.75 –5.71 to 4.22 0.768
≥ 9 15.0 (13.9); 58 22.9 (12.7); 64 –4.10 –8.21 to 0.01 0.051 –3.35 –9.76 to 3.06 0.305
21 months
≤ 8 18.6 (14.3); 22 20.2 (15.4); 19 2.84 –2.16 to 7.85 0.266
≥ 9 15.1 (13.8); 57 22.1 (13.4); 61 –4.60 –8.90 to –0.30 0.036 –7.44 –14.02 to –0.86 0.027
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TABLE 64 Participants responding ‘quite a lot’ or ‘very much’ to each of the items by whole trial and by
treatment group
Item
Whole sample (N= 279), n (%)
Trial arm, n (%)
p-value
CBT (N= 131) TAU (N= 148)
Quite a lot Very much Quite a lot Very much Quite a lot Very much
1 50 (17.9) 20 (7.2) 23 (17.6) 8 (6.1) 27 (18.2) 12 (8.1) 0.61
2 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.4) 0.18
3 8 (2.9) 2 (0.7) 4 (3.1) 0 (0.0) 4 (2.7) 2 (1.4) 0.65
4 6 (2.2) 1 (0.4) 3 (2.3) 0 (0.0) 3 (2.0) 1 (0.7) 0.83
5 4 (1.4) 1 (0.4) 2 (1.5) 1 (0.8) 2 (1.4) 0 (0.0) 0.56
6 1 (0.4) 1 (0.4) 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.7) 0.93
7 9 (3.2) 5 (1.8) 4 (3.1) 5 (3.8) 5 (3.4) 0 (0.0) 0.18
8 20 (7.2) 12 (4.3) 10 (7.6) 8 (6.1) 10 (6.8) 4 (2.7) 0.26
9 4 (1.4) 0 (0.0) 2 (1.5) 0 (0.0) 2 (1.4) 0 (0.0) 0.90
10 7 (2.5) 1 (0.4) 3 (2.3) 0 (0.0) 4 (2.7) 1 (0.7) 0.59
11 9 (3.2) 0 (0.0) 5 (3.8) 0 (0.0) 4 (2.7) 0 (0.0) 0.60
12 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.4) 0 (0.0) 0.18
13 2 (0.7) 2 (0.7) 1 (0.8) 0 (0.0) 1 (0.7) 2 (1.4) 0.38
14 0 (0.0) 1 (0.4) 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 0.29
15 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 0.35
16 3 (1.1) 0 (0.0) 2 (1.5) 0 (0.0) 1 (0.7) 0 (0.0) 0.49
17 2 (0.7) 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.7) 0 (0.0) 0.93
18 3 (1.1) 2 (0.7) 1 (0.8) 0 (0.0) 2 (1.4) 2 (1.4) 0.22
19 18 (6.5) 2 (0.7) 7 (5.3) 0 (0.0) 11 (7.4) 2 (1.4) 0.23
20 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 0.35
21 9 (3.2) 2 (0.7) 5 (3.8) 1 (0.8) 4 (2.7) 1 (0.7) 0.61
22 4 (1.4) 0 (0.0) 2 (1.5) 0 (0.0) 2 (1.4) 0 (0.0) 0.90
23 5 (1.8) 0 (0.0) 1 (0.8) 0 (0.0) 4 (2.7) 0 (0.0) 0.22
24 14 (5.0) 3 (1.1) 8 (6.1) 0 (0.0) 6 (4.1) 3 (2.0) 0.99
25 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 0.35
26 2 (0.7) 1 (0.4) 1 (0.8) 1 (0.8) 1 (0.7) 0 (0.0) 0.49
27a 15 (5.4) 5 (1.8) 12 (9.2) 1 (0.8) 3 (2.0) 4 (2.7) 0.09
a A response of ‘Quite a lot’ or ‘Very much’ indicates an improvement.
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Appendix 3 Economic analyses
TABLE 65 Baseline EQ-5D domain responses for participants with complete cost and QALY data
EQ-5D health states
Trial arm, n (%)
CBT (N= 76) TAU (N= 93)
Mobility
No problems 55 (72) 50 (54)
Slight problems 12 (16) 19 (20)
Moderate problems 5 (7) 15 (16)
Severe problems 4 (5) 8 (9)
Extreme problems 0 (0) 1 (1)
Self-care
No problems 48 (63) 64 (69)
Slight problems 15 (20) 15 (16)
Moderate problems 10 (13) 11 (12)
Severe problems 3 (4) 3 (3)
Extreme problems 0 0
Usual activities
No problems 27 (35) 32 (34)
Slight problems 19 (25) 22 (24)
Moderate problems 21 (28) 29 (31)
Severe problems 7 (9) 8 (9)
Extreme problems 2 (3) 2 (2)
Pain and distress
No problems 43 (57) 38 (41)
Slight problems 17 (22) 21 (23)
Moderate problems 11 (15) 16 (17)
Severe problems 4 (5) 12 (13)
Extreme problems 1 (1) 6 (6)
Anxiety and depression
No problems 9 (12) 12 (13)
Slight problems 25 (33) 20 (22)
Moderate problems 22 (29) 34 (36)
Severe problems 15 (20) 16 (17)
Extreme problems 5 (6) 11 (12)
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TABLE 66 The EQ-5D domain responses at 9 months for participants with complete cost and QALY data
EQ-5D health states
Trial arm, n (%)
CBT (N= 76) TAU (N= 93)
Mobility
No problems 54 (71) 47 (50)
Slight problems 12 (16) 21 (23)
Moderate problems 5 (6.5) 14 (15)
Severe problems 5 (6.5) 11 (12)
Extreme problems 0 (0) 0 (0)
Self-care
No problems 55 (72) 60 (65)
Slight problems 9 (12) 18 (19)
Moderate problems 10 (13) 10 (11)
Severe problems 2 (3) 5 (5)
Extreme problems 0 (0) 0 (0)
Usual activities
No problems 41 (54) 40 (43)
Slight problems 12 (16) 17 (18)
Moderate problems 18 (24) 26 (28)
Severe problems 4 (5) 10 (11)
Extreme problems 1 (1) 0 (0)
Pain and distress
No problems 47 (62) 42 (45)
Slight problems 12 (16) 20 (22)
Moderate problems 13 (17) 16 (17)
Severe problems 3 (4) 11 (12)
Extreme problems 1 (1) 4 (4)
Anxiety and depression
No problems 17 (22) 11 (12)
Slight problems 20 (26) 28 (30)
Moderate problems 24 (32) 32 (34)
Severe problems 11 (15) 12 (13)
Extreme problems 4 (5) 10 (11)
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TABLE 67 The EQ-5D domain responses at 21 months for participants with complete cost and QALY data
EQ-5D health states
Trial arm, n (%)
CBT (N= 76) TAU (N= 93)
Mobility
No problems 50 (66) 49 (53)
Slight problems 6 (8) 16 (17)
Moderate problems 14 (18) 16 (17)
Severe problems 6 (8) 10 (11)
Extreme problems 0 (0) 2 (2)
Self-care
No problems 55 (72) 51 (55)
Slight problems 12 (16) 30 (32)
Moderate problems 7 (9) 6 (7)
Severe problems 2 (3) 4 (4)
Extreme problems 0 (0) 2 (2)
Usual activities
No problems 38 (50) 36 (39)
Slight problems 22 (29) 20 (21)
Moderate problems 13 (17) 29 (31)
Severe problems 3 (4) 6 (7)
Extreme problems 0 (0) 2 (2)
Pain and distress
No problems 47 (62) 38 (41)
Slight problems 13 (17) 20 (21.5)
Moderate problems 10 (13) 20 (21.5)
Severe problems 5 (7) 12 (13)
Extreme problems 1 (1) 3 (3)
Anxiety and depression
No problems 17 (22) 15 (16)
Slight problems 23 (30) 18 (20)
Moderate problems 26 (34) 41 (44)
Severe problems 8 (11) 14 (15)
Extreme problems 2 (3) 5 (5)
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TABLE 68 Unit costs of health and social care services
Service type Unit costs (£) Source
Inpatient costs
Psychiatric ward 381.55 NHS Reference Costs161
Emergency/crisis centre 414.06 NHS Reference Costs161
General medical ward 538.63 NHS Reference Costs161
Alcohol-treatment ward 334.28 NHS Reference Costs161
Drug-treatment ward 334.28 NHS Reference Costs161
Respite care 389.16 NHS Reference Costs161
Maternity 919.45 NHS Reference Costs161
Outpatient and day visits
Psychiatric 105.08 NHS Reference Costs161
Hospital alcohol service 101.46 NHS Reference Costs161
Hospital substance use service 101.46 NHS Reference Costs161
A&E 146.86 NHS Reference Costs161
Day hospital 120.61 NHS Reference Costs161
Psychotherapy 199.06 NHS Reference Costs161
Clinical psychology/psychology 144.70 NHS Reference Costs161
Colonoscopy 455.82 NHS Reference Costs161
General diagnostic test 37.30 NHS Reference Costs161
Eating disorders 52.92 NHS Reference Costs161
Stroke 170.60 NHS Reference Costs161
Maxillofacial 118.90 NHS Reference Costs161
Neurosurgery 205.98 NHS Reference Costs161
Hepatology 255.35 NHS Reference Costs161
Clozapine clinic 3.37 NHS Reference Costs161
Crisis team 148 NHS Reference Costs161
Anticoagulant clinic 26.26 NHS Reference Costs161
Oncology 151.12 NHS Reference Costs161
Clinical oncology 126.60 NHS Reference Costs161
Haematology 160.58 NHS Reference Costs161
General surgery 130.06 NHS Reference Costs161
Cataract 123.98 NHS Reference Costs161
Spinal unit 280.03 NHS Reference Costs161
Obstetrics 127.54 NHS Reference Costs161
Plastic surgery 99.95 NHS Reference Costs161
Ear, nose and throat 96.87 NHS Reference Costs161
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TABLE 68 Unit costs of health and social care services (continued )
Service type Unit costs (£) Source
Radiography 37.30 NHS Reference Costs161
Neurology 175.60 NHS Reference Costs161
Diabetic 159.31 NHS Reference Costs161
Sexual health 84.11 NHS Reference Costs161
Drug services 21.30 NHS Reference Costs161
Endocrinology 157.74 NHS Reference Costs161
Ophthalmology 90.64 NHS Reference Costs161
Trauma and orthopaedics 117.01 NHS Reference Costs161
Gynaecology 133.01 NHS Reference Costs161
Gastroenterology 136.57 NHS Reference Costs161
Mammogram 37.30 NHS Reference Costs161
MRI 147.25 NHS Reference Costs161
Occupational therapy 65.85 NHS Reference Costs161
Orthotics 57.76 NHS Reference Costs161
Radiology 84.52 NHS Reference Costs161
Physiotherapist 48.33 NHS Reference Costs161
CT scan 107.04 NHS Reference Costs161
Ultrasound scan 52.55 NHS Reference Costs161
Midwifery 75.15 NHS Reference Costs161
Diagnostic biopsy 30.77 NHS Reference Costs161
Urology 105.19 NHS Reference Costs161
Audiology 58.33 NHS Reference Costs161
Dermatologist 101.63 NHS Reference Costs161
Dentist 124.14 NHS Reference Costs161
Pain management 139.12 NHS Reference Costs161
Nephrology 150.78 NHS Reference Costs161
Respiratory 154.77 NHS Reference Costs161
Dietitian 71.17 NHS Reference Costs161
General 116.92 NHS Reference Costs161
Podiatry 42.84 NHS Reference Costs161
Electrocardiography 162.09 NHS Reference Costs161
Endoscopy 259.73 NHS Reference Costs161
Lung function 115.59 NHS Reference Costs161
Knee surgery 130.06 NHS Reference Costs161
Gastric-band management 157.75 NHS Reference Costs161
continued
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TABLE 68 Unit costs of health and social care services (continued )
Service type Unit costs (£) Source
Abscess draining 121.60 NHS Reference Costs161
Simple blood test 3.37 NHS Reference Costs161
Rheumatology 142.74 NHS Reference Costs161
Gender reassignment 309.75 NHS Reference Costs161
Orthopaedics 117.01 NHS Reference Costs161
Fracture clinic 117.01 NHS Reference Costs161
Gall bladder pre surgery 201.25 NHS Reference Costs161
Cardiology 127.67 NHS Reference Costs161
Clinical neurophysiology 215.59 NHS Reference Costs161
Group therapy 46.72 NHS Reference Costs161
Primary, community and social care
GP, surgery visit 36.00 PSSRU 2016164
GP, home visit 115.32 PSSRU 2014,162 updated to
2016 prices164
GP (telephone call) 36.00 PSSRU 2016164
Practice nurse (at surgery) 11.11 Estimated from average time
per visit (PSSRU 2015163)
and cost per minute
(PSSRU 2016164)
Blood test/clozapine clinic 3.37 NHS Reference Costs161
Psychiatrist 105.08 NHS Reference Costs161
Psychologist 144.70 NHS Reference Costs161
Alcohol or drug treatment or rehabilitation
service
52.00 (per hour) PSSRU164
District nurse 38 NHS Reference Costs161
Community psychiatric nurse/case manager 77.24 NHS Reference Costs161
Social worker 79.00 (per hour) PSSRU164
Occupational therapist Individual: 78.54 (per hour) NHS Reference Costs161
Group: 46.72
Voluntary counsellor 32.00 (per hour) PSSRU164
Home help/care worker 24.00 (per hour) PSSRU164
Advocacy worker 58.00 (per hour) PSSRU164
Anticoagulant clinic 26.26 NHS Reference Costs161
Assertive outreach team 55.00 PSSRU164
Day care 32.00–34.00 PSSRU164
Community mental health team 38.00 (per hour) PSSRU164
Community rehabilitation team 78.31 NHS Reference Costs161
Crisis team 39.00 (per hour) PSSRU164
Dentist 121.00 PSSRU164
Debt advice 270.00 PSSRU164
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TABLE 69 Mean costs of health and social care for participants with complete cost and QALY data, by cost
category and assessment
Service type
Trial arm, mean cost (£), SE (95% CI)
CBT (N= 76) TAU (N= 93)
3 months prior to baseline
Hospital inpatient admission (psychiatric) 63, 63 (0 to 187) 308, 264 (0 to 829)
Hospital inpatient admission (non-psychiatric) 0, 0 (0 to 0) 0, 0 (0 to 0)
Hospital outpatient, day and emergency care 45, 17 (11 to 78) 62, 22 (19 to 104)
General practice, community and social care 704, 89 (529 to 879) 616, 63 (491 to 741)
Baseline to 3 months
Hospital inpatient admission (psychiatric) No cases using inpatient care No cases using inpatient care
Hospital inpatient admission (non-psychiatric) 50, 50 (0 to 148) 23, 23 (0 to 69)
Hospital outpatient, day and emergency care 34, 9 (17 to 51) 69, 18 (33 to 106)
General practice, community and social care 604, 60 (486 to 723) 577, 67 (445 to 710)
3–6 months
Hospital inpatient admission (psychiatric) No cases using inpatient care No cases using inpatient care
Hospital inpatient admission (non-psychiatric) 99, 99 (0 to 297) 122, 59 (5 to 238)
Hospital outpatient, day and emergency care 31, 8 (14 to 48) 81, 23 (35 to 127)
General practice, community and social care 457, 54 (350 to 564) 558, 60 (438 to 677)
continued
TABLE 68 Unit costs of health and social care services (continued )
Service type Unit costs (£) Source
Dermatologist 101.63 NHS Reference Costs161
Dietitian 81.32 NHS Reference Costs161
Diabetes mellitus clinic 70.59 NHS Reference Costs161
Gender identity 309.75 NHS Reference Costs161
Housing support – council 22.97 PSSRU164
Mindfulness 14.00 PSSRU164
One-to-one therapy 78.95 NHS Reference Costs161
Podiatrist 42.39 NHS Reference Costs161
Physiotherapy 48.94 NHS Reference Costs161
Support group 17.00 PSSRU164
Sexual health 84.11 NHS Reference Costs161
Support worker 21.94 (per hour) PSSRU 2015, inflated163
A&E, accident and emergency; CT, computerised tomography; MRI, magnetic resonance imaging.
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TABLE 69 Mean costs of health and social care for participants with complete cost and QALY data, by cost
category and assessment (continued )
Service type
Trial arm, mean cost (£), SE (95% CI)
CBT (N= 76) TAU (N= 93)
6–9 months
Hospital inpatient admission (psychiatric) No cases using inpatient care No cases using inpatient care
Hospital inpatient admission (non-psychiatric) 85, 85 (0 to 254) 145, 65 (15 to 275)
Hospital outpatient, day and emergency care 60, 18 (23 to 97) 64, 16 (33 to 95)
General practice, community and social care 507, 53 (400 to 613) 764, 125 (515 to 1013)
9–13 months
Hospital inpatient admission (psychiatric) No cases using inpatient care No cases using inpatient care
Hospital inpatient admission (non-psychiatric) 21, 16 (0 to 53) 46, 29 (0 to 105)
Hospital outpatient, day and emergency care 59, 19 (22 to 96) 55, 14 (26 to 83)
General practice, community and social care 731, 120 (492 to 970) 970, 268 (438 to 1502)
13–17 months
Hospital inpatient admission (psychiatric) No cases using inpatient care No cases using inpatient care
Hospital inpatient admission (non-psychiatric) 0, 0 (0 to 0) 81, 59 (0 to 200)
Hospital outpatient, day and emergency care 50, 18 (14 to 86) 46, 9 (28 to 65)
General practice, community and social care 807, 106 (597 to 1017) 832, 143 (549 to 1116)
17–21 months
Hospital inpatient admission (psychiatric) No cases using inpatient care No cases using inpatient care
Hospital inpatient admission (non-psychiatric) 269, 148 (0 to 564) 98, 56 (0 to 209)
Hospital outpatient, day and emergency care 71, 16 (39 to 104) 134 to 48 (38 to 230)
General practice, community and social care 867, 171 (526 to 1208) 802, 117 (569 to 1034)
TABLE 70 Total cost of health and social care at each follow-up assessment for participants with complete cost
and QALY data
Assessment period
Trial arm, mean cost (£), SE (95% CI)
CBT (N= 76) TAU (N= 93)
3 months prior to baseline 718, 100 (521 to 915) 661, 68 (527 to 795)
Baseline to 3 months 688, 83 (523 to 853) 670, 77 (517 to 823)
3–6 months 587, 116 (356 to 819) 761, 91 (581 to 941)
6–9 months 652, 113 (427 to 876) 973, 147 (681 to 1265)
9–13 months 811, 128 (557 to 1065) 1071, 275 (525 to 1616)
13–17 months 857, 108 (642 to 1072) 959, 165 (632 to 1287)
17–21 months 1208, 222 (765 to 1651) 1034, 136 (763 to 1305)
Baseline to 9-month follow-up 1927, 251 (1255 to 2184) 2404, 250 (1841 to 2827)
Baseline to 21-month follow-up 4635, 529 (3241 to 5204) 5277, 581 (4026 to 6417)
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TABLE 71 Mean cost of health and social care, by cost category and assessment point: MI data
Service type
Trial arm, mean cost (£), SE (95% CI)
CBT (N= 242) TAU (N= 245)
3 months prior to baseline (single imputation)
Hospital inpatient admission (psychiatric) 2170, 515 (1158 to 3183) 2581, 553 (1494 to 3668)
Hospital inpatient admission (non-psychiatric) 48, 25 (0 to 97) 44, 24 (0 to 92)
Hospital outpatient care 95, 19 (57 to 133) 95, 21 (54 to 135)
General practice, community and social care 796, 65 (668 to 924) 830, 78 (677 to 981)
Baseline to 3 months
Hospital inpatient admission (psychiatric) 2607, 588 (1451 to 3762) 2802, 627 (1569 to 4035)
Hospital inpatient admission (non-psychiatric) 57, 30 (0 to 117) 56, 39 (0 to 135)
Hospital outpatient care 56, 11 (34 to 77) 93, 19 (55 to 131)
General practice, community and social care 692, 68 (558 to 825) 715, 71 (575 to 855)
3–6 months
Hospital inpatient admission (psychiatric) 2932, 615 (1724 to 4139) 2889, 630 (1651 to 4126)
Hospital inpatient admission (non-psychiatric) 44, 35 (0 to 113) 59, 30 (0 to 120)
Hospital outpatient care 59, 12 (36 to 83) 87, 19 (50 to 125)
General practice, community and social care 650, 71 (510 to 789) 593, 49 (497 to 689)
6–9 months
Hospital inpatient admission (psychiatric) 3561, 834 (1921 to 5200) 2414, 591 (1253 to 3575)
Hospital inpatient admission (non-psychiatric) 81, 44 (0 to 169) 154, 60 (36 to 271)
Hospital outpatient care 63, 11 (41 to 85) 124, 21 (82 to 166)
General practice, community and social care 631, 73 (488 to 774) 881, 99 (686 to 1077)
9–13 months
Hospital inpatient admission (psychiatric) 2391, 597 (1219 to 3564) 2345, 598 (1170 to 3519)
Hospital inpatient admission (non-psychiatric) 56, 29 (0 to 113) 86, 51 (0 to 186)
Hospital outpatient care 155, 52 (13 to 217) 92, 32 (30 to 154)
General practice, community and social care 1017, 142 (738 to 1295) 958, 128 (706 to 1210)
13–17 months
Hospital inpatient admission (psychiatric) 2931, 693 (1569 to 4292) 2246, 587 (1094 to 3399)
Hospital inpatient admission (non-psychiatric) 131, 70 (0 to 269) 64, 39 (0 to 140)
Hospital outpatient care 95, 19 (57 to 133) 86, 20 (47 to 125)
General practice, community and social care 1093, 121 (854 to 1331) 969, 113 (743 to 1195)
17–21 months
Hospital inpatient admission (psychiatric) 3706, 876 (1985 to 5427) 3348, 814 (1748 to 4948)
Hospital inpatient admission (non-psychiatric) 242, 97 (51 to 433) 176, 78 (20 to 331)
Hospital outpatient care 121, 22 (78 to 164) 141, 27 (87 to 195)
General practice, community and social care 977, 105 (770 to 1183) 901, 91 (722 to 1080)
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TABLE 72 Net costs of CBT intervention, generalised linear regression, gamma (log) distribution: MI data, baseline
to 21 months
Model details
Number of imputations 10
Number of observations 487
Average RVI 0.02
Largest FMI 0.00
DF adjustment: large sample
Minimum 7481.84
Average 121,678.36
Maximum 438,186.39
Model F-test
Equal FMI F (6, 170,398.3) = 9.99
Within-VCE type: OIM Probability > F= 0.0000
Model results
Net cost Coefficient SE t-value p-value 95% CI
CBT 0.22 0.18 1.21 0.226 –0.14 to 0.58
Baseline cost 0.00 0.00 1.25 0.213 0.00 to 0.00
DI 0.00 0.00 –0.31 0.758 0.00 to 0.00
Taking clozapine 0.09 0.32 0.29 0.775 –0.54 to 0.72
Baseline PSP score –0.05 0.01 –7.11 0.000 –0.06 to –0.03
Baseline CDSS score –0.04 0.02 –2.15 0.032 –0.07 to 0.00
Constant 12.04 0.49 24.65 0.000 11.08 to 13.00
DF, degrees of freedom; FMI, fraction of missing information; OIM, observed information matrix; RVI, relative variance
increase; VCE, variance–covariance estimate.
The regression model used a gamma (log) distribution to account for the skewed distribution. The Stata® mimrgns command
was used to generate the predicted net cost for the CBT arm that is reported in Table 12.
TABLE 73 Net QALYs of CBT intervention, linear regression: MI data, baseline to 21 months
Model details
Number of imputations 10
Number of observations 487
Average RVI 0.08
Largest FMI 0.20
Complete DF 478
DF adjustment: small sample
Minimum 151.20
Average 328.53
Maximum 439.92
Model F-test F (8, 455.1) = 20.88
Equal FMI 0.0000
Within-VCE type: OLS 151.20
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TABLE 73 Net QALYs of CBT intervention, linear regression: MI data, baseline to 21 months (continued )
Model details
Model results
Net cost Coefficient SE t-value p-value 95% CI
CBT 0.053 0.027 1.96 0.050 0.000 to 0.106
Age –0.006 0.001 –4.58 0.000 –0.009 to –0.004
Taking clozapine 0.036 0.050 0.73 0.468 –0.062 to 0.133
Number of benzodiazepines –0.036 0.038 –0.93 0.351 –0.111 to 0.040
Baseline CDSS score –0.001 0.001 –0.81 0.420 –0.003 to 0.001
Baseline QPR score –0.013 0.003 –3.980 0.000 –0.020 to –0.007
Baseline EQ VAS score 0.005 0.001 3.350 0.001 0.002 to 0.008
DF, degrees of freedom; FMI, fraction of missing information; OLS, ordinary least squares; RVI, relative variance increase;
VCE, variance–covariance estimate.
TABLE 74 Net costs and QALYs of CBT vs. TAU for participants with complete cost and QALY data
Complete case analysis Net cost (£), SE (95% CI); p-value Net QALYs, SE (95% CI)
Unadjusted for baseline covariates (N = 169)
Baseline to 9 months 1793, 359 (1085 to 2501); p< 0.001 0.06, 0.03 (0.005 to 0.11); p= 0.031
Baseline to 21 months 1628, 800 (48 to 3208); p= 0.043 0.15, 0.05 (0.04 to 0.26); p= 0.006
Adjusted for baseline covariates (N = 169)
Baseline to 9 months 3151, 562 (2050 to 4253); p< 0.001 0.05, 0.02 (0.01 to 0.10); p= 0.020
Baseline to 21 months 2872, 715 (1471 to 4274); p< 0.001 0.15, 0.05 (0.06 to 0.25); p= 0.002
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